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Summary 
Cardiovascular disease (CVD) is the leading cause of death in the UK, accounting for 
more than a third of all deaths, with atherosclerotic coronary artery disease (CAD) being 
the commonest type of CVD.  Recently, it has become recognised that in addition to 
traditional cardiovascular (CV) risk factors such as dyslipidaemia, hypertension, 
smoking, and diabetes, inflammation plays an important role in the development and 
progression of atherosclerosis.  A concept has emerged that atherosclerosis to some 
extent can be viewed as a chronic inflammatory  autoimmune disease in which the 
adaptive immune system is targeted against vascular self-antigens modified by 
hypercholesterolaemia, involving both the innate and adaptive immune response.  Much 
work has been done in determining how the immune system is involved, however 
relatively little is known about natural killer (NK) cells – an important component of the 
innate immune system which acts against virally infected cells and neoplastic 
transformation.  In addition NK cells possess cytolytic ability and provide an early source 
of immunoregulatory cytokines.  Recently, there has been increasing evidence to support 
a role for NK cells in the development of atherosclerosis.   
 
The work in this thesis examines NK cell function with the aim of determining whether 
any changes in the function of this immune cell could have a role in the development of 
CVD.  In order to do this, we chose two patient populations at high CV risk and 
compared NK cell subsets and function to healthy controls.  Firstly, 66 patients with 
dyslipidaemia on a variety of lipid lowering treatments attending a lipid clinic, and 
secondly 143 patients with chronic kidney disease (CKD) including 11 with end-stage   22 
renal disease (ESRD) on hospital haemodialysis (HD).  It is known that CVD is the 
leading cause of death in patients with CKD, and in ESRD patients have a 20-100 fold 
risk of premature CV death compared to age matched controls from the general 
population.  The increased CV risk results from additional risk factors that are unique to 
this patient population, but in particular, these patients have an immune dysfunction that 
is not completely understood and a resultant inflammatory state.   
 
We determined T-cell, NKT-cell, and NK cell subsets from peripheral blood 
mononuclear cells (PBMCs) by flow cytometry.  We then isolated NK cells from PBMCs 
and assessed NK cell function using a 51-Chromium release assay.  These results were 
then correlated with clinical and laboratory results.  In the patients with dyslipidaemia, 
we did not find any correlations between lipid levels and NK cell numbers, subsets, or 
cytoxicity.  The presence of statin therapy or any other lipid lowering treatment did not 
result in a reduction in NK cell cytotoxicity.  In the CKD patient group, we found a 
correlation between NK cell cytotoxicity and creatinine, although this did not retain 
significance after multivariate analysis.  Interestingly, we also found a correlation 
between NK cell cytotoxicity and serum phosphate level, which did remain significant 
after multivariate regression.  We are the first to report a relationship between phosphate 
and NK cytotoxicity.  This is an interesting finding as there is increasing evidence 
supporting a role for hyperphosphataemia in CVD and increased mortality in both the 
general population and particularly in patients with ESRD.  Phosphate has been shown in 
some studies to be an independent predictor of inflammation, and may provide the link 
between the high risk of CVD and CKD.   23 
 
The next part of this thesis was an in vitro study of membrane cholesterol in NK cells.  
The cell membrane supports cholesterol-rich microdomains termed “lipid rafts”, which 
concentrate receptors and signal transduction molecules to facilitate high efficiency 
signal transduction.  Statins have a number of pleiotropic effects which have been 
explained by reduced production of isoprenoid intermediates, and depletion of cell 
membrane rafts. This study aimed to investigate the effects of membrane cholesterol 
manipulation on NK cell function, and specifically, whether the actions of statins on NK 
cells are due to depletion of membrane cholesterol or inhibition of isoprenylation.  The 
NK92MI cell line was used.  Cells were either cholesterol loaded, or cholesterol depleted 
using statins, and NK cell function assessed using a 51-Chromium release assay.  
Cholesterol was successfully incorporated into the membrane and rafts and was 
concentration dependent.  The addition of cholesterol to statin treated cells restored the 
cholesterol content in the cell membrane and in rafts.  NK cell cytotoxicity decreased 
with statin treatment in correspondence with raft levels, however in contrast with the 
increased raft levels of cells which were cholesterol loaded, NK cytotoxicity was also 
decreased.  Measurement of active Ras (a small G-protein that is localised by 
isoprenylation in membrane rafts when activated), showed that statin treatment reduced 
Ras within the raft which was not rescued by the addition of cholesterol, suggesting that 
statins deplete membrane cholesterol and rafts as well as inhibiting isoprenylation.  
Replenishment of membrane cholesterol restores non-isoprenylated, raft-associated 
proteins, but does not correct the functional effects of statins. 
   24 
The final part of this thesis aimed to evaluate the relationship between NK cells and 
potential CV risk biomarkers in these two patient populations at high risk of CVD.  High 
sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), pentraxin-3 (PTX-3), 
adiponectin, and soluble ST2 (sST2) levels were determined by ELISA, and correlated 
with NK cell numbers, phenotype, and function, as well as other routine biochemical and 
haematological parameters.  We were not able to determine any definite relationships 
between the biomarkers studied and NK cell function, although there was an association 
between PTX-3 and NK cytotoxicity that was only found in inflamed (hsCRP>2mg/L) 
patients. 
 
In conclusion, these studies have provided further insight into the role of NK cells in a 
group of patients that have not previously been studied: patients with a range of CKD, in 
addition to patients with dyslipidaemia.  This study is the first to associate NK cell 
cytotoxicity with serum phosphate levels which may have clinical implications.  Further 
studies are needed to clarify whether other immune abnormalities occur in the context of 
hyperphosphataemia, and the causes and consequences of this.  We have also 
demonstrated that statins deplete membrane lipid rafts as well as inhibit isoprenylation, 
suggesting a novel dual mechanism of action which merits further investigation.  
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1.1   Background 
Cardiovascular disease (CVD) is the leading cause of death in the UK, accounting for 
almost 198,000 deaths per year.  More than a third of all deaths (35%) are from CVD.  
Coronary heart disease (CHD) is the commonest type of cardiovascular disease causing 
death in the UK, resulting in around 94,000 deaths in the UK each year [1].  Ischaemic 
stroke  makes  up  the  other  main  form  of  CVD.    Atherosclerosis  is  the  main 
pathophysiological process causing CVD.  Atherosclerosis is a multi-factorial, complex 
process that is now widely accepted as an inflammatory disease, and consists of focal 
lesions (plaques) in the arterial tree.  Atherosclerotic lesions are composed of cell debris, 
lipid, inflammatory cells, including lipid-laden macrophage foam cells, and a covering 
cap of smooth muscle cells and collagen.  It is fissuring and rupture of these plaques that 
leads to thrombus formation, occlusion of vessels, and acute ischaemia.  Recently, it has 
emerged  that  both  the  innate  and  acquired  immune  system  are  involved  in 
atherosclerosis, in keeping with the inflammatory nature of this disease.  
 
 
1.2  Dyslipidaemia 
Dyslipidaemia is a heterogeneous disorder with multiple aetiologies, although in western 
societies,  the  majority  of  dyslipidaemia  is  secondary  to  lifestyle  and  dietary  habits.  
Amongst the numerous risk factors for CVD, the relationship between elevated serum 
cholesterol and CVD has long been recognised [2].  Over the last two decades, multiple   27 
clinical  and  epidemiological  studies  have  further  established  this  relationship  beyond 
reasonable  doubt,  with  studies  showing  that  lowering  serum  cholesterol  leads  to 
decreased CVD mortality.  Indeed it has been shown that even more intensive lowering 
of  low-density  lipoprotein  cholesterol  (LDL-C)  by  statins  is  associated  with  greater 
clinical benefits [3].  The guidelines of the National Cholesterol Education Program‟s 
Adult  Treatment  Panel  III  (ATP  III)  [4]  are  summarised  in  table  1.    Low-density 
lipoprotein cholesterol is the primary target of cholesterol lowering therapy. 
 
Table 1.1  ATP III Classification of LDL, Total, and HDL Cholesterol (mg/dL)*  
High ≥60
Low <40
HDL cholesterol
High ≥240
Borderline high 200-239
Desirable <200
Total cholesterol
Very high ≥190
High 160-189
Borderline high 130-159
Near or above optimal 100-129
Optimal <100
LDL cholesterol
High ≥60
Low <40
HDL cholesterol
High ≥240
Borderline high 200-239
Desirable <200
Total cholesterol
Very high ≥190
High 160-189
Borderline high 130-159
Near or above optimal 100-129
Optimal <100
LDL cholesterol
 
*ATP indicated Adult Treatment Panel; LDL, low-density lipoprotein; and HDL, high-
density lipoprotein  
   28 
Table 1.2  Classification of serum triglycerides 
≥500mg/dL <1000 mg/dL Very high triglycerides
200-499 mg/dL 400-1000 mg/dL High triglycerides
150-199 mg/dL 200-399 mg/dL Borderline-high 
triglycerides
<150 mg/dL <200 mg/dL Normal triglycerides
ATP III Levels ATP II Levels Triglyceride Category
≥500mg/dL <1000 mg/dL Very high triglycerides
200-499 mg/dL 400-1000 mg/dL High triglycerides
150-199 mg/dL 200-399 mg/dL Borderline-high 
triglycerides
<150 mg/dL <200 mg/dL Normal triglycerides
ATP III Levels ATP II Levels Triglyceride Category
 
Table 1.3  ATP III classification of HDL cholesterol 
High HDL cholesterol ≥60 mg/dL
Low HDL cholesterol <40 mg/dL
Serum HDL cholesterol (mg/dL)
High HDL cholesterol ≥60 mg/dL
Low HDL cholesterol <40 mg/dL
Serum HDL cholesterol (mg/dL)
 
Table 1.4  Definitions of dyslipidaemia 
>150 <40 >100 Diabetes Mellitus
>150 <40 >160 <2 NCEP RF’s
>150 <40 >130 2 NCEP RF’s
>150 <40 >100 CAD,PVD,CVD
Triglycerides HDL LDL
Value (mg/dl) Category
>150 <40 >100 Diabetes Mellitus
>150 <40 >160 <2 NCEP RF’s
>150 <40 >130 2 NCEP RF’s
>150 <40 >100 CAD,PVD,CVD
Triglycerides HDL LDL
Value (mg/dl) Category
 
Risk  Factors  (RF)  are  defined  as  hypertension,  tobacco  use,  diabetes  mellitus,  family 
history of CAD, men > 55 years, women > 60 years 
   29 
1.3   Cholesterol 
Cholesterol  is  a  fat-like  substance  (lipid)  that  is  present  in  cell  membranes  and  is  a 
precursor of bile acids and steroid hormones.  Cholesterol travels in the blood in distinct 
particles  which contain  both  lipid  and proteins (lipoproteins).  There are three major 
classes of lipoproteins: low density lipoproteins (LDL), high density lipoproteins (HDL), 
and  very  low  density  lipoproteins  (VLDL).    There  is  another  lipoprotein  class, 
intermediate density lipoprotein (IDL) that lies between VLDL and LDL.  In clinical 
practice, IDL is included in the LDL measurement. 
 
1.3.1  Atherogenic dyslipidaemia 
Atherogenic dyslipidaemia is characterised by high triglycerides, elevated small dense 
LDL-C and low HDL-C.  This pattern of dyslipidaemia confers a high risk of CHD.  LDL 
cholesterol comprises 60-70% of total serum cholesterol.  LDL is the major atherogenic 
lipoprotein and is the primary target of cholesterol-lowering therapy as outlined by NCEP 
[4].  HDL cholesterol makes up 20-30% of total serum cholesterol.  HDL cholesterol 
levels are inversely associated with CHD risk.  In an observational study, it was found to 
have a 2-3% decrease in the risk of CHD for every 1 mg/dL increase in HDL [5].  The 
mechanism is not clear, however it has been suggested that the anti-atherogenic effect of 
HDL-C  may  be  a  result  of  reverse  cholesterol  transport,  and  anti-oxidant  and  anti-
inflammatory  properties  [6].  Triglycerides  have  been  reported  in  prospective 
epidemiological studies to have a positive relationship with incidence of CHD [7, 8].  
Non-lipid risk factors of CHD such as hypertension, obesity, diabetes and smoking are   30 
interrelated  with  triglycerides,  along  with  emerging  risk  factors  (insulin  resistance, 
glucose intolerance, prothrombotic state) [9].   
 
1.3.2  Biosynthetic Pathway 
Cholesterol is a four-ring, 27-carbon compound, synthesised from acetyl CoA. The first 
step is when acetyl CoA is derived from an oxidation reaction in the mitochondria and is 
transported  to  the  cytoplasm.    Two  moles  of  acetyl  CoA  are  condensed,  forming 
acetoacetyl-CoA.  Acetoacetyl-CoA and a third mole of acetyl CoA are converted to 3-
hydroxy-3-methylglutaryl-CoA  (HMG-CoA)  by  the  action  of  HMG-CoA  synthase.  
HMG-CoA is converted to mevalonate, in a rate limiting step catalysed by the enzyme 
HMG-CoA  reductase.    Mevalonate  is  then  activated  by  three  successive 
phosphorylations, yielding 5-pyrophosphomevalonate.  After phosphorylation, an ATP-
dependent  decarboxylation  yields  isopentenyl  pyrophosphate  (IPP),  an  activated 
isoprenoid  molecule.    Isopentenyl  pyrophosphate  is  in  equilibrium  with  its  isomer, 
dimethylallyl  pyrophosphate  (DMAPP).    One  molecule  of  IPP  condenses  with  one 
molecule  of  DMAPP  to  generate  geranyl  pyrophosphate  (GPP),  catalysed  by  GPP 
synthase.    GPP  further  condenses  with  another  IPP  molecule  to  produce  farnesyl 
pyrophosphate (FPP).  This  step is  catalysed by  FPP synthase.  FPP condenses with 
another  IPP  molecule  to  yield  geranylgeranyl  pyrophosphate  (GGPP),  catalysed  by 
GGPP synthase.  The head-to-tail condensation of two molecules of FPP is catalysed by 
squalene synthase and yields squalene.  Squalene undergoes a two-step cyclization to 
yield lanosterol, which is converted to cholesterol through a series of nineteen additional   31 
reactions (Figure 1.1).  There is a regulatory system co-ordinating the biosynthesis of 
cholesterol with the availability of dietary cholesterol. 
 
 
 
 
Figure 1.1  The cholesterol biosynthesis pathway (adapted with permission: Liao et al   
           [10]) 
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1.3.3  Isoprenylated Proteins 
Recently,  numerous  investigators  have  highlighted  the  role  played  by  intermediate 
metabolites of the cholesterol biosynthetic pathway in the pathogenesis of atherosclerosis 
[10, 11].  As a result of statin inhibition (as discussed in detail below), the downstream 
pathways affected are those that depend on the supply of intermediate products of the 
cholesterol biosynthetic pathway.  In particular, FPP and GGPP, have attracted interest 
because they act as adjuncts in post-translational prenylation of various cell-signalling 
proteins [12].   
 
Protein  isoprenylation  allows  the  covalent  attachment,  subcellular  localisation,  and 
intracellular trafficking of water soluble membrane-associated proteins.  Members of the 
Ras and Rho GTPase family are major substrates for post-translational modification by 
isoprenylation.  As  will  be  discussed  further  below,  by  inhibiting  L-mevalonic  acid 
synthesis, statins also prevent the synthesis of other important isoprenoid intermediates of 
the cholesterol biosynthetic pathway, such as FPP and GGPP.  These intermediates serve 
as important lipid attachments for the posttranslational modification of a variety of cell 
signalling  proteins,  particularly  small  GTPase,  and  by  inhibiting  its  synthesis,  statins 
deplete cells of these lipids and thus elicit the retention of small GTPase in the cytosol, 
where they cannot exert their biological actions. 
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1.4  Atherosclerosis 
 
1.4.1    Atherosclerosis and Dyslipidaemia 
The  endothelium  is  a  monocellular  layer  lining  the  inside  of  vessels  that  normally 
provides a non-adhesive, non-thrombogenic surface for blood constituents, acting as a 
dynamic interface regulating blood vessel functions.  In addition to playing a crucial role 
in  regulating  vascular  tone,  the  endothelium  controls  other  processes  such  as 
inflammation,  coagulation  and  thrombosis  [13].    Normal  endothelial  function  can  be 
altered by traditional risk factor abnormalities.  This altered endothelial function leads to 
a cascade of events that cause plaque formation with subsequent inflammation, altered 
thrombosis, altered vessel tone, and biochemical interactions.  Plaque enlargement then 
results in vascular shear stress, plaque fissure or rupture, platelet adhesion, and finally, 
vessel thrombosis.   
 
In  human  and  experimental  atherosclerosis,  hypercholesterolaemia  is  the  major 
precipitating  factor  initiating  inflammatory  activation  of  the  vascular  endothelium.  
Certainly the importance of hypercholesterolemia has been well documented in animal 
models.    Mice  that  are  homozygous  for  a  targeted  disruption  of  the  low  density 
lipoprotein (LDL) receptor gene (LDLD
-/- mice) fed a high cholesterol diet showed a 
marked  rise  in  total  plasma  cholesterol  associated  with  the  development  of  massive 
xanthomatous infiltration of skin and subcutaneous tissues, and gross atheroma of the 
aorta and coronary ostia [14].  Similarly, mice genetically modified to lack apolipoprotein   34 
E (apoE
-/-), a ligand  for receptors  that  clear remnants  of  chylomicrons and very low 
density  lipoproteins  (VLDLs),  have  grossly  elevated  cholesterol  and  foam  cell-rich 
deposits  in  their  proximal  aortas  by  3  months  [15].  The  importance  of 
hypercholesterolaemia  in  humans  as  a  risk  factor  for  coronary  heart  disease  was 
recognised in the 1950s [16].  Subsequently, the indisputable clinical effects of lowering 
LDL-C  levels  have  been  demonstrated  in  large  clinical  trials  using  statins,  showing 
reductions  in  deaths  from  coronary  artery  disease  and  in  the  incidence  of  acute 
myocardial infarction in patients with established coronary heart disease and elevated 
[17] or average [18] cholesterol levels, as well as in subjects with hypercholesterolaemia 
without overt coronary heart disease [19].   
 
 The earliest detectable event in atherogenesis is the accumulation of plasma lipoproteins 
in the subendothelium, or intima, of focal areas of the arterial tree [20].  Retention here 
sequesters lipoproteins within the intima, isolating them from plasma antioxidants, which 
together with increased plasma levels of LDL-C may result in enhanced oxidation or 
other modifications of LDL within the vascular wall.  Endothelial cells normally resist 
leukocyte adhesion, however pro-inflammatory stimuli, such as hypercholesterolaemia 
(the  retained  lipoproteins),  hyperglycaemia,  hypertension,  and  smoking,  activate  the 
overlying endothelium to secrete chemokines, and trigger the endothelial expression of 
adhesion  molecules  for  monocytes  and  T-cells,  such  as  P-selectin  and  vascular  cell 
adhesion  molecule-1  (VCAM-1)  [21].    These  immune  cells  then  migrate  across  the 
endothelial barrier and into the arterial intima.  A similar activation can be caused by 
disturbed  flow  haemodynamics,  common  at  branching  points  of  the  arterial  tree  –   35 
common  sites  for  atherosclerotic  lesions  [22].    Once  embedded  in  the  intima,  the 
monocytes  differentiate  into  macrophages,  stimulated  by  the  monocyte-colony 
stimulating  factor  (M-CSF).    These  macrophages  encounter  native  and  modified 
lipoproteins, most of which are bound to the matrix, and ingest the lipoprotein particles 
[23, 24], which are taken up by a class of cellular pattern-recognition receptors (PRRs) 
called  scavenger  receptors,  which  are  expressed  on  macrophages  [25].  Cholesterol 
molecules  contained  in  these  LDL  particles  accumulate  in  the  cytoplasm  of  the 
macrophage, where it is esterified, generating cholesterol ester droplets, transforming the 
macrophage into a foam cell, the prototypic cell of the atherosclerotic lesion.  Oxidised 
phospholipids  moieties  of  oxidised  lipoproteins  signal  to  many  of  the  cells  in  the 
evolving plaque, especially to the endothelium overlying the accumulating oxidised LDL 
and foam cells.  This increases the expression of adhesion molecules as described above, 
that attract monocytes and lymphocytes to this localised activated endothelium.  Not all 
macrophages  however,  are  transformed  into  foam  cells.    Some  act  to  promote 
inflammation in the artery. 
 
1.4.2    Atherosclerosis and Inflammation 
In addition to traditional risk factors, inflammatory factors also activate the endothelium 
resulting  in  endothelial  dysfunction.    Activation  by  cytokines  or  other  inflammatory 
mediators leads to increased expression of a variety of cell surface adhesion molecules as 
described above.  Endothelial dysfunction has been shown to correlate with inflammatory 
markers  and  other  accepted  markers  or  predictors  of  cardiovascular  disease,  such  as 
increased high-sensitivity C-reactive protein (hs-CRP) levels in patients with coronary   36 
artery disease [26].  C-reactive protein has been shown to stimulate the expression of 
VCAM-1  in  vitro  [27],  in  keeping  with  the  idea  of  endothelial  dysfunction  and 
inflammation. 
 
1.4.2.1  Clinical trials 
Nested case-control studies within the Multiple Risk Factor Intervention Trial [28], the 
Cardiovascular  Health  Study  [29],  the  Physicians‟  Health  Study  [30],  the  British 
Regional Heart Study [31], the Women‟s Health Study [32, 33], and the Helsinki Heart 
Study [34] showed that measurements of baseline levels of CRP predicted the risk of 
future  cardiovascular  death,  myocardial  infarction,  or  stroke.    In  the  MONICA 
(MONItoring of trends and determinants in Cardiovascular disease) Augsburg cohort, a 
study  of  over  900  men  between  the  ages  of  45  to  64  years,  CRP  was  significantly 
associated with the risk of coronary events during a follow up period of eight years, even 
after adjusting for potential confounders [35].  Elevation of the inflammation markers 
CRP  and  serum  amyloid  A  (SAA)  have  been  shown  in  a  subgroup  analysis  of  the 
Cholesterol and Recurrent Events (CARE) study to be associated with the highest risk of 
development  of  recurrent  non-fatal  myocardial  infarction  or  a  fatal  coronary  event, 
although this risk was attenuated becoming no longer significant among those patients 
randomised to statin treatment [36], which will be discussed further in section  1.6.2. 
 
1.4.2.2  C-Reactive Protein 
It  is  now  widely  recognised  that  atherosclerosis  is  a  specific  example  of  a  chronic 
inflammatory  response,  mainly  to  dyslipidaemia  and  other  risk  factors  as  described   37 
above.  The chronic inflammatory influence of hypercholesterolaemia is thought to be 
mediated  by  the    induction  of  cytokines  and  chemokines  [37],  up-regulation  of 
endothelial  adhesion  molecules,  and  immune  reactions  against  oxidised  moieties  on 
lipoproteins [38].  In keeping with this, atherosclerotic lesions contain abundant immune 
cells, particularly macrophages and T-cells, smooth muscle cells, and matrix components.  
Among the numerous inflammatory biomarkers, the largest amount of published data 
supports a role for C-reactive protein (CRP) not only as a robust and independent risk 
marker in the prediction of primary and secondary adverse cardiovascular events, with 
prognostic value exceeding that of LDL cholesterol [39], but also as an active participant 
in atherogenesis.   
 
CRP is a primitive acute phase inflammatory protein that is produced in the liver and 
released  in  response  to  acute  injury,  infection  or  inflammation,  and  in  particular  the 
inflammatory cytokine interleukin-6 (IL-6).  Discovered in 1930 by Tillet and Frances, 
measurement of CRP has become part of routine biochemical testing.  Its‟ name relates to 
the ability of this protein to precipitate pneumococcal C-polysaccharide in the presence of 
calcium,  and  it  is  a  member  of  a  family  of  proteins  called  the  pentraxins.  Several 
epidemiological  studies  have  shown  that  CRP  is  an  important  risk  factor  for 
atherosclerosis and coronary heart disease, and indeed higher levels of CRP have been 
shown to be related to increased risk of coronary events in patients with both stable [40] 
and unstable angina [41].  The most important studies to show that the addition of CRP to 
global risk assessment by the Framingham Risk Score (which is based on age, gender, 
hypercholesterolaemia  and  smoking  status)  leads  to  an  improved  prediction  of   38 
cardiovascular disease are MONICA [42], Cardiovascular Health Study (CHS) [43], and 
Women‟s  Health  Study  (WHS)  [39].  However,  the  mechanisms  underlying  this 
association  are  not  clear,  more  specifically,  whether  CRP  is  merely  a  marker  of  the 
inflammatory  response,  or  whether  it  plays  a  direct  role  in  the  pathogenesis  of 
atherosclerosis is uncertain. CRP has been demonstrated within the arterial plaque [44] 
and has also been shown to bind to LDL [45], thus potentially being entrapped in the 
intima by deposited lipids. It has also been shown to bind to complement factor C1q and 
factor H and activate the classical complement system [46].  Deposition of CRP in the 
arterial intima at sites of atherogenesis has been demonstrated to precede the appearance 
of monocytes, and has also been shown to be chemotactic for freshly isolated human 
blood monocytes which express a CRP receptor [44] supporting the notion that CRP 
itself may directly contribute to early atherogenesis.   
 
CRP has also been found to cause adverse changes to cultured endothelial cells, resulting 
in  up-regulation  of  the  cellular adhesion  molecules, intercellular adhesion  molecule-1 
(ICAM-1) and VCAM-1 [27].  CRP also directly affects endothelial function by altering 
nitric oxide (NO) bioavailability.  Nitric oxide is synthesised by the endothelial nitric 
oxide synthase enzyme (eNOS), and acts locally as a potent vasodilator.  CRP down 
regulates eNOS transcript and destabilizes eNOS mRNA, with resultant decreases in both 
basal and stimulated NO release [47].  It has also been shown to facilitate endothelial cell 
apoptosis  and  inhibit  angiogenesis  [47]  and  in  a  rat  balloon  injury  model,  local 
administration  of  CRP  increased  neointimal  formation,  which  was  attenuated  by 
angiotensin  receptor  blockade  [48].  More  recently,  human  aortic  endothelial  cells   39 
cultured with CRP showed up regulation of Lectin-like oxidized LDL receptor-1 (LOX-
1), which binds oxidized LDL, generating superoxide anions, decreasing NO production, 
and activating the transcription factor nuclear factor κB (NF-κB) [49].  In addition this 
receptor LOX-1 increases monocyte binding to endothelial cells.   
 
The increased expression of adhesion  molecules  in  the vascular wall is  an important 
factor in the development of atherosclerosis and may enhance the local inflammatory 
response within atherosclerotic plaques by recruiting monocytes and lymphocytes.  In 
addition, the up regulation of the LOX-1 receptor and the resulting effects leads to an 
endothelial  cell  phenotype  that  is  pro-inflammatory,  pro-oxidant  and  atherogenic.  
Therefore,  lowering  CRP  levels  may  have  beneficial  effects  on  the  evolution  of 
atherosclerosis and may reduce the risk of coronary events.  This will be discussed in 
detail in section 1.6.2. 
 
1.4.3    Atherosclerosis and the immune system   
Recently, the current concept of atherosclerosis as an inflammatory disease has allowed 
the description of atherosclerosis as a chronic inflammatory autoimmune-like disease that 
occurs  in  the  context  of  enhanced  plasma  lipid  levels  [50-52].    The  inflammatory 
component of atherosclerosis can be thought of as an innate immune response involving 
monocytes  and  macrophages  which  are  responding  to  the  excessive  uptake  of 
lipoproteins,  and secondly an adaptive immune response involving antigen-specific T 
cells. 
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The innate immune system is critical to the initial inflammatory response, and primarily 
involves the monocyte-macrophage as described above.  There is increasing evidence that 
other immune cells may also have a role, including natural killer (NK) cells, dendritic 
cells, mast cells, and B cells [53].  NK cells will be discussed in detail below.  Dendritic 
cells play an important role in antigen presentation, expressing high levels of scavenger 
receptors  and  class  II  major  histocompatibility  complexes  (MHCs),  which  present 
antigens to cells of the adaptive immune system.  Additionally, mast cells when activated 
release histamine, leukotrienes, platelet-activating factor, proteases, and cytokines. 
 
The adaptive immune system  responds  to  endogenous  neoantigens,  such as  apoptotic 
cells or oxidised LDL [38], or exogenous antigens, resulting in the activation of T-cells 
and B-cells.  A T cell response is generated when the naïve T cell encounters an antigen-
presenting cell (APC) that presents an antigenic peptide for which the T cell is specific.  
CD8
+  T  cells  recognise  peptides  presented  on  MHC  class  I,  whereas  CD4
+  T  cells 
recognise MHC class II [54].  The primary activation takes place in secondary lymphoid 
organs such as the peripheral lymph nodes to which dendritic cells that have ingested 
antigens  migrate.  The  T cell then leaves  and  migrates to  non-lymphoid  tissue for a 
second activation by APCs that present the same antigen.  Therefore naïve T cells are 
rarely found in non-lymphoid tissues.  This also applies to atherosclerotic plaques, where 
most T cells that are found in human lesions are effector or memory T cells [55, 56].  It 
has also been shown that the proportion of activated T cells increase with severity of 
coronary disease [57].  The mechanism for T-cell and macrophage entry into the arterial 
wall are similar, however specific antigens, such as those mentioned, and also microbial   41 
antigens, are needed to activate the T-cell.  Because the most prevalent type of T-cell in 
the  lesion  is  the  CD4
+  Th1  cell,  effector  responses  to  antigenic  stimulation  include 
secretion of interferon-γ (IFN-γ), which results  in  the activation of macrophages and 
endothelial cells.   
 
1.4.3.1  T-cells 
Atherosclerotic lesions are characterised by an infiltration of leukocytes at all stages of 
disease progression.  The presence of T cells in human atherosclerotic plaques was first 
described in 1985 [58], and in human and animal models of atherosclerosis the most 
prominent cells infiltrating evolving lesions are macrophages and T-cells [59, 60].  CD4
+ 
T cells are the predominant T cell subset in atherosclerotic lesions in apoE
-/- and LDLR
-/- 
mice  [61].  Mice  lacking  adaptive  immunity  (apoE
-/-/scid/scid  mice)  have  reduced 
atherosclerosis  [62],  and  reconstitution  of  the  immunodeficient  scid/scid  mice  with 
transfer of CD4
+ T cells from atherosclerotic donors accelerates disease [62], suggesting 
that CD4
+ T cells play a proatherogenic role.  Additionally, depletion of CD4
+ T cells by 
depleting anti-CD4 antibodies reduced fatty streak development in C57BL/6 mice fed an 
atherogenic diet [63].  There is less evidence to define the exact role of CD8
+ T cells in 
atherogenesis.  One study showed that ApoE
-/- CD8
-/- mice showed no change in lesion 
formation compared with ApoE
-/- mice [64], although CD8
+ T cells have been shown to 
promote atherogenesis when triggered by antigenic stimulation [65].   
 
T cell receptor (TCR) ʱβ
+ T cells are present in much larger numbers than TCR γʴ
+ cells 
in atherosclerotic lesions and therefore would seem to have a more important role in   42 
atherogenesis.  Indeed TCR γʴ
+ cells represent less than 5% of the T cell population in 
the peripheral human blood [66], although they are enriched in specific tissues such as 
skin, spleen, gastrointestinal mucosa, and also at sites of chronic inflammation such as 
the joint synovium in inflammatory arthritis [67].  TCRʱβ-deficient apoE
-/- mice have 
been shown to develop less atherosclerosis, whereas mice that were deficient in TCR γʴ
+ 
cells were only marginally affected [64].      
 
 
Whilst  there  is  abundant  evidence  to  support  the  participatory  role  of  T-cells  in 
atherosclerosis,  the  importance  of  other  cells  of  the  innate  immune  system  remains 
undefined.  More recently, two less prominent immune components – natural killer (NK) 
cells and natural killer T (NKT) cells have also been shown to contribute.   
 
1.4.3.2  NKT cells 
NKT cells are a subset of lymphocytes characterised by that fact that they have surface 
markers and functions of both T cells and NK cells.  Makino et al coined the term NKT 
cells in 1995 [68] to describe a heterogeneous subset of mouse T lymphocytes that share 
characteristics with NK cells and appear to function by linking the innate and adaptive 
immune systems.  A number of criteria have developed to define this class of lymphocyte 
as different from NK cells; (i) the ability of NKT cells to show autoreactivity to the non-
classical MHC molecule CD1d; (ii) the expression of a specific TCR reservoir of the 
NKT cell; (iii) the presence of NK cell receptors; (iv) the responsiveness of the cell to the 
synthetic CD1d ligand, ʱ-galactosylceramide (ʱ-GalCer), which is derived from marine 
sponges  [69].  Once  activated,  all  NKT  cell  populations  have  the  capacity  to  exert   43 
immunoregulatory functions by releasing large quantities of T helper (Th) 1 or Th 2 
cytokines.   
 
Given that NKT cells link the two arms of the immune system it would seem logical that 
they participate in the pathogenesis of atherosclerosis.  In human atherosclerotic lesions, 
macrophage foam cells have been shown to strongly express all four human CD1 proteins 
(CD1a, -b, -c, and –d) [70].  The TCR Vʱ14Jʱ18 mRNA of NKT cells has been detected 
within atherosclerotic lesions in mice [71].  Also activation of NKT cells by feeding mice 
an  atherogenic  diet  can  decrease  NKT  cell  number  in  the  liver  and  spleen  [71].  
Interestingly, NKT cells were not found in the vascular wall in control mice, which may 
suggest that the development of the atherosclerotic lesions involves recruitment of NKT 
cells from peripheral blood into atherosclerotic plaques.  This group has also shown that 
NKT cells are decreased in the peripheral blood of patients with both stable and unstable 
angina [72].  One possible explanation for this observation is that activated NKT cells 
secrete tumour necrosis factor-ʱ, IFN-γ, and other cytokines, and subsequently undergo 
activation-induced apoptosis [66].  Alternatively, it has also been reported that activation 
of NKT cells may instead lead to a down regulation of the TCR and NK1.1/cd161 to 
prevent over stimulation [73].  Other studies supporting the proatherogenic role of NKT 
cells have shown that in apoE
-/- mice, exogenous administration of ʱ-GalCer increased 
atherosclerosis,  whereas  CD1d-deficient  mice  showed  reduced  atherosclerotic  lesion 
development [71, 74].  The ʱ-GalCer-driven increase in atherosclerosis was accompanied 
by a dramatic increase of IFN-γ, ʱ-GalCer and IL-4 by NKT cells [75].  Further evidence 
comes from in vitro studies, where macrophages incubated with oxidised LDL display   44 
increased expression of CD1d, which in turn can induce NKT cells to produce IFN-γ 
[71].  Whilst the exact role of NKT cells has not yet been defined, it does appear that 
CD1d-mediated activation of NKT cell leads to expression of inflammatory cytokines 
that drive the progression of atherosclerosis. 
 
1.4.3.3  NK cells 
NK cells are a crucial component of the innate immune system against virally infected 
cells and neoplastic transformation.  They have cytolytic ability and also provide an early 
source of immunoregulatory cytokines [76].  NK cells participate in innate immunity 
through the production of cytokines such as IFN-γ, TNF-ʱ, IL-10, and GM-CSF, as well 
as  various  chemokines  that  generate  an  immediate  immune  response.    They  have 
spontaneous  cytotoxic  activity  against  some  virally-infected,  leukaemic,  and  other 
cancerous  cells,  and  also  mediate  antibody-dependent  cellular  cytotoxicity  through 
FcγRIII (CD16), a receptor molecule on the surface of NK cells that specifically binds 
the Fc part of an antibody [77], or antibody-coated (opsonized) target and signals through 
associated  subunits  containing  an  immunoreceptor  tyrosine-based  activation  motif 
(ITAM) to direct antibody-dependent cellular cytotoxicity [78].  Additionally, IFN-γ can 
elicit  innate  and  adaptive  immune  responses  by  increasing  the  expression  of  major 
histocompatibility  complex  (MHC)  class  I  and  II  molecules  and  by  activating 
macrophages.  The cytotoxic function of NK cells is the result of a balance between 
activating  and  inhibitory  signals  delivered  by  specific  membrane  receptors  [77,  79].  
Thus, NK cells express receptors (NKRs) that can be either activatory or inhibitory of 
NK cytotoxicity.  Three major superfamilies of NKRs have been described in humans –   45 
the killer cell Ig-like receptor (KIR) superfamily, which primarily recognises HLA-A, -B, 
and  –C;  the  C-type  lectin  superfamily,  which  includes  CD94  and  NKG2  receptors, 
recognising HLA-E; and a class of natural cytotoxicity receptors (NCRs) with unknown 
ligands [79].  The inhibitory receptors specifically interact with MHC class I molecules, 
inhibiting killing of target cells bearing the appropriate class I allotypes, in other words, 
these receptors are crucial for distinguishing normal cells from foreign or transformed 
cells. 
 
NK cells comprise approximately 10-15% of all circulating lymphocytes [79] and are 
defined phenotypically by their expression of CD56 and lack of expression of CD3 [80].  
Additionally, NK cells are not a homogeneous population. It has been recognised that 
two  distinct  populations  of  human  NK  cells  can  be  identified,  based  upon  their  cell 
surface density of the CD56 antigen.  Resting CD56
dim cells comprise 90% of total NK 
cells and are the more cytotoxic subset, and also the mature NK cell subset [79, 81].  The 
CD56
bright  NK-cell  subset  (comprising  the  remaining  10%)  mediates  low  or  no 
cytotoxicity but has the capacity to produce large amounts of various immunoregulating 
cytokines [80], and are considered immature NK cells [82].  In contrast to NKT-cells, NK 
cells do not express TCR molecules.  The NK cell subsets also show differences in their 
NK receptor repertoires, for example, most CD56
bright NK cells lack expression of CD16, 
and as would be expected, greater than 95% of CD56
dim NK cells are CD16
bright [79]. 
 
The roles of NK-cell subsets in vivo is not entirely clear.  For example, normal ratios of 
NK-cell subsets are altered during aging – numbers of CD56
dim NK cells are expanded in   46 
elderly populations, whereas there is no significant change in the numbers of CD56
bright 
NK cells [81, 83, 84].  Functionally, NK cells in the elderly are less responsive to IL-2-
induced  proliferation  [85],  perhaps  as  a  consequence  of  and  increased  percentage  of 
CD56
dim NK cells.  Additionally, in patients with chronic heart failure, NK cells have 
been shown to be present in lower circulating numbers, and to exhibit impaired cytolytic 
function [86]. 
 
The  potential  role  of  NK  cells  in  atherosclerosis  has  been  receiving  more  attention 
recently.  NK cells have been detected in mouse aortic atherosclerotic-like lesions [87], 
and  more  recently  in  human  atherosclerotic  lesions  [88,  89],  providing  convincing 
support of the participation of NK cells in the atherogenic process.  More in depth study 
has been hampered by the lack of an animal model that is selectively deficient in NK 
cells.  Initial studies used the beige mutation in mice and found conflicting results [90, 
91].  However, the mutation in the beige mouse model, which involves the Lyst gene, 
results in a complicated phenotype that is more complex than decreased NK cell activity 
[92,  93].    Recently,  transgenic  mice  have  been  developed  with  defective  natural 
cytotoxicity  and  a  selective  deficiency  in  functional  NK1.1
+  CD3
-  cells,  while 
maintaining functionally normal T and B lymphocytes [94].  Whitman et al have shown 
that ldl-r-/- mice deficient in functional NK cells, fed an atherogenic diet (cholesterol and 
saturated fat-enriched) had a statistically significant reduction in atherosclerotic lesions 
[87].  This was achieved by transplanting the bone marrow of lethally irradiated ldl-r-/- 
mice with bone marrow cells obtained from Ly49A transgenic mice or gender-matched 
nontransgenic littermates.     47 
 
There  have  been  few  comparable  studies  in  human  atherosclerotic  disease.  NK  cell 
activity in humans has been studied in patients with vascular disease with conflicting 
results.  A significant reduction in circulating NK cells with a concomitant decrease in 
NK cell function has been found in patients with coronary artery disease when compared 
with healthy controls, although the actual cytotoxicity per NK cell did not differ between 
groups, suggesting that the NK cell defect in these patients is a quantitative one [95].  The 
authors observed that this may in part be due to long term treatment of patients with 
coronary artery disease with statins and beta-blockers.  However, they suggested that 
conversely  a  loss  of  NK  cell  activity  might  lead  to  increased  susceptibility  to 
atherosclerotic-related pathogens with resulting consequences such as increased plaque 
burden and enhanced formation of vulnerable plaques [96].  This group went on to find 
increased  percentages  of  apoptotic  NK  cells  in  peripheral  blood  of  coronary  artery 
disease  patients  when  compared  with  healthy  subjects,  possibly  related  to  increased 
oxidative stress [97].  The mechanism of NK cell deficiency influencing atherosclerosis 
is unclear, although the influence that NK cells have on multiple cytokines, in particular 
IFN-γ undoubtedly plays an important role.  Interferon gamma has been implicated in the 
atherosclerotic process directly and indirectly and will be discussed further below. 
 
In contrast, it has also been shown that patients with abdominal aortic aneurysms (AAA) 
have significantly higher percentages of peripheral blood NK cells than patients with 
peripheral vascular disease and control subjects [98].  This is of particular relevance as 
AAA can be thought of as a chronic inflammatory disorder of uncertain aetiology.  Not   48 
only were there higher numbers of NK cells, but the NK cells from patients with an AAA 
had increased cytotoxicity, and CRP values.  CRP will be discussed in further detail 
below. 
 
1.5    Cell Membrane Lipids 
 
The Singer-Nicholson fluid mosaic concept remains the classical model of how the cell 
membrane is organised [99], proposing that the lipid bilayer functions as a neutral two-
dimensional solvent.  However, it has been found that lipids exist in several phases in 
model  lipid  bilayers,  including  gel,  liquid-ordered,  and  liquid  disordered,  in  order  of 
increasing  fluidity.  The  lipid  composition  of  the  cell  membrane  is  highly  complex, 
consisting of up to 500 different lipid species, cholesterol being a major lipid component.  
Eukaryotic  cells,  viewed  in  transverse  section,  are  organised  in  heterogeneous  multi-
layers.  This begins with the extracellular matrix, followed by a semipermeable lipid 
bilayer, the plasma membrane consisting of lipids and embedded proteins, and ending in 
a  cytoskeletal  meshwork  loosely  attached  to  the  plasma  membrane  via  anchoring 
proteins.  More recently, the lateral organisation of the cell surface has received the most 
interest. 
   
1.5.1   Lipid Rafts   
Since the fluid mosaic model of the plasma membrane, numerous studies revisiting the 
architecture of the plasma membrane have provided a much more complex picture of the 
cell  surface  organisation.    Of  particular  interest  is  the  relatively  recent  proposal  of   49 
membrane  lipid  rafts.    Lipid  rafts  are  dynamic  assemblies  of  proteins  and  lipids  – 
microdomains  -  that  float  freely  within  the  liquid-disordered  bilayer  of  cellular 
membranes, but have the ability to cluster, forming larger ordered platforms [100].  A 
comprehensive definition was adopted at the Keystone Symposium on Lipid Rafts and 
Cell  Function,  2006;  “Membrane  rafts  are  small  (10-200nm),  heterogeneous,  highly 
dynamic,  sterol-  and  sphingolipid-enriched  domains  that  compartmentalise  cellular 
processes.   Small rafts can sometimes be  stabilized to  form  larger platforms  through 
protein-protein and protein-lipid interactions”.  These microdomains are in liquid ordered 
phase  and  are  resistant  to  solubilisation  with  non-ionic  detergents.  Lipid  rafts  are 
enriched in glycosphingolipids, sphingomyelin, and cholesterol, creating an environment 
which  attracts  and  segregates  specific  proteins,  while  excluding  others  [100].  The 
attachment  of  lipid  anchors,  particularly  those  containing  saturated  fatty  acyl  chains, 
facilitates  interaction  with  the  liquid-ordered  phase,  leading  to  localisation  of  the 
modified  protein  to  the  lipid  raft.    Proteins  with  raft  affinity  include 
glycosylphosphatidylinositol (GPI)-anchored proteins [101, 102], proteins modified by 
dual acylation, typically myristoylation and/or palmitoylation such as Src-family kinases, 
or the ʱ-subunits of heterotrimeric G proteins [103].  Rafts have been associated with a 
variety  of  signalling  and  sorting  properties  of  many  membrane  components,  and 
conversely,  cholesterol  depletion  has  been  shown  to  disturb  sorting  and  signalling 
properties  of  many  membrane  proteins.  The  proposed  platforms  are  composed  of 
cholesterol and sphingolipids in the outer exoplasmic leaflet, where the preponderance of 
saturated hydrocarbon chains in cell sphingolipids allows for cholesterol to be tightly 
intercalated, connected to phospholipids and cholesterol in the inner cytoplasmic leaflet   50 
of  the  lipid  bilayer  [104].    Cholesterol  is  thought  to  act  as  a  spacer  between  the 
hydrocarbon chains of the sphingolipids and to function as a dynamic glue that holds the 
raft assembly together. 
 
 
 
 
Figure 1.2  Organisation of the plasma membrane and microdomains.  (A) Intracellular 
space or cytosol; (B) Extracellular space or vesicle/Golgi apparatus lumen; (1) Non-raft 
membrane; (2) Lipid raft; (3) Lipid raft associated transmembrane protein; (4) Non-raft 
membrane protein; (5) Glycosylation modifications (on glycoproteins and glycolipids); 
(6) GPI-anchored protein; (7) Cholesterol; (8) Glycolipid. 
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Biological functions attributed to lipid rafts include endocytosis, pinocytosis, and sorting 
and transport of proteins, however the most important role of rafts at the cell surface may 
be  their  function  in  signal  transduction.  It  has  been  suggested  that  rafts  form 
concentrating platforms for individual receptors, activated by ligand binding [105].  Raft 
binding recruits proteins to a new microdomain, where the phosphorylation state can be 
modified by local kinases and phosphatases, resulting in downstream signalling.  Upon 
receptor stimulation, small lipid rafts may coalesce into bigger structures or become more 
rigid,  possibly  by  associating  to  the  cytoskeleton.    Specialised  microdomains  called 
„caveolae‟ constitute a distinct subset of lipid rafts.  They are cell surface flask-shaped 
invaginations that contain caveolin as a major structural protein [106].  Lipid rafts have a 
relatively short lifespan, however caveolae appear to be more stable structures with a 
lower turnover rate.  Caveolae and lipid rafts not only differ in stability, shape, lifespan 
and protein content, but also in proposed roles. 
 
1.6    Statins 
 
The  introduction  of  3-hydroxy-3-methylglutaryl  coenzyme  A  (HMG-CoA)  reductase 
inhibitors, or statins, in the late 1980s represented a breakthrough in the treatment of 
hyperlipidaemia and CVD in both primary and secondary prevention of CVD.  In recent 
years, statins have emerged as the most important class of lipid lowering agents.  They 
are  potent  inhibitors  of  cholesterol  biosynthesis  through  inhibition  of  HMG-CoA 
reductase, the rate-limiting step of cholesterol synthesis, resulting in a dramatic reduction   52 
in circulating LDL-cholesterol.  In addition, the reduction of LDL-cholesterol leads to up-
regulation of LDL receptors on the cell membrane and increased LDL clearance.   
 
1.6.1   Role in cardiovascular disease 
Several landmark clinical trials, such as the Scandinavian Simvastatin Survival Study 
(4S)  (the  first  randomised  controlled  trial  to  show  significant  risk  reduction  in 
cardiovascular mortality in patients with coronary artery disease) [17], Cholesterol and 
Recurrent  Events  (CARE)  [18],  West  of  Scotland  Coronary  Prevention  Study 
(WOSCOPS) [19], Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) 
[107], Air Force/Texas Coronary Prevention Study (AFCAPS/TexCAPS) [108], and the 
Heart  Protection  Study  (HPS)  [109],  have  demonstrated  beyond  doubt  the  beneficial 
effects of statin therapy for both primary and secondary prevention of cardiovascular 
disease.  Lowering of serum cholesterol has been thought to be the primary mechanism 
underlying the therapeutic benefits of statin therapy in CVD.  In the Atorvastatin versus 
Revascularisation Treatment (AVERT) study [110], aggressive cholesterol reduction with 
high  dose  atorvastatin  was  compared  to  coronary  angioplasty  in  patients  with  stable 
angina.  Those in the atorvastatin group had a significantly longer time to first ischaemic 
event, as well as a lower incidence of ischaemic events (although this was not statistically 
significant).  In keeping with the findings of this study, other trials of angioplasty versus 
medical therapy in stable angina have not shown any benefit in terms of reduction of 
incidence of myocardial infarction or coronary mortality [111, 112].  Given the current 
understanding  of  atherosclerosis  as  an  inflammatory  disease,  some  of  the  benefits  of   53 
statin therapy are likely to be due to anti-inflammatory effects which will be discussed 
further below. 
 
1.6.2  Clinical evidence of anti-inflammatory and pleiotropic effects 
The strong association between serum cholesterol levels and coronary artery disease has 
led to the general assumption that the mechanism underlying the beneficial effects in 
CVD of statins is cholesterol reduction.  However, subgroup analyses of large clinical 
trials have highlighted the possibility that the beneficial effects of statins extend beyond 
cholesterol reduction.  Subgroup analysis of the WOSCOPS and CARE studies found 
that despite comparable serum cholesterol levels among the statin-treated and placebo 
groups, the statin-treated patients had a significantly lower risk of coronary heart disease 
than age-matched placebo-controlled individuals [113].  Statins have also been found to 
reduce  cardiovascular  events  in  normo-cholesterolaemic  patients  with  coronary  heart 
disease  or  cardiovascular  risk  [108].    Further  strength  is  added  to  the  possibility  of 
cholesterol-independent  benefits  in  that  meta-analyses  of  lipid-lowering  trials  suggest 
that the risk of myocardial infarction in statin treated patients is significantly lower than 
in  patients  treated  with  other  lipid-lowering  agents,  despite  comparable  reduction  in 
serum cholesterol levels [114, 115].  In line with this, the level of efficacy and early 
treatment benefits as a result of statin therapy have so far been greater than the beneficial 
effects of non-statin lipid-lowering therapies.  Angiographic studies in patients on statins 
have found that the reduction in lesion progression achieved was too mild to fully explain 
the reduced mortality and reduction in the incidence of coronary events [116], attributing 
the beneficial effects to plaque stabilization and remodelling.  In the Myocardial Ischemia   54 
Reduction With Aggressive Cholesterol Lowering (MIRACL) trial [117], a benefit in 
reduction  of  recurrent  ischaemic  events  was  seen  as  early  as  16  weeks  after  acute 
coronary ischaemia, a period which may be too short for appreciable changes in vascular 
remodelling to have occurred.  These observations have led to the consensus that statins 
indeed  exert  cholesterol  independent,  or  “pleiotropic”  effects.  Various  inflammatory 
markers have been studied to analyse the effect of statins on the inflammatory state.  As 
discussed  in  section  1.4.2.2  high  sensitivity  CRP  (hsCRP)  has  been  widely  studied.  
Human studies have shown that along with a reduction in cholesterol, statin treatment 
leads to a reduction in CRP [118-120].  In a recent trial, long-term treatment with statins 
was associated with a reduction in serum CRP levels and a better clinical outcome after 
acute myocardial infarction [119].  
 
It also seems that the higher the dose of statin, the greater the beneficial effects [3, 117, 
121].    However,  it  is  difficult  to  ascertain  whether  the  benefits  are  due  to  lower 
cholesterol levels or to greater pleiotropic effects.  Statins also appear to have therapeutic 
benefits in diseases that are unrelated to elevated serum cholesterol levels, for example 
rheumatological  diseases  [122],  stroke  [123],  Alzheimer  disease  [124],  and  multiple 
sclerosis [125].  Additionally, there is interest in the potential immunomodulatory effect 
of statins, in particular with regards to solid organ transplantation [126, 127]. 
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1.6.3       Mechanism of action 
 
1.6.3.1   Statins and cholesterol lowering 
 
The majority of serum cholesterol is derived from hepatic synthesis, and the predominant 
pharmacological  site  of  action  in  terms  of  lipid  lowering  is  the  liver.    HMG-CoA 
reductase  is  the  crucial  rate-limiting  enzyme  in  the  cholesterol  biosynthetic  pathway, 
inhibition of this enzyme by statins results in a dramatic reduction in circulating LDL-
cholesterol.    Additionally,  statins  result  in  up  regulation  of  the  LDL  receptor  and 
therefore increased LDL clearance.  Until recently, lowering of serum cholesterol has 
been thought to be the primary mechanism underlying the therapeutic benefits of statin 
treatment in cardiovascular disease. 
 
1.6.3.2   Statins and anti-inflammatory effects 
In addition to the clinical evidence outlined above, in vitro studies uniformly support the 
anti-inflammatory role of statins.  As already discussed in section 1.4.1 one of the earliest 
stages in atherogenesis is the adhesion of monocytes to the endothelium as a result of 
various  adhesion  molecules.    Statins  have  been  found  to  interfere  with  this 
proinflammatory pathway of adhesion and migration at the levels of protein expression 
and function.  Lovastatin and cerivastatin have been found to reduce the expression of 
CD11b-dependent  adhesion  of  monocytes  and  inhibit  the  adhesion  of  leukocytes  to 
endothelial  cells  [128,  129].    Statins  selectively  inhibit  leukocyte  adhesion  by  direct 
interaction with the leukocyte-function antigen-1 (LFA-1) [130].  Atorvastatin, lovastatin,   56 
pravastatin, fluvastatin, and simvastatin reduce expression of the chemokine monocyte 
chemoattractant protein-1 (MCP-1) [131, 132].  Migration of monocytes/macrophages as 
well  as  vascular  wall  cells  such  as  endothelial  and  smooth  muscle  cells  depends  on 
adhesion molecules and chemokines, but also on the activity of matrix metalloproteinases 
(MMPs), matrix-degrading enzymes [133] which may participate in weakening of the 
fibrous  cap, making atherosclerotic lesions more likely to  rupture.  Statins lower the 
expression  and  function  of  a  broad  range  of  MMPs  in  many  cells  involved  in 
atherogenesis  [134,  135].    Additionally  statins  may  have  a  protective  role  once  the 
atherosclerotic  plaque  has  ruptured  by  diminishing  expression  of  procoagulant  tissue 
factor in macrophages [135] and endothelial cells [136], promoting fibrinolytic activity 
[137], and modulating platelet function [138]. 
 
1.6.3.3   Statins and immunomodulation 
The triggers of the inflammatory response observed in atherosclerosis have not yet been 
completely defined.  It is suggested that autoantigens expressed in the atherosclerotic 
plaque may induce an immune response, and possible antigens include heat-shock protein 
70  [139],  LDL  and  non-LDL  oxidative  epitopes  [140],  and  infectious  agents  [141].  
Constitutive  expression  of  MHC-II  molecules  is  restricted  to  professional  antigen 
presenting cells (APC), although several cell types can express MHC-II molecules upon 
cytokine stimulation, in  particular by  IFN-γ.  Statins are able to  inhibit this  MHC-II 
expression on a variety of cell types, particularly IFN-γ induced expression of MHC-II 
molecules on endothelial cells, macrophages and microglia [142-144].  Statins are also 
able  to  suppress  constitutive  and  IFN-γ  induced  expression  of  the  co-stimulatory   57 
molecules  CD40,  CD80  and  CD86  on  lymphocytes,  macrophages,  microglia  and 
endothelial cells, and inhibit the up regulation of these molecules during maturation of 
dendritic cells (DC) [144-147].  Statin treatment has consequently been shown to result in 
suppression of DC  maturation and therefore their ability to  properly stimulate T cell 
proliferation [146].  In addition to MHC-TCR and co-stimulatory molecule interactions, 
cytokine signalling by APC is also an important factor in T cell activation.  The effect of 
statins on cytokines has been widely studied both in vitro and in vivo.  They have been 
found to inhibit the production of pro-inflammatory cytokines such as IFN-γ, TNF-ʱ, and 
IL-6 [148, 149], and additionally reduce the secretion of other inflammatory mediators as 
described above. 
 
Different  effects  of  statins  on  lymphoid  cell  function  have  been  shown.    T  cell 
proliferation in vitro is suppressed and cytokine production inhibited [144, 150, 151].  
Natural  killer  cell  function  has  been  shown  to  be  reduced  following  treatment  with 
simvastatin  in  healthy  volunteers  both  ex  vivo  and  in  vitro.    In  patients  with 
cardiovascular  disease,  both  T  cell  proliferation  and  NK  cell  cytotoxicity  have  been 
shown to be reduced following statin treatment [150, 152, 153]. 
 
1.6.3.4   Statins and isoprenoid biosynthesis 
The cholesterol biosynthetic pathway has been described in section 1.3.1.  The inhibition 
of mevalonate biosynthesis by statins does not solely lead to lowered cholesterol levels, 
but  also  to  reduced  production  of  intermediate  products  of  the  mevalonate  pathway 
(Figure 1) such as FPP and GGPP.  This leads to inhibition of various cellular processes   58 
that  depend  on  the  synthesis  of  these  molecules.    The  role  of  these  isoprenoid 
intermediates  is  as  lipid  attachments  for  the  post-translational  modification 
(isoprenylation) of a variety of proteins important in intracellular signalling, including the 
γ subunit of heterotrimeric G proteins and the small GTP-binding protein Ras, and Ras-
like proteins such as Rho and Rac.  Isoprenylation is a mechanism of post-translational 
lipid  modifications  leading  to  targeting  of  proteins  to  the  cell  membrane  of  other 
subcellular compartments.  Isoprenylation is important for proper membrane localisation 
and function of these small GTP-binding proteins [154] and members of the Ras and Rho 
GTPase  family  are  the  major  substrates  for  isoprenylation  [155].  The  Rho  signal 
transduction  pathway  is  involved  in  the  activation  of  inflammatory  cytokines  and 
chemokines.  Rho also plays an important role in the formation and maintenance of the 
actin cytoskeleton and thereby affects intracellular transport, mRNA stability, and gene 
transcription.  The Ras proteins are responsible for cell proliferation and hypertrophy, 
whereas  the  Rac  proteins  are  involved  in  the  production  of  reactive  oxygen  species 
through activation of NADPH oxidase.  Inhibition of HMG-CoA reductase by statins 
results in a decrease in farnesylated and geranylgeranylated proteins, and a subsequent 
dose-dependent reduction in downstream signalling pathways mediated by Rho, Ras, and 
Rac.  Statins have been shown to induce changes in the actin cytoskeleton and assembly 
of  focal  adhesion  complexes  by  inhibiting  RhoA  and  Rac1  isoprenylation  [10].  
Inhibition of RhoA by statins also increases eNOS expression and decreases severity of 
cerebral ischaemia in a mouse model of ischaemic stroke [156].  Statins also increase the 
expression  of  tissue-type  plasminogen  activator  and  inhibit  the  expression  of 
plasminogen  activator  inhibitor-1  [137]  and  endothelin-1  by  mechanisms  involving   59 
inhibition of geranylgeranylation [157].  As Ras and Rho also regulate the cell cycle, the 
antiproliferative  effects  of  statins  may  act  via  this  mechanism,  indeed  statins  inhibit 
vascular smooth muscle cell proliferations in transplant-associated arteriosclerosis [152] 
and may have clinical benefits in inhibiting certain breast cancers [158].  Additionally, 
statin  inhibition  of  Rac1  geranylgeranylation  and  Rac1-mediated  NAD(P)H  oxidase 
activity attenuates angiotensin II induced reactive oxygen species production in vascular 
smooth muscle cells and cardiac myocytes [159, 160].  Finally, statins have been shown 
to affect T cell proliferation by reducing the functional activity of Ras-dependent ERK 
pathways and Rho-dependent p38 activation [151].       
 
1.6.3.5   Statins and lipid rafts 
As  discussed  in  section  1.5,  cholesterol  plays  an  important  role  in  the  intracellular 
transport of proteins to the cell membrane.  Within the cell membrane, lipid rafts play an 
important role in the recruitment and concentration of cell signalling molecules to the 
plasma  membrane,  and  have  important  roles  in  both  T  and  B  cell  signalling.    As 
cholesterol  is  one  of  the  major  components  of  lipid  rafts,  statin  treatment  leads  to 
disruption of these rafts [105, 145, 153].  Further evidence for this theory that statins have 
some of their actions by causing the disruption of lipid rafts, comes from studies showing 
that  statin  treatment  of  various  cell  types  does  not  affect  membrane  expression  of 
molecules known not to be associated with lipid rafts such as CD4 or the  transferrin 
receptor (CD71) [145].  It has also been shown that in vitro statin treatment results in 
disruption  of  lipid  rafts,  resulting  in  impaired  Fcγ-receptor  signalling  at  the  level  of 
tyrosine kinase activation [161] and more recently, statin treatment of NK cells in vitro   60 
caused reduction of NK cytotoxicity and reduction of lipid rafts [153], suggesting lipid 
raft disruption as a potential mechanism for some of the pleiotropic effects of statins.  
Further  support  for  this  has  been  shown  where  simvastatin  treatment  of  healthy 
volunteers lead to a reduction in lymphocyte lipid raft levels [150].   With cell signalling 
molecules  concentrated  within  lipid  rafts,  their  disruption  results  in  impairment  of 
immune  receptor  signalling,  reduced  activation  of  downstream  signal  transduction 
cascades  important  for  the  induction  of  inflammatory  mediators,  thereby  affecting 
immune activation. 
 
1.7  Chronic Kidney Disease 
 
Chronic kidney disease (CKD) has been defined as persistent kidney damage (confirmed 
by renal biopsy or markers of kidney damage) and/or glomerular filtration rate (GFR) 
<60 mL/min/1.73m
2 for longer than three months [162].  CKD is a large and increasing 
problem worldwide, in fact using the above definition, there are an estimated 11 million 
individuals and rising with CKD [162].  With our aging population, the rates of treated 
end-stage renal disease (ESRD) in the elderly has increased by more than 50% over the 
last decade [163].  Whilst only a minority progress to ESRD, the significance of CKD is 
gaining increasing importance following the recognition that even mild renal impairment 
is associated with higher mortality from any cause [164-167], but in particular, from 
cardiovascular causes [165, 166, 168, 169].  Indeed, patients with CKD have a higher 
probability of death than of receiving renal replacement therapy. 
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1.7.1  CKD and cardiovascular disease 
We now know that cardiovascular disease is the leading cause of death in patients with 
CKD [170].  The cardiovascular mortality rate in dialysis patients is approximately 30 
times the risk in the general population and remains 10 to 20 times higher even after 
stratification for age, gender, and presence of diabetes.  Indeed cardiovascular disease 
accounts for more than half the deaths in patients with ESRD.  The high incidence of 
cardiovascular disease is due in part to a high incidence of traditional cardiovascular risk 
factors such as diabetes, hypertension, LVH, anaemia, advanced age, and 
hypercholesterolaemia.  Additionally, there are factors that are unique to this patient 
population, such as vascular calcification, uraemic toxins, hyperphosphataemia, 
hyperhomocysteinaemia, chronic inflammation, and oxidative stress (Table 5).  
Additionally, decreased glomerular filtration rate has also been shown to be a risk factor 
for cardiovascular disease [168, 171] and it seems that the risk of death is inversely 
proportional to the GFR [172].     
 
In recent years, attention has focused on identifying those risk factors specific to the state 
of uraemia to attempt to explain the massively increased rates of mortality in this patient 
population.  In the early stages of CKD, the more traditional risk factors are more 
important, as generally, many patients who develop CKD have a history of hypertension, 
diabetes, hyperlipidaemia etc.  As renal function worsens, the non-traditional risk factors 
become more important, for example, the degree of anaemia and secondary 
hyperparathyroidism will worsen with decreasing GFR.  Among the so-called non-
traditional risk factors, inflammation has been shown to be an epidemiologically   62 
important risk factor for cardiovascular disease in the general population [32].  In the 
ESRD population, inflammation strongly predicts all-cause [173] and cardiovascular 
mortality rates [173, 174]. 
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Table 1.5  Cardiovascular risk factors in CKD patients 
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1.7.2  CKD and dyslipidaemia 
The prevalence of dyslipidaemias in CKD patients is very high.  In one study of patients 
on both haemodialysis and peritoneal dialysis patients, the prevalence of dyslipidaemia 
was approximately 67% [175], where dyslipidaemia had been defined as at least one 
abnormal lipid parameter.  In fact, peritoneal dialysis seems to be associated with a 
relatively more atherogenic lipid profile than haemodialysis [176], which may be related 
to the continuous glucose load.  Typically in ESRD patients have either normal or 
slightly increased LDL, increased VLDL and IDL, leading to elevated triglyceride levels, 
and decreased levels of HDL.  The hypertriglyceridaemia results from increased synthesis 
and decreased clearance, the later as a result of low expression and activity of lipoprotein 
lipase (LPL) and hepatic lipase (HL).  The characteristic low levels of HDL arises from 
low activity of lecithin cholesterol acyltransferase (LCAT), which esterifies cholesterol 
taken up by HDL, therefore enabling HDL to acquire subsequent cholesterol particles 
[177].  The low levels of HDL cholesterol are also a consequence of increased cholesterol 
ester transfer protein (CETP) activity and of acyl CoA:cholesterol acyltransferase 
(ACAT), as well as decreased activity of LPL and HL [178]. 
 
Patients with ESRD additionally undergo qualitative changes in dyslipidaemia with a 
shift to a more atherogenic profile, with a shift of LDL particle size toward a small, dense 
apo-B-rich LDL predominance.  Lipoprotein (a) is an LDL-like particle whose protein 
moiety contains apolipoprotein (a) which has been shown to be an independent risk factor 
for CVD in both the general and the CKD population [179].  Levels of lipoprotein (a) 
have been shown to be increased in CKD, in particular in patients with nephrotic   64 
syndrome and in peritoneal dialysis due to significant protein losses and subsequent 
apolipoprotein overproduction [180, 181].  Therefore, even when the concentration of 
LDL cholesterol is normal, LDL particles are more atherogenic in ESRD.  Of particular 
note, in nephrotic syndrome, hypercholesterolaemia is a typical feature, triggered by 
increased apolipoprotein production.  This is followed by an increase in cholesterol 
biosynthesis resulting in profound hypercholesterolaemia.  There is also impaired 
lipoprotein clearance.  Animal studies show that cholesterol synthesis is increased in 
CKD [182].  Gene expression and activity of HMG-CoA reductase is significantly 
augmented in experimental CKD [183].   
 
As described above, in the general population, the relationship between hyperlipidaemia 
and CVD (predominantly coronary artery disease) is well established, as are the proven 
benefits of lipid-lowering with statins.  There is only limited epidemiological and even 
more limited interventional data on the relationship between dyslipidaemia and CVD in 
ESRD and the clinical implications, creating uncertainties with regards to the impact of 
dyslipidaemia on CVD in ESRD, and also with regards to treatment.  In patients 
receiving maintenance haemodialysis, reports suggest either no relationship or 
paradoxical correlations, the so-called “reverse epidemiology” paradox, where a lower 
total cholesterol level has been associated with a higher risk of death [184-186], or 
conversely, a higher serum cholesterol has been found in long-term dialysis survivors 
[187].  These studies have often used registry data, and either all cause mortality or 
unspecified CV mortality.  Similar “J” or “U”-shaped relationships between lipid levels 
and all cause mortality have been reported in other populations and are thought to reflect   65 
a high prevalence of co-morbid disease (specifically malignancy and associated 
malnutrition) in patients with low cholesterol levels.  It is likely that similar relationships 
are present in patients with advanced renal failure, further compounded by the atypical 
mix of CV outcomes in this population.  The notion that hyperlipidaemia is not harmful – 
and even protective – in ESRF may also be flawed by the tendency to look at 
hypercholesterolaemia rather than dyslipidaemia.  “Uraemic dyslipidaemia” involves 
quantitative and qualitative changes in a variety of lipid subfractions that may contribute 
to premature CVD, even though total and LDL cholesterol levels are low.  Additionally, 
the so-called reverse epidemiology phenomenon may simply be an observation 
confounded by the effects of protein energy malnutrition (PEM) and inflammation [188] 
and will be discussed in further detail below.   
 
The clinical implications of dyslipidaemia in CKD patients are not solely limited to the 
development of atherosclerotic CVD.  There is growing evidence that hyperlipidaemia 
contributes also to renal disease progression.  Animal models have shown that a high-fat 
diet (hypercholesterolaemia) causes macrophage infiltration and foam cell formation in 
rats, leading to glomerulosclerosis [189].  Human studies have supported this; a 
relationship between serum cholesterol levels and GFR decline has been shown in several 
studies [190-192].  This has also been shown in patients with type 2 diabetes and overt 
nephropathy; a post hoc analysis of the Reduction of Endpoints in NIDDM with the 
Angiotensin II Antagonist Losartan (RENAAL) study [193] showed that both total 
cholesterol and LDL cholesterol measured at baseline were independent risk factors for 
ESRD.  In line with these findings, statins have shown beneficial effects in different   66 
models of progressive renal failure [194], although there is not yet a large interventional 
study on the effect of statin therapy in the progression of renal damage, there is evidence 
from post hoc analyses to suggests that statins are likely to be effective in the treatment of 
renal disease.  The use of statins in CKD will be discussed in further detail below. 
 
1.7.3  CKD and inflammation 
The inflammatory state of renal failure, particularly in its advanced stages is widely 
recognised.  As mentioned above, a factor that contributes to the cholesterol paradox is 
the presence of malnutrition and inflammation.  Protein-energy malnutrition is present in 
a large proportion of patients with CKD and is a strong risk factor for CV mortality in 
dialysis patients [195].  Low serum albumin, an index of malnutrition, is also highly 
associated with increased mortality in patients with ESRD [184], and correlated with high 
concentrations of acute phase proteins, such as CRP indicative of systemic inflammation 
[196, 197].  Available evidence suggests that CRP is a precise objective index of the 
inflammatory activity and that it accurately reflects generation of pro-inflammatory 
cytokines, such as IL-6 and TNF-ʱ.  Accordingly, elevated serum levels of pro-
inflammatory cytokines have been demonstrated to be associated with increased mortality 
in dialysis patients [198, 199].  Inflammation is now an established risk factor for 
coronary artery disease, and has an inconsistent relationship with serum lipids in the 
general population.  In ESRD intercurrent illness, inflammation and malnutrition in 
ESRD may confound the relationships between dyslipidaemia and CVD.  This hypothesis 
has been explored in a study that examined the relationship between markers of 
inflammation and CVD in a cohort of 1243 haemodialysis patients followed,   67 
prospectively for 10 years [200].  In patients with low serum cholesterol levels the 
mortality rate was significantly higher even after adjusting for possible confounders 
affecting baseline levels of serum cholesterol, such as age, body mass index (BMI) and 
serum albumin.  However, in the subgroup of patients with normal serum albumin, 
hypercholesterolaemia was a significant risk factor for death, and low total cholesterol 
was in fact associated with a lower risk of death.  In addition, death from CV events was 
more prevalent in patients with high levels of serum cholesterol than in those with low 
levels. 
 
Thus, there is a U-shaped, or J-shaped relationship between cholesterol levels and 
mortality.  Total cholesterol levels appear to influence survival in two ways; first as a 
marker of malnutrition and poor health, which identifies patients at high risk of death, 
and second as a more traditional CV risk factor (and a causative factor in atherosclerosis).  
More recently, the effect of inflammation and malnutrition has been investigated in more 
detail.  Liu and colleagues [201] followed up 823 chronic haemodialysis patients for a 
median of 2.4 years, and categorised the study population into two subgroups based on 
the presence or absence of inflammation or malnutrition (defined as achievement of 
specified cut-offs for any of serum albumin, CRP and IL-6 derived from studies of the 
general population).  Overall, 77% of the patients had evidence of 
inflammation/malnutrition, which was associated with older age, increased co-morbidity, 
prevalent CVD, diabetes, and lower total cholesterol levels.  A U-shaped association 
between cholesterol levels and mortality was seen in the overall cohort and in the 
subgroup with inflammation/malnutrition.  However, in the absence of   68 
inflammation/malnutrition, total cholesterol was positively associated with all-cause 
mortality and even more strongly associated with CV mortality.  This was also true when 
the analysis was repeated with non-high-density lipoprotein cholesterol (non-HDL-C) as 
the independent variable.  This is further supported by the finding that CRP is an 
independent predictor of the number of atherosclerotic plaques in the carotid arteries of 
dialysis patients [202], and a strong relationship between elevated CRP levels and 
atherosclerosis has also been documented in ESRD patients [203].  
 
Whether there is a mechanistic relationship between hypocholesterolaemia and 
hypoalbuminaemia, both are negative “acute-phase” responses to inflammatory stimuli.  
Elevated levels of pro-inflammatory cytokines are one of the reported causes of 
hypocholesterolaemia [198].  Hypocholesterolaemia and hypoalbuminaemia are also 
markers of malnutrition and an indicator of energy intake.  PEM is a recognised 
complication of ESRD to which anorexia, low nutrient intake, nutrient losses during 
dialysis, intercurrent illness, oxidative and carbonyl stress and chronic inflammation 
contribute [204].  Both PEM and inflammation may reduce serum concentrations of acute 
phase proteins, such as albumin, transferrin, pre-albumin, and cholesterol-carrying 
lipoproteins, thus acting as markers of concomitant illness that may themselves 
predispose to CVD. 
 
Causes of inflammation in ESRD are multi-factorial and include patient-specific 
processes, such as infections and clotted access grafts, however increased production and 
decreased renal clearance of pro-inflammatory cytokines, co-morbid disease processes,   69 
accumulation of advanced glycation end-products (AGEs) and multiple factors associated 
with dialysis itself, may also contribute to inflammation in ESRD. 
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Table 1.6  Causes of inflammation in end-stage renal disease 
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1.7.4  CKD and immune dysfunction 
Although the medical determinants of mortality in patients with ESRD are well 
recognised, the contribution of immunologic parameters to survival is unclear.  Patients 
with ESRD undergoing haemodialysis display a state of immunodeficiency, and 
dysregulation of cytokine metabolism has long been appreciated.  It has been shown that 
higher levels of circulating proinflammatory cytokines are associated with mortality 
[198], while immune parameters reflecting improved T-cell function are associated with 
survival in ESRD patients on haemodialysis , independent of other medical risk factors.  
Immune dysfunction in uraemia is associated with alterations in both the innate and 
adaptive branches of the immune system.   
 
All classes of the innate immune system pattern recognition receptors (secreted, 
endocytic, signalling) are affected in ESRD [205], resulting in impaired function of the 
effector cells.  Monocytes from patients with ESRD have been shown to have impaired 
function [206] and  when normal monocytes are cultured in uraemic serum their function 
also becomes impaired [207].  Bactericidal activity of neutrophils have been found to be 
reduced in haemodialysis patients [208].  Natural killer cell activity in renal failure will 
be discussed in further detail below.  ESRD results in various cytokine disturbances 
involving both anti-inflammatory and pro-inflammatory cytokines, supporting the idea of 
uraemia and dialysis as a chronic inflammatory state.  The increased levels of cytokines 
in ESRD is thought to be as a result of reduced rate of removal and increased generation 
[209], and the development of PEM and atherosclerosis has been discussed above.   71 
 
The increased rate of infections, together with an impaired response to vaccination and a 
common failure of tuberculin skin test to diagnose latent tuberculosis indicates that 
adaptive immunity is impaired in patients with ESRD [210].  Non response to vaccination 
is closely associated with an impaired proliferation of T-cells in vitro and a reduced 
production of the autocrine T-cell growth promoting cytokine IL-2 [211].  Lymphocyte 
numbers as well as the CD4/CD8 relation are diminished in dialysis patients [212], and 
reduced lymphocyte counts have been identified as predictors of mortality in 
haemodialysis patients [213]. In addition to this however, there is also reduced co-
stimulation by antigen presenting cells.  In other words, not only is the quantity of T-cell 
activation affected, but the quality is also reduced.  The altered T-cell function has been 
attributed to impaired function of APCs [210], possibly secondary to a disorder in toll-
like receptor expression or activity.  A reduction in B-cells has also been shown and 
suggested that this is due to increased apoptosis [214]. 
 
The causes of the immune dysfunction seen in ESRD are multiple and are related both to 
the state of uraemia and to the dialysis that corrects uraemia.  The accumulation of 
uraemic toxins, interactions between blood and dialyser, endotoxins in water, access-
related infections, peritoneal dialysis solutions with high glucose concentration, low pH 
and the presence of glucose degradation products all present chronic stimuli to the 
inflammatory response.  It is interesting to speculate that with the well established 
associated between inflammation and cardiovascular disease there may also be evidence 
for a causal relationship between infections and cardiovascular disease [215], and   72 
accordingly a link between the immune dysfunction in ESRD and cardiovascular disease 
through these infections and inflammation. 
 
1.7.4.1  CKD and natural killer cell function 
Studies in the immune dysfunction of renal failure have focused mainly on T- and B-cell 
adaptive immunity.  However, there is increasing interest in the NK cell compartment 
with some conflicting reports, some suggesting that a NK deficit occurs in haemodialysis 
patients [216], and more recent studies suggesting that NK cell counts are enhanced 
[212].  It is possible that this change may be related to improvements in modern dialysis 
technique and efficiency, water purity, and membranes.  A decrease in the cytotoxic 
activity of the NK cells compared with controls has been found in patients on 
haemodialysis [217], in particular those dialysed with cuprophan membranes.  Natural 
killer cell activity has also been shown to be related to the total time on haemodialysis, 
with a shorter time on dialysis being related to lower NK cell activity [217]. More 
recently, it has been demonstrated that patients on chronic haemodialysis have a normal 
number of lymphocytes and NK cells, however there is decreased NK cell activity as 
indicated by decreased expression of the δ-chain on NK cells, an early marker of NK cell 
activation [218].  The high incidence of cardiovascular disease in this patient population 
together with the participation of NK cells in atherosclerosis make this an important area 
to investigate further. 
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1.7.5  CKD and Phosphate 
Hyperphosphataemia is invariably present among patients with advanced CKD, resulting 
from decreased excretion and increased parathyroid hormone (PTH) through its action to 
release calcium and phosphate from bone.  Several studies have found an association 
between higher phosphate levels and cardiovascular events and mortality in patients with 
both CKD and normal renal function [219-223].  Notably, in one study of 3490 older, 
predominantly male veterans with CKD stages 3 to 4, each 1mg/dl higher serum 
phosphate concentration was associated with a statistically significant 23% greater 
adjusted risk for all-cause mortality [220].  This is in keeping with data from two large, 
national, randomised, cross-sectional samples of 6407 haemodialysis patients who had all 
dialysed for at least one year, which showed that patients with a serum phosphate level of 
> 6.5mg/dL had a 27% higher mortality risk than patients with serum phosphate levels of 
2.4 to 6.5 mg/dL [223].  A high calcium-phosphate product (Ca x P) in excess of 72 
mg
2/dL
2 was also associated with a relative risk (RR) of mortality of 1.34 (P < 0.01) 
compared with patients with a Ca x P between 42 and 52 mg
2/dL
2.  The increased 
mortality risk was not associated with serum calcium concentrations suggesting that the 
increased risk results from the phosphate levels.  The exact mechanism responsible for 
the increased mortality in patients with hyperphosphataemia is not entirely clear, however 
is thought to be primarily cardiovascular in nature.  Several observational studies in 
populations with CKD have suggested a role for phosphate in vascular calcification of 
smaller arterial beds, in particular the coronary arteries.  Recent studies have shown that 
patients with ESRD on dialysis have a higher prevalence and severity of coronary artery 
calcification (CAC) than healthy subjects of the same age and sex [224, 225].    74 
Cardiovascular calcification has been linked to an increased risk of cardiovascular events, 
including myocardial infarction, fatal arrhythmia, congestive cardiac failure, and valvular 
heart disease [226, 227].  In addition to the traditional cardiovascular disease risk factors, 
studies in dialysis patients have shown a correlation between CAC and a number of 
dialysis-related factors, such as dialysis vintage, hyperphosphataemia, high Ca x P 
product, and vitamin D therapy [225, 227].  The exact mechanisms resulting in vascular 
calcification have not been completely elucidated.  In vitro, phosphate acts directly on 
cultured vascular smooth muscle cells to initiate phenotype transformation, characterised 
by loss of contractility, expression of bone-specific markers, and calcification of matrix 
proteins [228, 229].  Thus high phosphorous levels seem to stimulate osteoblastic 
differentiation of vascular smooth muscle cells and directly enhance extracellular 
calcification.  It would therefore appear that the high serum phosphate levels play an 
important role in contributing to the markedly increased prevalence of cardiovascular 
calcification and therefore cardiovascular mortality in patients with CKD. 
 
1.8  Other Biomarkers 
 
The role of inflammation in atherosclerosis is undisputed, and much interest has 
developed surrounding the association of inflammatory biomarkers with cardiovascular 
disease, and in particular the possibility of a pathogenic role of these biomarkers in the 
atherosclerotic process.  Not only has an association been established, but inflammatory 
markers have been shown to predict and correlate independently with major 
cardiovascular end points such as myocardial infarction and death [30, 39].  The potential   75 
of identifying a biomarker that will be able to facilitate the diagnosis of cardiovascular 
disease is hugely attractive, potentially resulting in more accurate risk stratification and 
treatment selection, particularly when in a reasonable proportion of patients, the 
traditional cardiovascular risk factors do not provide information on the presence of 
atherosclerosis, and other specific factors such as inflammation need to be considered. 
 
1.8.1  High Sensitivity CRP 
High sensitivity CRP is the term applied to a test that detects serum CRP concentration at 
lower levels than previous generations of laboratory tests.  High sensitivity CRP detects 
the same CRP molecule but its lower limit of detection is substantially lower, it can 
therefore detect much lower levels of inflammation, so when testing CRP for vascular 
risk assessment, hsCRP is used as the levels of CRP are low in comparison to other 
inflammatory states such as sepsis.  As discussed previously, elevated serum hsCRP has 
been shown to be a stronger predictor of incident cardiovascular events in healthy men 
than LDL cholesterol and to be additive to the Framingham risk score [39].  In healthy 
men and women, a significant relationship has been found between high blood pressure, 
hsCRP and IL-6 [230] 
 
1.8.2  Interleukin-6 
The plasma cytokine IL-6 plays an important role in mediating inflammation, and is a 
central stimulus for the acute-phase response, in particular it induces the hepatic synthesis 
of CRP [231], and thus circulating levels of IL-6 and CRP are physiologically linked.  
Elevations of IL-6 however have been shown to have independent associations with   76 
cardiovascular events, even after controlling for CRP.  In the Physician‟s Health Study, 
elevated levels of IL-6 in apparently healthy males predicted up to a 2.3-fold increase in 
myocardial infarction over 6 years [232].  Among these men, the number of risk factors 
at baseline was correlated with the plasma concentration of IL-6.  Baseline levels of IL-6 
have also been found to predict cardiovascular events in the Women‟s Health Study [33].  
In addition, IL-6 levels have also been shown to be a better predictor of mortality than 
CRP [233, 234].  IL-6 and CRP have also been shown to be associated with traditional 
risk factors for cardiovascular disease independent of lipid levels, supporting a separate 
or concurrent pathway to atherosclerosis [235].  More recent studies have suggested that 
CRP and IL-6 may not always track each other, and in actual fact divergent levels may be 
seen under certain conditions, suggesting that IL-6-independent pathways may exist in 
the regulation of circulating levels of CRP [235].   
 
1.7.5  Pentraxin-3 
The pentraxins are a family of proteins which includes CRP, considered to be markers of 
the acute phase of inflammation, structurally distinguished by a characteristic pentameric 
structure [236].  Pentraxin 3 (PTX3) is a long pentraxin that is structurally related to, 
although  distinct  from,  prototypic  classic  short  pentraxins  such  as  CRP  and  serum 
amyloid P (SAP).  PTX3 was the first long pentraxin to be discovered, and its expression 
is induced in response to inflammatory stimuli, for example infections, IL-1, and TNF-ʱ, 
but not IL-6 [237-240].  PTX3 is produced by a number of different cell types including 
in  particular  two  of  the  major  cellular  components  of  atherosclerotic  lesions  – 
macrophages  and  endothelial  cells  –  as  well  as  monocytes  and  fibroblasts,  however   77 
unlike CRP it is not produced in the liver.  It is found in advanced atherosclerotic lesions 
[241], and as it is produced from vascular endothelial cells and not hepatocytes, it is 
interesting  to  speculate  that  PTX3  levels  may  more  directly  reflect  the  inflammatory 
status  of  the  vasculature,  and  therefore  have  a  greater  sensitivity  and  specificity  for 
cardiovascular inflammation.  In a mouse model, systemic administration of microbial 
products and inflammatory cytokines, or ligation of the left coronary artery results in 
expression of PTX3 at high levels  [239].   It  is  induced by oxidized LDL in  smooth 
muscle cells [242] and interestingly PTX3 has been found to be suppressed by statin 
treatment  in  human  umbilical  vein  endothelial  cells  (HUVEC)  by  cDNA  microarray 
analysis [243].  PTX3 levels have been found to be increased in patients with unstable 
angina [244] and myocardial infarction [245], and to be predictive of outcome. 
 
1.7.6  Adiponectin 
Adipose  tissue  is  now  considered  an  endocrine  organ  as  it  is  able  to  release  many 
biologically active substances – adipocytokines, or adipokines – in response to specific 
extracellular  stimuli  or  to  variations  in  metabolic  conditions.  These  adipokines  may 
directly contribute to obesity-linked metabolic and vascular diseases [246].  Adiponectin 
is  an  adipocyte-specific  plasma  protein  [247]  that  circulates  in  high  concentrations 
(approximately 0.01% of total plasma protein) [248].  The relationship of this protein to 
fat and body mass is the converse of leptin, another adipokine.  Adiponectin levels are 
significantly  reduced  among  obese  subjects  when  compared  to  lean,  healthy  controls 
[248], and in fact weight loss results in a marked increase in plasma adiponectin levels 
among  both  normal  controls  and  type  2  diabetics  [249].  Plasma  adiponectin   78 
concentrations are higher in woman than men, low in diabetics, and inversely related to 
plasma glucose, insulin, and triglyceride levels  [249].  Hypoadiponectinemia has also 
been observed in patients with coronary artery disease, and is highly associated with 
coronary artery disease prevalence even after adjustment for established coronary artery 
disease risk factors such as diabetes mellitus, dyslipidaemia, hypertension, smoking, and 
BMI [250] in men.  In patients with ESRD, adiponectin has been shown to be a strong 
and independent (inverse) predictor of cardiovascular outcomes [251]. 
 
Adiponectin appears to play a protective role in experimental models of vascular injury 
with  anti-inflammatory  and  anti-atherogenic  properties.    Plasma  adiponectin  rapidly 
accumulates in the subendothelial space of the injured human artery.  It has been shown 
to  inhibit  monocyte  adhesion  to  endothelial  cells  and  macrophage-to-foam  cell 
transformation,  as  well  as  TNF-ʱ  secretion  from  macrophages  and  vascular  smooth 
muscle  cell  proliferation  in  vitro  [252-255].  Other  effects  include  increased  insulin 
sensitivity and free fatty acid oxidation, and decreased hepatic glucose production and 
intracellular  triglycerides  [256].  It  would  therefore  seem  that  adiponectin  acts  as  a 
modulator of the inflammatory response in the vascular wall, and hypoadiponectinemia 
may cause an excessive inflammatory response in coronary arteries.  Indeed in humans, 
low levels of adiponectin appear to be closely correlated with severity of endothelial 
dysfunction [257].  In keeping with this, an inverse correlation has been demonstrated 
between the levels of adiponectin and CRP [258] and it has recently been reported that 
adiponectin significantly decreases CRP mRNA and protein levels [246]. 
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1.8  Statin trials in chronic kidney disease 
 
1.8.1  4-D Study 
Despite the enormously increased incidence of cardiovascular disease in patients with 
ESRD, observational studies have so far not demonstrated a positive relationship between 
total cholesterol and mortality in haemodialysis patients.  As discussed above, this is 
complicated  by  the  phenomenon  of  “reverse  epidemiology”  and  confounded  by 
invariable  underlying  comorbidity.  A  reverse  relationship  between  lipid  levels  and 
mortality exists where low cholesterol is in fact associated with higher mortality rates 
[201],  however  the  question  of  whether  lipid  lowering  is  beneficial  in  this  patient 
population remains a contentious issue.  Aside from the high cardiovascular risk, this 
patient  group  may  actually  benefit  more  from  statin  therapy  given  the  prominent 
oxidative stress and inflammation that is know to occur, as well as the highly atherogenic 
lipid profile that occurs, that cannot be detected by measuring and correlating serum 
cholesterol on its own. 
 
The 4D study (Die Deutsche Diabetes Dialyse Studie) [259] was a study of atorvastatin 
versus placebo in 1255 type 2 diabetics on regular haemodialysis, those patients who 
represent the highest risk for cardiovascular disease.  Atorvastatin lowered mean LDL-
cholesterol levels by 42% to 72mg/dl without a significant reduction in the primary end-
point (a composite of cardiac death, non-fatal MI, and fatal or non-fatal stroke).  The 
investigators  speculated  that  the  results  reflected  a  different  pathogenesis  of  vascular   80 
events in diabetic patients with ESRD, or that the intervention was too late in the natural 
history of such complex disease, although atorvastatin therapy did reduce the incidence 
of MI.  Therefore, an alternative explanation is that in the complex mixture of CVD that 
affects patients with ESRD, the relationship between cholesterol and MI is present (and 
lipid-lowering reduces this end-point) but that MI is not the dominant CV end-point.   
 
1.8.2  AURORA 
A more recent trial, the AURORA study (A Study to Evaluate the Use of Rosuvastatin in 
Subjects  on  Regular  Haemodialysis:  An  Assessment  of  Survival  and  Cardiovascular 
Events) was designed to investigate the effects of statin therapy in a more wide-ranging 
population of patients with ESRD on regular haemodialysis [260].  2776 patients were 
randomly  assigned  to  double-blind  treatment  with  rosuvastatin  or  placebo.  
Approximately  half  of  the  patients  had  diabetes,  and  the  inclusion  criteria  specified 
patients aged 50-80 years, who had been on haemodialysis for at least three months and 
not expected to receive a renal transplant within a year.  This study population were 
therefore  at  higher  cardiovascular  (and  all  cause)  risk  than  the  general  maintenance 
haemodialysis population.  Rosuvastatin treatment was associated with modification in 
serum lipids comparable to the effects of statin therapy in other populations and an 11% 
reduction in CRP, however despite these favourable effects, those patients randomised to 
rosuvastatin showed no reduction in the composite cardiovascular end-point (non-fatal 
MI, cardiovascular death or stroke), any individual end-points, or all-cause mortality.  
Although these findings support the 4D study, there were limitations in the AURORA 
study.    In  particular,  the  exclusion  of  patients  already  on  statin  treatment  which   81 
presumably includes those patients at highest risk of coronary disease, and also the age 
restrictions. 
 
1.8.3  ALERT 
The relationship between lipid concentrations and cardiovascular events is less clear in 
renal transplant recipients than in other populations.  The ALERT trial (Assessment of 
LEscol in Renal Transplantation) is the only major cardiovascular outcome trial in this 
patient population [261].  This was a multicentre, randomised, double-blind, placebo-
controlled trial in 2102 cyclosporin treated adult renal transplant recipients with a total 
cholesterol  between  4.0-9.0  mmol/L,  randomly  assigned  to  fluvastatin  (Lescol)  or 
placebo, and followed up for 5-6 years.  For the primary end-point, the occurrence of a 
major  adverse  cardiac  event  (a  composite  of  cardiovascular  death,  non-fatal  MI  and 
coronary  intervention),  there  was  a  13%  reduction  that  did  not  reach  statistical 
significance.  Failure to achieve statistical significance resulted from the fact that the 
study was underpowered to detect a significant reduction in the chosen primary endpoint 
as  the  recruited  population  had  an  event  rate  lower  than  registry  data  suggested.  
However, fluvastatin therapy was associated with a reduction in risk of MI, of cardiac 
death, and of the secondary end-point of cardiac death and non-fatal MI, consistent with 
the beneficial effects of statins in other populations. 
 
The ALERT extension trial was a 2 year open-label extension of the core trial during 
which all patients were offered fluvastatin treatment [262].  The patients randomised to 
fluvastatin  had  a  significantly  reduced  risk  of  the  primary  end-point  (major  adverse   82 
cardiac events) by 21%, and a 29% reduction in cardiac death or non-fatal MI.  This is in 
keeping with reductions of between 9% and 37% seen in other primary prevention trials 
of statin therapy, suggesting that fluvastatin achieves a similar cardioprotective effect in 
renal transplant recipients. 
 
1.8.4  JUPITER 
Although this trial was not carried out in the CKD population, it is mentioned here due to 
the support it lends to the inflammatory nature of cardiovascular disease.  The JUPITER 
study (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating 
Rosuvastatin) was a randomised, double-blind, placebo-controlled, multicentre trial of 
17,802 patients, investigating rosuvastatin versus placebo in apparently healthy persons 
with LDL-C levels below current treatment threshold (<130 mg/dL), but with elevated 
levels of hsCRP (>2.0mg/dL) [263].  By 12 months, in the rosuvastatin group, the median 
LDL-C  had  fallen  by  50%,  and  the  median  hsCRP  level  had  fallen  by  37%.    The 
rosuvastatin group had a 44% lower incidence of the primary end-point (P < 0.00001) 
(defined  as  the  composite  of  cardiovascular  death,  myocardial  infarction,  stroke, 
hospitalisation  for  unstable  angina,  or  arterial  revascularisation),  as  well  as  a  20% 
reduction in all-cause mortality.  The study was terminated early after an average follow-
up period of 1.9 years due to statistically significant reductions in the incidence of acute 
MI,  stroke,  revascularisation,  unstable  angina,  and  cardiovascular  death  in  the 
rosuvastatin group.  This trial lends support to the idea that where LDL-C is concerned 
“lower  is  better”.    The  JUPITER  study  does  not  offer  any  further  clarification  as  to 
whether hsCRP is a mechanistic participant in atherosclerosis, or simply a biomarker, but   83 
certainly adds weight to the use of hsCRP as a non-lipid marker to identify those who 
may benefit from statin therapy. 
 
1.9  Background Work to Aims and Hypothesis 
 
The background to this thesis was previous work that had been carried out in our research 
group on statins and lymphocyte function, as briefly described in section 1.6.3.5.  This 
work was carried out to investigate the hypothesis that the pleiotropic effects of statins 
may  result  from  lipid  raft  disruption,  rather  than  by  the  reduction  of  isoprenoid 
intermediates, and that the disruption of membrane rafts, and therefore cell signalling 
apparatus, may be one mechanism by which statins exert their immunomodulatory and 
anti-inflammatory effects.   
 
Both  T lymphocytes  and NK  cells  have been implicated in  experimental  and human 
atherosclerosis, although NK cells are less well studied.  It has been shown already that 
NK cell function is sensitive to both in vitro (Figure 1.3) and in vivo statin treatment, 
with reductions in NK cell cytotoxicity that recover following withdrawal of treatment, 
and that the changes in NK cell cytotoxicity appear to parallel changes in LDL-C in statin 
treated patients [150, 153].                                                                                           
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Figure 1.3  Pre-incubation of NK92MI cells with either fluvastatin (Fluv) or simvastatin 
(Simv) reduced NK killing of K562 cells (% killing of K562 cells) in a dose-dependent 
manner, with simvastatin being more potent than fluvastatin. Incubation of cells with 
methyl-beta-cyclodextran (MBCD), a cholesterol depleting agent, also results in reduced 
NK cell cytotoxicity.  (Reproduced with permission) [153]  
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As many isoprenylated proteins are localised in membrane rafts, membrane cholesterol 
depletion and inhibition of isoprenylation may have similar physiological effects.  This 
was investigated by using specific inhibitors of farnesyl and geranylgeranyl transferase.  
Proteins  that  are  incorporated  into  the  cell  membrane  by  unrelated  processes  were 
studied.  Inhibition of farnesyl and geranygeranyl transferase have been shown to have 
little  effect  on  NK  cell  cytotoxicity,  suggesting  that  NK  cell  cytotoxicity  is  less 
susceptible to inhibition of isoprenylation than proliferation and function of other cells 
types (Figure 1.4). 
 
Figure 1.4  NK92MI cell cytotoxicity (% killing of K562 cells) after treatment for 48 
hours  with  varying  concentrations  of  farnesyl  (FTI)  and  geranylgeranyl  transferase 
(GGTI) inhibitors was not affected.  This also shows that one millimolar of mevalonate 
(rescued) the inhibition of 5μM simvastatin.  p < 0.001 t-test vs. control.  (Reproduced 
with permission) [153]   86 
 
 
It has been shown that fluvastatin disrupted lipid rafts in a U937 monocyte line [161], and 
that statin therapy lead to a reduction in raft-associated proteins in healthy volunteers 
treated  for  4  weeks  with  simvastatin  40mg  daily  [150].  These  findings  were  also 
confirmed using an immortalised NK cell line (NK92MI) with fluvastatin and simvastatin 
[153].  Levels of raft associated proteins were restored with mevalonate rescue, however 
incubation  of  cells  with  FTI  and  GGTI  had  no  measurable  effect  on  raft  associated 
proteins supporting the notion that inhibition of cholesterol synthesis by fluvastatin and 
not isoprenoid synthesis is responsible for membrane raft disruption.   
 
1.11  Aims and Hypothesis 
 
The general hypothesis was that membrane and plasma cholesterol (and therefore the 
density  of  membrane  rafts)  may  change  in  parallel.    If  increased  plasma  lipids  are 
associated with an increase in membrane rafts (and raft associated proteins), this may 
provide  a  generalisable  link  to  CVD.    Therefore  a  treatment  that  lowers  circulating 
cholesterol is likely to reduce membrane cholesterol, and correspondingly, cell functions 
that are dependent on membrane cholesterol (and cholesterol rafts). Our original intention 
had  been  to  confirm  whether  changes  in  lipid  rafts  did  parallel  changes  in  serum 
cholesterol, and whether this was an effect unique to HMG-CoA reductase inhibitors 
(providing an alternative explanation for the pleiotropic effects of statins), or whether all 
forms of lipid lowering therapies resulted in a reduction of membrane lipid rafts, with a   87 
corresponding reduction in cell function.  NK cells were chosen as we had experience 
with this cell line, and pilot experiments had been carried out as described above.  Also, 
the previous work from our group described above interestingly showed a correlation 
between the activity of NK cells and circulating lipid levels, consistent with a wider link 
between NK cells and CV risk.  Thus the core of this thesis was the role of lipid rafts and 
isoprenoids in NK cell cytotoxicity. 
 
Preliminary experiments found that using the centrifugation apparatus available to our 
laboratory (SW60-ti rotor) to isolate lipid rafts, the amount of venous blood required to 
yield a sufficient number of PBMCs was too much to be feasible.  The focus of this study 
therefore moved to examining NK cell function in patients at particular cardiovascular 
risk, namely patients with CKD, to determine whether any changes in the function of this 
important immune cell could have any role in the hugely increased cardiovascular risk 
which develops in these patients. 
 
 
 
 
 
 
 
 
   88 
1.11.1  Aims 
The aims of this project were: 
  To evaluate the relationship between lipid profiles and NK cell function and   
phenotype 
  To determine if NK cell function and phenotype alters with differing stages of  
CKD 
  To examine the relationship between NK cell cytotoxic activity and traditional  
and novel predictors of CV risk and renal function 
  To examine the effects of manipulation of membrane cholesterol (depleting and  
replenishing) on NK cell function 
  To establish the relationship between NK cell function, renal function, and  
biomarkers of inflammation and CVD 
 
1.11.2  Hypothesis 
The studies performed are to examine the hypothesis that changes in NK cell function 
may relate to serum cholesterol, reflecting changes in cell membrane and specifically 
lipid raft function, and that NK cell function is altered in renal failure, supporting a role 
for NK cells in atherosclerosis and CVD. 
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1.12  Outline of the studies contained within this thesis 
Four principle studies were performed and are detailed in Chapters 3-6: 
 
Chapter 3:  A study of natural killer cells in patients with dyslipidaemia 
Chapter 4:  A study of natural killer cells in chronic kidney disease 
Chapter 5:  An in vitro study of membrane cholesterol in natural killer cells  
Chapter 6:  A study of biomarkers in patients at high risk of cardiovascular disease 
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CHAPTER 2 
 
Materials and Methods 
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2.1  Subjects 
 
Subjects were recruited from out-patients attending the general nephrology and low-
clearance renal clinics, the lipid clinic, and the regular dialysis unit.  None of the patients 
had infections or malignancy, and none were immunosuppressed.  We had initially 
planned to exclude diabetic subjects (as a potential confounder), but to increase numbers, 
diabetics were later included.  Fifty millilitres of blood was taken into BD vacutainer 
collection tubes from a peripheral vein at routine visits to their clinic.  In the patients on 
haemodialysis, blood samples were taken within 15 minutes of the start of the dialysis 
session in all the patients on dialysis.  Biochemical, haematological, and clinical 
parameters (observations and blood samples taken at the same time the study samples 
were taken) were recorded.  All patients and controls gave written consent, the forms 
being approved by the North Glasgow Hospitals University NHS Trust Ethics 
Committee. 
 
2.2  Blood sampling 
 
50ml of venous blood was drawn into BD vacutainer tubes.  Routine biochemistry and 
haematology were analysed in the hospital laboratories for haemoglobin, electrolytes, 
urea, creatinine, glucose, and lipid profile (total cholesterol, low-density lipoproteins, 
high-density lipoproteins, and triglycerides).  Approximately 20ml was used immediately 
for peripheral mononuclear cell extraction, and then NK cell isolation as described below.    92 
Approximately 15ml was centrifuged and frozen within 30 minutes of collection to -70
oC 
for later use. 
 
2.3  Materials 
 
2.3.1  Biochemicals 
Unless otherwise stated, all chemicals were purchased from Sigma (Poole, UK).  Tissue 
culture products including foetal calf serum (FCS), L-glutamine, RPMI 1640 penicillin 
and streptomycin were purchased from Gibson (Paisley, UK). 
 
2.3.2  Immunochemicals 
The antibodies used in this study are shown in table 2.1. 
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NEB Western Blot Rabbit ERK
NEB Western Blot Rabbit pERK p44/42 MAP kinase (Thr202/Tyr204)
Upstate Western Blot Rabbit HMG-CoA reductase
DakoCytomation FACS Mouse Negative control, Mouse IgG1
Amersham W 2y antibody Donkey Anti-rabbit:HRP
Upstate Western Blot Rabbit Lyn
Upstate Western Blot Rabbit LAT
DakoCytomation FACS Mouse Anti-human CD3/APC
DakoCytomation FACS Mouse Anti-human CD56/RPE (C5.9)
DakoCytomation FACS Mouse Anti-human CD16/FITC (DJ130c)
Source3 Usage2 Species Specificity (clone)1
NEB Western Blot Rabbit ERK
NEB Western Blot Rabbit pERK p44/42 MAP kinase (Thr202/Tyr204)
Upstate Western Blot Rabbit HMG-CoA reductase
DakoCytomation FACS Mouse Negative control, Mouse IgG1
Amersham W 2y antibody Donkey Anti-rabbit:HRP
Upstate Western Blot Rabbit Lyn
Upstate Western Blot Rabbit LAT
DakoCytomation FACS Mouse Anti-human CD3/APC
DakoCytomation FACS Mouse Anti-human CD56/RPE (C5.9)
DakoCytomation FACS Mouse Anti-human CD16/FITC (DJ130c)
Source3 Usage2 Species Specificity (clone)1
 
Table 2.1  Antibodies.  
1Clone number and/or species in which antibody was raised.  
2FACS: fluorescent activated cell scanning; W 2y antibody: western blot secondary 
antibody.  
3Manufacturer; DakoCytomation, Cambridgeshire, UK; Upstate, Upstate 
Biotechnology, Lake Placid, USA; Amersham, Amersham, UK;  New England Biolabs, 
Ipswich, UK 
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2.4  Cell biology techniques 
 
2.4.1  Cell Culture 
2.4.1.1  NK-92MI Cell Line 
NK-92MI is an interleukin-2 (IL-2) independent natural killer cell line derived from the 
NK-92 cell line by stable transfection with human IL-2 cDNA in a retroviral vector by 
particle-mediated gene transfer.  The parental NK-92 cell line was an IL-2 dependent cell 
line derived from peripheral blood mononuclear cells from a 50 year old Caucasian male 
with rapidly progressive non-Hodgkin‟s lymphoma [264].  NK-92 cells were routinely 
cultured in Alpha minimum essential medium without ribonucleosides and 
deoxyribonucleosides and containing 2mM L glutamine, 1.5g/L sodium bicarbonate, 
0.2mM inositol, 0.1mM 2-mercaptoethanol, 0.02mM folic acid, 12.5% horse serum, 
12.5% foetal bovine serum, penicillin (10U/ml) and streptomycin (10μg/ml) (Gibco, 
Paisley, UK).  They were maintained at 37
oC in a water-saturated atmosphere containing 
5% carbon dioxide. 
 
2.4.1.2  K562 Cell Line 
The human erythroleukaemic cell line K562 was established from the pleural fluid of a 
53 year old female with chronic myelogenous leukaemia in terminal blast crisis [265].  
The cell population has been characterized as highly undifferentiated and of the 
granulocytic series [266].   The K562 cells were routinely cultured in RPMI 1640 
medium supplemented with FCS (10% v/v), glutamine (2mM), penicillin (10U/ml) and   95 
streptomycin (10μg.ml).  They were maintained at 37
 oC in a water saturated atmosphere 
containing 5% carbon dioxide, in 25cm
2 tissue culture flasks in a volume of 10mls.  
 
2.4.1.3  Human peripheral blood mononuclear cell isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from 20 mls of human 
peripheral venous blood freshly drawn into lithium heparin tubes.  The blood was 
centrifuged on a Ficoll-Hypaque (1.077g/ml) gradient (Histopaque-1077; Sigma, Poole, 
UK).  The cells at the interface were collected and washed with phosphate buffered saline 
(PBS).  The cellular pellet was resuspended in K562-media (RPMI 1640 medium with 
10% foetal calf serum, 100 U/ml penicillin and 100μg/ml streptomycin) and incubated in 
6cm Petri plates at 37
oC for 45 minutes, to allow adherent monocytes to attach.  Non-
adherent cells were collected and counted on a haemocytometer. 
 
2.4.2  NK cell isolation 
NK cells were isolated from the PBMCs collected using the MACS NK cell human 
isolation kit (Miltenyi Biotec).  An indirect magnetic labeling system for the isolation of 
untouched NK cells from human PBMCs.  Isolation of highly pure NK cells is achieved 
by depletion of magnetically labeled cells.  PBMCs were resuspended in buffer (PBS 
with 0.5% bovine serum albumin (BSA) and 2mM EDTA), and were labeled with 10μl of 
NK Cell Biotin-Antibody Cocktail per 10
7 total cells.  After incubation for 10 minutes at 
4-8
oC, the cells were washed with 30μL of buffer per 10
7 total cells, and then 20μL of 
NK Cell MicroBead Cocktail per 10
7 total cells was added.  The cells were incubated at 
4-8
oC for 15 minutes and then washed with buffer, adding 10 – 20 X the labeling volume,   96 
and then centrifuged for 10 minutes at  300 x g for 10 minutes.  The supernatant was 
removed, and up to 10
8 cells were resuspended in 500μL of buffer.  MS columns 
(Miltenyi Biotec) were used.  The columns were placed in the magnetic field of a MACS 
Separator and prepared by rinsing with 500μL of buffer which was then discarded.  The 
cell suspension was applied onto the column and the eluate, representing the unlabeled 
enriched NK cell fraction was collected.  The column was washed with 500μL of buffer x 
3, and the eluate collected.  Cell viability was assessed by trypan blue exclusion, the 
percentage of viable cells being calculated as follows:  (Number of unstained cells/Total 
number of cells) X 100 = Percent viable cells.  The flow-through cells were retained and 
fluorescence-activated cell-sorting (FACS) was used to ensure pure isolation.  
 
2.4.3  Natural Killer Cell Cytotoxicity Assay 
The human chronic myelogenous leukaemia cell line – K562, was used as a target for NK 
cells.  The K562 cells, at a concentration of 2 x 10
6 cells/ml were incubated with 5MBq 
of 
51Cr at 37
oC for 2 hours, and washed thoroughly with PBS.  The effector cell 
concentration was established and equalised in all patient samples (the isolated NK cells 
described in section 2.4.2), and the target cell concentration was then adjusted to 5:1 E/T 
ratio.  One hundred microlitres of effector cells and 100μl of target cells were mixed in 
V-bottomed plates; six replicates were carried out.  Controls included 100μl of target 
cells plus 100μl of media as a negative control, and 50μl of target cells (in suspension) as 
a positive control.  After incubation for 3 hours at 37
oC, plates were centrifuged at 400 x 
g (1000rpm) for 5 minutes, 100μl of supernatant was collected and released radioactivity 
was measured by gamma counter.  Cytotoxicity was determined as the release of   97 
radiolabel from “killed” K562 cells [percentage killing = (sample – negative 
control)/(positive control – negative control) x 100] [267]. 
 
2.4.4  Flow Cytometry 
Three colour flow cytometry (BD Biosciences FASCalibur) of PBMCs prior to NK cell 
isolation was carried out to determine NK cell phenotype and distribution of NKT- and 
T-cells.  Phycoerythrin (PE)-anti-CD56, fluorescein isothiocyanate (FITC)-anti-CD16, 
and allophyocyanin (APC)-anti-CD3 (DakoCytomation Denmark A/S) were used.  
CD56+CD16+CD3- were defined as NK cells, CD56+CD16+CD3+ were defined as 
NKT cells, and CD56-CD16-CD3+ were defined as T cells.  Analysis was carried out 
using CELL Quest Prosoftware.  Ten microlitres of PBMCs was transferred to 2 FACS 
tubes, and made up to 100μl with K562-media.  Into one tube was added 5 μl of isotype 
controls (FITC, PE, APC), and into the other tube, 5 μl of the above antibodies.  The cells 
were incubated in the dark for 30 minutes, washed in media, and centrifuged at 1000rpm 
for 5 minutes.  The supernatant was discarded and the cells were resuspended in 500 μl of 
formyl saline.  The lymphocyte subsets were expressed as a percentage of gated events, 
with 10,000 gated events recorded. 
 
Peripheral blood mononuclear cell isolation, NK cell purification, NK cell cytotoxicity 
assays and FACS were carried out by myself with the assistance of Dr Dianne Hillyard 
and Ms Helen Miller (Renal Research Group, BHF Glasgow Cardiovascular Research 
Centre). 
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2.4.5  Cholesterol Loading 
Soluble cholesterol (Sigma, Poole, UK) was dissolved in NK92MI media to a stock 
concentration of 1mg/ml and added to cells at various concentrations.  The NK92MI cell 
line was used.  NK92MI cell were treated with increasing concentrations of cholesterol 
(as a cholesterol-methyl-beta-cyclodextran complex).  To load cells, varying 
concentrations ranging from 5 - 100μg/ml of the cholesterol-MBCD complex were added 
to 1 x 10
6 cells/ml to a volume of 2 ml RPMI media.  Cells were then incubated at 37
oC 
for increasing lengths of time; from 30 minutes to overnight incubation.  They were then 
washed with PBS.   
 
2.5  Biochemical Assays 
 
2.5.1  Cell Membrane Preparation 
The NK-92MI cell line was used.  Cells were washed twice in cold nuclear preparation 
buffer (10mM Tris-HCl, pH 7.4, 2mM Magnesium Chloride, 140mM Sodium Chloride).  
Cells were then lysed by three dry ice freeze-thaw cycles in nuclear preparation buffer 
containing 2% (v/v) Tween 40, protease inhibitors (1mM pheylmethylsulfonyl fluoride 
and 1μg/ml each of chymostatin, leupeptin, antipain and pepstatin) and phosphatase 
inhibitors (1mM vanadate and 1mM NaF).  Cell debris and nuclei were removed by 
centrifugation at 15,000 x g (13,000 rpm) for 5 minutes and membranes were precipitated 
by ultracentrifugation (Beckman Instruments, High Wycombe, UK) of the supernatant at 
100,000 x g (55,000 rpm), 4
oC for 1 hour.  Following ultracentrifugation, the supernatant   99 
represents the cytosolic fraction.  Membrane pellets were resuspended in cold membrane 
preparation buffer. 
 
2.5.2  Lipid Raft Isolation 
The cells being used were lysed by mixing with 2.5ml of MNE (25mM, pH 6.5, 150mM 
NaCl, 2mM EDTA) containing 1% Triton X-100 (v/v).  The samples were then mixed (1 
in 2) with 80% sucrose MNE (2.5ml), 30% sucrose (7ml) was then carefully layered on 
top, and finally 5% sucrose MNE (1.3ml) was layered on top.  Samples were kept on ice 
throughout and the rotor and rotor buckets were chilled to fridge temperature.  The 
samples were then subjected to sucrose gradient centrifugation at 32,000 rpm for 16 
hours at 4
oC in a SW60-ti rotor and a Beckman Coulter Optima L-80 XP Ultracentrifuge 
(Beckman Instruments, High Wycombe, UK).   
 
2.5.2.1  Lipid raft fractions 
Lipid rafts were collected from the 5% and 30% sucrose interface, diluted 1:1 with MNE 
and micro-centrifuged.  The pellet was resuspended in RIPA lysis buffer (1% (v/v) Triton 
X-100, 50mM Tris-HCl, pH 7.5, 0.25% (w/v) sodium-deoxycholate, 150mM NaCl, 1mM 
EDTA, 1mM vanadate and 1mM NaF) for subsequent analysis by SDS-PAGE and 
Western Blot.  LAT or Lyn antibodies were used as markers for rafts.    
 
2.5.3  Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was carried out using the NuPAGE Pre-Cast Gel System (Invitrogen, 
Paisley, UK).  The NuPAGE system works with bis-tris buffered (pH 6.4)   100 
polyacrylamide gels, available at 3 different acrylamide concentrations (10% (w/v), 12% 
and 4-12% gradient gels) allowing different separation ranges to be selected.  By varying 
the running buffer used, the separation range can be altered further.  Samples were 
denatured in NuPAGE LDS (Lithium Dodecyl Sulphate) sample buffer by heating to 
70
oC for 10 minutes. 
 
2.5.4  Western Blot Analysis 
Proteins were transferred to nitrocellulose (Schleicher and Schuel GmbH) using the 
Novex XCell II blotting apparatus.  Transfer efficiency was ascertained by staining with 
Ponceau S solution for five minutes followed by washing with dH2O.  Ponceau S was 
removed by washing with TBS (20mM Tris.HCl, pH 7.6, 136mM NaCl) containing 0.1% 
(v/v) Tween 20 (TBST).  Nitrocellulose membranes were blocked in TBST with 4% 
(w/v) non-fat powdered milk (e.g. Marvel) for at least 1 hour at room temperature.  
Typically, blots were incubated with primary antibodies at a final concentration of 0.1 - 
1μg/ml in 4% milk-TBST overnight at 4
oC.  Blots were then washed vigorously three 
times for five minutes with TBST and incubated with a HRP conjugated secondary 
antibody diluted 1 in 2000 for two hours at room temperature.  Blots were washed 
extensively with large volumes of TBST (typically 5 x 5 minute washes) followed by a 
final wash in H2O prior to developing.  Blots were developed using the enhanced 
chemiluminescence (ECL) detection system (Amersham, UK). 
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2.6  Manufactured kits 
 
2.6.1  Amplex Red Cholesterol Assay (Manufactured Kit) 
Cholesterol content in cell membrane preparations and cytosol was quantified using the 
Molecular Probes‟ Amplex Red Cholesterol Assay Kit (Invitrogen) as per manufacturer‟s 
instructions.  This kit provides a fluorometric method for quantification of cholesterol, 
measuring H2O2 detected using 10-acetyl-3,7-dihydroxyphenoxazine (Amplex Red 
reagent), a highly sensitive and stable probe for H2O2, producing highly fluorescent 
resorufin.  NK-92 cells at a density of 1 x 10
6 cells/ml were loaded with cholesterol as 
described in section 2.4.5, and cell membrane preparations made as described in section 
2.5.1.  The membrane pellet was suspended in 200μL of Amplex Red reaction buffer 
(0.1M potassium phosphate, 0.05 M NaCl, 5mM cholic acid, and 0.1% TritonX-100), 
50μL aliquots of the lysates were pipetted in triplicate into a 96-well plate.  Fifty-
microlitre aliquots of Amplex Red working solution was added to each well.  (300 μM 
Amplex Red reagent, 2U/ml horseradish peroxidase, 2U/mL cholesterol oxidase and 
0.2U/mL cholesterol esterase).  Plates were incubated for 1 hour at 37
oC protected from 
light.  Fluorescence was measured on a Wallac – Victor2 (Perkin Elmer, Beaconsfield, 
UK) microplate reader, using an excitation wavelength of 560 nm and an emission 
wavelength of 590 nm. A cholesterol standard curve was also determined for each assay 
using a provided cholesterol reference standard. 
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2.6.2  Ras Assay 
The Ras small GTPase was assayed using an Upstate biotech Ras activation assay kit 
(TCS Biologicals, Claydon, Buckingham, UK).  The kit comprised of glutathione agarose 
bound GST fusion proteins of the Ras binding domain (RBD) of Raf-1, which binds 
Ras:GTP.  Briefly, cells were stimulated and then lysed with Mg
2+ lysis buffer (MLB – 
25mM HEPES, pH 7.5, 150mM NaCl 1% Igepal CA-630, 10mM MgCl2, 1mM EDTA, 
and 2% glycerol).  Typically, 500μg cell lysate at a concentration of 1mg/ml was used for 
each assay sample.  Active Ras was precipitated with 5μl Raf-1 RBS agarose for 30 
minutes.  Precipitates were washed three times with 500μl MLB followed by SDS-PAGE 
(section 2.5.3) and Western blotting (section 2.5.4).  Ras was detected with specific 
monoclonal antibody included in the kit.  The Ras assay was carried out by Dr Dianne 
Hillyard (Renal Research Group, BHF Glasgow Cardiovascular Research Centre). 
 
2.7  Measurement of biomarkers 
 
Blood for measurement of biomarkers was collected in plain tubes and allowed to clot at 
room temperature.  Samples were then centrifuged at 3000rpm for 15 minutes at ambient 
temperature, the supernatant serum was then collected and immediately frozen and stored 
at -70
oC until later analysis. 
 
2.7.1  High Sensitivity CRP measurement 
High sensitivity CRP measurements were performed by the Dr Lynne Cherry (Senior 
Research Technician, Department of Vascular Biochemistry, Glasgow Royal Infirmary)   103 
and staff of the routine lipids section of the Biochemistry Department at Glasgow Royal 
Infirmary using a Hitachi Modular P analyzer.  The assay was an immunoturbidimetric 
assay, and kits were supplied by Roche Diagnostics GMBH, D-68298 Mannheim. 
 
2.7.2  Interleukin-6 measurement 
Interleukin-6 was quantified using a DuoSet ELISA kit (R&D Systems, Abingdon, UK). 
 
2.7.3  Pentraxin-3 measurement 
Pentraxin-3 was quantified using DuoSet ELISA kit (R&D Systems, Abingdon, UK). 
 
2.7.4  Adiponectin measurement 
Adioponectin was quantified using DuoSet ELISA kit (R&D Systems, Abingdon, UK). 
 
The ELISAs for IL-6, Pentraxin-3, and Adiponectin were carried out by myself with the 
assistance of Dr Dianne Hillyard and Ms Helen Miller (Renal Research Group, BHF 
Glasgow Cardiovascular Research Centre). 
 
2.7.5  Serum Soluble ST2 measurement 
Serum sST2 was quantified using human ST2/IL-1 R4 ELISA kit (R&D Systems, 
Abingdon, UK).  The ELISA was performed by Dr Grace Murphy, Division of 
Immunology, Infection and Inflammation, Glasgow Biomedical Research Centre. 
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2.8  RNA Extraction 
 
HMG-CoA reductase: We measured gene expression for HMG-CoA reductase by real time PCR 
and quantified enzyme protein by Western blotting. Quantitative real time PCR was used to 
quantify of mRNA transcripts following reverse transcription (Invitrogen, Paisley, UK) of RNA 
extracted  from  NK  cells  using  the  RNeasy  mini-kit  (Qiagen,  Crawley,  UK).  Primers  were 
designed  using  Primer-3  software  to  generate  a  DNA  product  of  around  100  base  pairs  to 
maximise reaction efficiency (HMG-CoA Reductase - For: 5‟GACCATCTGCATGATGTCCA 
3‟,  Rev:  5‟GGCCAGCAATACCCAAAATA  3‟.    18S  (rRNA  small  subunit)  –  For: 
5‟AAACGGCTACCACATCCAAG  3‟,  Rev:  5‟CGCTCCCAAGATCCAACTAC  3‟  (VHBio, 
Gateshead, UK)). Reactions were performed in triplicate 20µl volumes in 96-well optical reaction 
plates, using SYBR Green PCR Master Mix (Finnzymes, Espoo, Finland) containing modified 
Thermus brockianus DNA Polymerase, SYBR Green I dye, optimized PCR buffer, 5 mM MgCl2, 
and  dNTP  mix.  Each  reaction  was  performed  with  either  0.1µl  diluted  cDNA  or  reverse 
transcription control. Forward and reverse primers were each present at a concentration of 300nM 
(150nM for 18S). The thermal cycling profile started with a 15 minute hot-start at 95C followed 
by 35 cycles - 30 seconds at 95C, 30 seconds at 56C and 60 seconds at 72C. Results were 
analysed  using  Bio-Rad  Icycler  software  (Bio-Rad,  Hemel  Hempstead,  UK).  The  RNA 
extraction and real time PCR was carried out by Dr Dianne Hillyard (Renal Research Group, 
BHF Glasgow Cardiovascular Research Centre). 
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 CHAPTER 3 
 
A study of natural killer cells in patients with 
dyslipidaemia 
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3.1  INTRODUCTION 
 
There is an established relationship between lipids and atherosclerotic cardiovascular 
disease.  The growing interest in atherosclerosis as an inflammatory disorder has now 
identified inflammation as a key regulatory process that links multiple risk factors for 
atherosclerosis and its complications.  These findings are providing new insight into the 
pathophysiology of atherosclerosis and are opening new avenues for treatment of this 
important and prevalent disease.  No cholesterol lowering treatment has been as effective 
as HMG-CoA reductase inhibitors.  As discussed previously, not only do these agents 
successfully lower cholesterol levels, they appear to have several cholesterol-
independent, or “pleiotropic” effects [154, 268]. For example, there is substantial 
evidence that statins modulate immune responses.  In experimental models, statin treated 
rats showed reduced chronic rejection in addition to decreased graft atherosclerosis, 
following heart and liver transplants [269, 270].  Similarly in humans, increased 1-year 
survival and reduced rates of acute rejection in heart transplant recipients receiving 
pravastatin, compared with controls receiving standard immunosuppression have been 
reported [152].  There have been inconsistent findings in studies of renal transplant 
recipients with regards to rejection rates [127, 271].  In other studies, reduced levels of 
CRP, a marker of inflammation, have been observed [119].  Numerous studies have 
shown that statins have inhibitory effects on immune cells [130, 150, 161, 272] which 
appears to be a cholesterol-independent effect, although it is accepted that 
hypercholesterolemia promotes the development of a pro-inflammatory phenotype in 
large vessels with disease.  Whilst the role of plasma lipoproteins in atherogenesis is   107 
accepted, the physiological relevance of their immunoregulatory properties is still not 
clear.  It is known that in experimental animal models and human studies, diet and 
nutritional status affect immune cell function [273].  It has been shown that a T helper-1-
skewed cytokine profile of NKT cells which was induced by feeding mice an atherogenic 
diet was responsible for exacerbation of atherosclerosis by these cells [71].  These 
findings suggest that dietary factors, in particular lipids, may influence adaptive 
immunity via NKT cells.  It is also known that obesity influences host immunity [274].  
In vitro, NK cells express different lipoprotein receptors, and in experimental studies, 
responses of NK cell activity to lipoproteins have been shown to vary according to the 
concentrations of lipoproteins [275], and in addition NK cells stimulated with different 
lipoproteins secrete a variety of cytokines, such as IL-2, which may in turn affect NK cell 
activity [276]. 
The purpose of this study was to attempt to evaluate the physiological relevance of the 
immunoregulatory properties of plasma lipoproteins by evaluating the relationship of 
serum lipid profile with NK cell phenotype and function in a group of patients with 
dyslipidaemia, on various lipid lowering therapies.   
 
3.2  METHODS 
 
3.2.1  Patients 
Blood samples were taken from 36 healthy volunteers and 66 patients attending a 
specialist lipid disorder clinic.  All patients were fasting.  50 millilitres of blood was 
taken into BD vacutainer collection tubes.  Biochemical, haematological, and clinical   108 
parameters including age, gender, BMI, presence of vascular disease – ischaemic heart 
disease, history of  previous cerebrovascular accident or transient ischaemic attack, or 
peripheral vascular disease – was recorded, along with smoking status and drug therapy.  
None of the patients had infection or malignancy, and none were immunosuppressed.  In 
all 99 patients, NK cells were isolated and NK cell phenotype and distribution of NKT- 
and T-cells was determined.  Routine biochemical parameters including urea and 
electrolytes, albumin, phosphate, calcium, glucose, lipid profile, and creatinine were 
obtained from biochemistry laboratory reports, and full blood counts were obtained from 
haematology laboratory reports. 
 
3.2.2  Human peripheral blood mononuclear cell isolation 
Approximately twenty millilitres of blood was used.  Peripheral blood mononuclear cells 
were isolated from peripheral venous blood as described in section 2.4.1.3 using Ficoll-
Hypaque centrifugation (Histopaque-1077; Sigma, Poole, UK). 
 
3.2.3  NK cell isolation 
From the PBMCs isolated, NK cells were then isolated using the MACS NK cell human 
isolation kit (Miltenyi Biotec) as described in section 2.4.2. 
 
3.2.4  51-Chromium Release Assay 
Natural killer cell cytotoxicity was measured using a standard 51-Chromium Release 
Assay, using the human chronic myelogenous leukaemia cell line – K562 as target cells,   109 
as described in section 2.4.3.  Percentage killing was calculated: (sample – negative 
control)/(positive control – negative control) x 100. 
 
3.2.5  Flow Cytometry 
Three colour flow cytometry of PBMCs was carried out (BD Biosciences FASCalibur) 
before isolation of NK cells to determine NK cell phenotype and distribution of NKT- 
and T-cells as described in section 2.4.4.  The NK-, NKT-, and T-cells were expressed as 
a percentage of total lymphocyte count, and the CD56
bright and CD56
dim subsets were 
expressed as a percentage of NK cells. 
 
3.2.6  Statistical Analysis 
Statistical analysis was carried out using SPSS statistical package (version 15.0).  
Comparisons between groups were made using the independent samples T-test.  The 
association between continuous variables was analysed using Pearson correlation test.  
Non parametric data were logarithmic transformed and Pearson correlation was used.  
Multiple linear regression was used to assess the contribution of different factors to 
changes in lymphocyte subsets and NK cell cytotoxicity.  A probability value of p<0.05 
was considered significant. 
 
3.3  RESULTS 
 
3.3.1  Patient Characteristics and Laboratory Data   110 
The clinical and laboratory data are shown in Table 3.1.  The pattern of drug treatment is 
shown in Table 3.2 and Figures 3.1 and 3.2.  No-one in the control group was on lipid 
lowering therapy.  There were significant differences between the control and lipid clinic 
group with regards to age (41.6±12.8 vs. 57.9±10.1, p<0.001), BMI (24.7±4.8 vs. 
30.3±6.0, p<0.05), creatinine (82.1±10.8 vs. 98.5±25.4, p<0.001), glucose (5.0±0.9 vs. 
6.4±2.2, p<0.005), and haemoglobin (13.4±1.3 vs 14.5±1.4, p<0.005).  However there 
was no significant difference between groups between serum phosphate or albumin.  
With regards to lipids, there were significant differences between HDL-C (1.4±0.3 vs. 
1.19±0.3, p<0.005) and triglycerides (1.2±0.7 vs. 2.9±1.6, p<0.001) between groups, 
however there were no significant differences between total cholesterol and LDL-C.   
 
In the lipid patient group, there was no difference in creatinine between those on ace 
inhibitors and those not.  In terms of lipid profile, there was a significant difference in 
total cholesterol (6.04±1.65 vs 4.99±0.95, p < 0.05) and LDL-C (3.61±1.43 vs 2.6±0.75, 
p < 0.05) between those patients not taking a statin and those who were.  There was no 
difference in HDL-C or triglycerides however.  There was also no difference in 
creatinine, phosphate, adjusted calcium or albumin in those taking a statin compared with 
those who were not.  LDL-C was lower in the lipid patients not taking ezetimibe 
(2.64±1.05 vs 3.36±1.04, p < 0.05), although of thirteen patients taking ezetimibe only 
four of these were not also on dual therapy with a statin.  There were no differences in 
lipid fractions in those patients in the lipid group whether they were taking omacor, or a 
fibrate, or not. 
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In the control group, there was a significant correlation between creatinine and age (r = 
0.506, p < 0.01).  Creatinine did not correlate with any other routine biochemistry or 
haematological parameters, and specifically there were no correlations between creatinine 
and serum lipids.  Age correlated with serum glucose (r = 0.486, p < 0.05).  Haemoglobin 
correlated with serum albumin (r = 0.434, p < 0.05).  Total cholesterol correlated 
significantly with haemoglobin (r = 0.491, p < 0.01) and also with albumin (r = 0.472, p 
< 0.01).  LDL-C correlated with age (r = 0.466, p < 0.05).  HDL-C correlated with 
phosphate (r = 0.385, p < 0.05), albumin (r = 0.369 p < 0.05), and glucose (r = -0.414, p < 
0.05).   
 
In the lipid patient group, creatinine also correlated with age (r = 0.252, p < 0.05), but 
also negatively with haemoglobin (r = -0.290, p < 0.05).  Haemoglobin also correlated 
with albumin (r = 0.428, p < 0.01).  White cell count correlated with adjusted calcium (r 
= 0.384, p < 0.01) and albumin (r = -0.316, p < 0.05), whilst platelets correlated with 
haemoglobin (r = -0.304, p < 0.05), WCC (r = 0.269, p < 0.05) and albumin (r = -0.253, p 
< 0.05).  Total cholesterol correlated with creatinine (r = -0.264, p < 0.05) although 
neither LDL-C or HDL-C had any correlations with routine biochemistry or 
haematology. 
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Table 3.1  Clinical characteristics of the controls and the lipid patients. 
 
 
22.2 Omacor
14.3 Fibrate
20.6 Ezetimibe
50.8 Statin
Number (%) Drug
22.2 Omacor
14.3 Fibrate
20.6 Ezetimibe
50.8 Statin
Number (%) Drug
 
Table 3.2  Shows the percentage of patients on various lipid lowering drugs 
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Figure 3.1  Shows the number of lipid lowering drugs being taken by the subjects 
sampled (number of subjects is shown as a percentage)   114 
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Figure 3.2 (a) Shows the percentage of subjects on or not on statin treatment (b) shows 
the how many lipid lowering drugs subjects are taking, further divided into whether or 
not this includes statin therapy. 
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3.3.2 Distribution of peripheral blood lymphocytes 
There was no difference in total lymphocyte count between groups.  There was also no 
difference in number of NK cells or T cells between groups.  There was however a 
significant difference between NKT cells (p<0.01), and CD56
bright (p<0.001) and CD56
dim 
cells (p<0.001) (Figure 3.3) between groups (Table 3.3).  This was true when comparing 
the control group with patients in the lipid group whether or not they were on a statin.   
 
In the control group, total cholesterol, LDL-C and triglycerides had no correlations with 
lymphocyte subsets.  HDL-C however correlated with T cells (r = 0.382, p < 0.05), 
CD56
bright cells (r = 0.429, p < 0.01) and CD56
dim cells (r = -0.432, p < 0.01) (Figure 3.4).  
NK cells correlated with creatinine (0.392, p < 0.05) (Figure 3.5), haemoglobin (r = 
0.405, p < 0.05), WCC (r = -0.393, p < 0.05), and phosphate (r = -0.464, p < 0.01).  In 
addition to correlating with HDL-C, T cells also correlated with glucose (r = -0.403, p < 
0.05).  Interestingly, there was a significant correlation between CD56
dim cells and age (r 
= 0.350, p < 0.05) as has been previously shown.   
 
In the lipid group, neither total cholesterol, LDL-C nor HDL-C had any correlations with 
lymphocyte subsets.  Triglycerides however correlated with T cells (r = 0.314, p < 0.05).  
There were no correlations between NKT cells or CD56
dim cells, but NK cells correlated 
with haemoglobin (r = 0.262, p < 0.05) and adjusted calcium (r = -0.371, p < 0.01), and 
CD56
bright cells correlated with haemoglobin (r = -0.254, p < 0.05).  The presence of 
statin therapy in the lipid group did not result in any difference in NK-, NKT-, or T-cell 
numbers, or in the distribution of NK cell phenotype, between those taking a statin and   116 
those who were not.  Notably there was no significant age difference in those prescribed a 
statin versus those who were not.  There was no difference in lymphocyte distribution 
between those lipid patients taking a fibrate or omacor, and those who were not.  There 
were no correlations between BMI and lymphocyte subsets in the lipid patient group. 
 
Excluding those patients who by ATP III classification of lipid levels [4] have “optimal” 
LDL-C levels (those with LDL-C < 100 mg/dL) (23 of 36 controls; 33 of 63 lipid clinic 
patients), therefore including only those patients who have a raised LDL-C, does not 
unmask any novel inter-relationships, however it does strengthen the correlation between 
triglycerides and T cells (r = 0.430, p < 0.05) in the lipid group.  Similarly, in the control 
group, it strengthens the correlation between creatinine and NK cells (r = 0.535, p < 
0.01), and between HDL-C and T cells (r = 0.551, p < 0.01). 
 
Examining only those patients who have an eGFR > 60 ml/min/1.73m
2 (33 of 36 controls, 
mean eGFR 80.73±11.36 ml/min/1.73m
2; 50 of 63 lipid clinic patients, mean eGFR 
78.24±11.5 ml/min/1.73m
2), in the control group, the correlation between creatinine and 
NK cells is strengthened (r = 0.452, p<0.01), and the correlation of HDL-C with T-cells 
still exists.  In the lipid group, the correlation between creatinine and age is lost, but 
creatinine does still correlate significantly with CD56
bright cells (r = -0.292, p<0.05), but 
not CD56
dim cells. 
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< 0.05 6.79±8.61 4.23±3.35 NKT cells (%)a
ns 65.50±8.61 65.66±12.26 T cells (%)a
< 0.001 94.81±3.67 91.01±4.14 CD56dim cells (%)b
< 0.001 4.81±3.36 8.72±3.93 CD56bright cells (%)b
ns 13.16±5.95 11.71±5.61 NK cells (%)a
ns 2.14±0.73 2.05±0.50 Lymphocytes (x109/L)
P Lipid patients Controls Blood cells
< 0.05 6.79±8.61 4.23±3.35 NKT cells (%)a
ns 65.50±8.61 65.66±12.26 T cells (%)a
< 0.001 94.81±3.67 91.01±4.14 CD56dim cells (%)b
< 0.001 4.81±3.36 8.72±3.93 CD56bright cells (%)b
ns 13.16±5.95 11.71±5.61 NK cells (%)a
ns 2.14±0.73 2.05±0.50 Lymphocytes (x109/L)
P Lipid patients Controls Blood cells
 
 
Table 3.3.  Lymphocyte subset counts in control patients and lipid clinic patients.  
aPercentage of lymphocytes; 
bpercentage of NK cells. 
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Figure 3.3.  Boxplot graphs showing the distribution of (a) CD56
bright and (b) CD56
dim 
cells in the normal and lipid patient groups.   119 
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Figure 3.4.  A scatterplot showing the relationship between HDL-C and T cells and NK 
cell subsets in the control group.  T-cells are expressed as a percentage of lymphocytes, 
and CD56
bright/dim cells are expressed as a percentage of NK cells, as per table 3.3. 
 
r=0.392
p<0.05
 
Figure 3.5.  A scatterplot showing the relationship between NK cells (expressed as 
percentage of total lymphocytes) and creatinine in the control group.   120 
 
3.3.3  Natural killer cell cytotoxicity 
There was no significant difference in mean NK cell cytotoxicity between the control and 
the lipid patient groups.  When the controls were compared with only those on statin 
therapy in the lipid patient group there was also no significant difference in NK cell 
cytotoxicity.  There was a significant negative correlation between NK cell cytotoxicity 
and LDL-C in both the control (r = -0.485, p < 0.05) and lipid patient groups (r = -0.282, 
p < 0.05) (Figure 3.6).  In the lipid patient group NK cell cytotoxicity also correlated with 
albumin (r = 0.259, p < 0.05).  In both groups, NK cell cytotoxicity did not correlate with 
creatinine or phosphate, or any routine haematological parameters, or age.  In the lipid 
patient group there was no correlation between NK cell cytotoxicity and BMI or blood 
pressure.  Blood pressures were not available for the control group. 
 
Looking at the lipid patient group, there was no difference in NK cell cytotoxicity 
between those taking a statin and those who were not.  NK cell cytotoxicity was 
significantly lower in those patients who were taking ezetimibe (37.07±11.37 vs 
46.83±12.08, p < 0.05).  Again, it should be noted again that of the thirteen patients 
taking ezetimibe, only 4 of these were not also on a statin.  None of the patients taking 
ezetimibe were on a fibrate or omacor.  There was also no difference in NK cell 
cytotoxicity between those patients taking a fibrate or not, and those taking omacor or 
not.  Finally, there was no difference in NK cell cytotoxicity in those patients taking an 
ACE inhibitor.   121 
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Figure 3.6.  Scatterplots showing the relationship between NK cell cytotoxicity and LDL-
C in both the control and the lipid patient groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
   122 
3.4   DISCUSSION 
 
The present study considers potential relationships between serum lipids and the immune 
system.  It is known of course that hyperlipidaemia, specifically increased total 
cholesterol and LDL-C, is associated with increased cardiovascular mortality which 
results from increased atherosclerosis.  That the process of atherosclerosis is an 
inflammatory condition involving the immune system has been discussed at length 
previously.  The relationship between hyperlipidaemia and mortality is less clear cut in 
the elderly.  Some studies have shown that lower HDL-C levels are a stronger predictor 
of mortality than total cholesterol in the elderly [277, 278].  However, there appears to be 
a J-shaped relationship between total cholesterol and mortality, even with adjustment for 
health status and indicators of frailty [279, 280].  Many studies over the past few decades 
have suggested that having a low serum cholesterol is associated with increased age-
adjusted mortality from non-atherosclerotic diseases, including chronic diseases and 
malignancy, which is not simply attributable to smoking or alcohol consumption [281].  
A potential explanation for observed relationships between cholesterol and non-
atherosclerotic disease is a link between serum lipids and immune function.  The immune 
system provides resistance to infections and tumours, and plays a role in most, if not all, 
chronic diseases. 
   
We have found that there are significantly higher numbers of NKT cells in the lipid group 
patients, and although NK cell numbers were not different between groups, there were 
proportionately more CD56
dim cells in the lipid group patients, and significantly fewer   123 
CD56
bright cells.  This applies whether on statin therapy or not.  This would suggest that 
NK cell cytotoxicity would be higher in the lipid patient group however this was not the 
case.  Additionally, there was no significant difference in NK cell numbers between 
groups that may have accounted for the lack of difference in cytotoxicity, although NK 
cell numbers were equalised for the cytotoxicity assay.  It is possible that lipid lowering 
alters NK cell phenotype, but perhaps more likely is that NK cell phenotype is altered 
with a disease state, in other words by dyslipidaemia.  It should be noted that there was 
no difference in NK cell subsets or activity whether or not patients had ischaemic heart 
disease or diabetes, although the number of diabetics included was very small (7 out of 
66) as previously stated, diabetics were included later on in the study.  The patients in the 
lipid patient group were significantly older, which may also explain the alterations in NK 
cell subsets, as CD56
dim cells are know to be expanded in elderly populations [84].  
Reassuringly, this was confirmed in the current study where a significant correlation was 
shown between CD56
dim cells and age in the control group. 
  
In the control group, there was a positive correlation between HDL-C and T cells and 
HDL-C and CD56
bright cells (with a negative correlation with CD56
dim cells) which is in 
keeping with the higher HDL-C values in the control group.  Interestingly, NK cell 
numbers correlated with creatinine in the control group.  It may be that this is simply a 
reflection of muscle mass.  There were no differences in NK-, NKT-, or T-cell numbers 
between patients on different lipid lowering therapies, and notably there was no 
difference whether or not on statin treatment.  This is in keeping with findings from a 
previous double-blind, randomised, placebo-controlled study [282] of 24 adult renal   124 
transplant recipients, receiving cyclosporin for immunosuppression.  They randomised 
patients who had high or borderline high cholesterol levels to receive 10mg of 
simvastatin or placebo, and quantified NK cells by FACS at randomisation and at day 90, 
to investigate whether a reduction in NK cell numbers with statin therapy could serve as 
an explanation for reduced rates of graft rejection that have been observed in statin 
treated recipients of organ transplantation [152, 271].  Whilst cholesterol levels were 
significantly reduced, they found no changes in numbers of NK cells.   
 
We did not find a difference in NK cell cytotoxicity between control and lipid patient 
groups whether or not they were on statin therapy.  These results are consistent with other 
studies where no changes in NK cell cytotoxicity in patients with high or low cholesterol 
levels [283], or with statin treatment [283].  One particular study found no change in NK 
cell numbers and no reduction in NK cell activity in 25 stable renal transplant recipients 
on either cyclosporin or azathioprine, all treated with 20mg of pravastatin [284].  Patients 
were assessed at 6 and 12 weeks, and in fact an increase in NK cell activity at 12 weeks 
in the cyclosporin treated group was observed. 
  
Interestingly we found a negative correlation between NK cytotoxicity and LDL-C in 
both groups.  This is not consistent with findings from studies previously carried out by 
our group which showed significant and reversible reductions in NK cell cytotoxicity ex 
vivo, in subjects treated with simvastatin, and also a correlation between NK cell 
cytotoxicity and total and LDL-C [150].  The current study involves larger numbers, and 
more importantly, NK cells have been purified in this study, whereas the previous studies   125 
were carried out using a crude lymphocyte preparation.  Another previous study from this 
group in 146 diverse patients or various treatments including statins and 
immunosuppressants, did not find lower NK cell cytotoxicity with statin treated patients, 
but found total cholesterol and weight to be independently associated with NK cell 
cytotoxicity [153].  It is interesting to consider that rather than directly as a result of statin 
treatment itself, changes in immune cell function may be a consequence of changes in 
circulating cholesterol levels, and thus changes in cell membrane cholesterol.  The 
negative correlation between NK cell cytotoxicity and LDL-C does not appear to be 
simply a lipid lowering effect as the relationship is also shown in the control group.  
A study by Jonasson et al. [95] investigated NK cell subset distribution and cytotoxicity 
in 95 patients with coronary artery disease (CAD).  These patients had significantly 
higher total cholesterol, LDL-C and triglycerides, and lower HDL-C.  They found lower 
numbers of NK cells and CD56
dim cells in the patients with CAD, and reduced NK 
cytotoxicity, although this was thought to be due to reduced NK cell numbers in the CAD 
group.  Conversely, higher NK cell cytotoxicity has been found to be related to HDL-C in 
a study of 47 elderly males [285].  The relationship between NK activity and LDL-C may 
relate to oxidative stress.  NK cells are particularly susceptible to oxidative stress and in 
several studies, oxidised LDL cholesterol (oxLDL), a key component of human 
atherosclerotic tissue particularly abundant in unstable lesions [286], has been shown to 
inhibit NK cell cytotoxicity [97, 287].  Another interesting theory is that loss of NK cell 
function increases susceptibility to atherosclerosis-related infections, for example 
Chlamydia pneumoniae, and in the context of an increased LDL-C may result in 
increased plaque burden.   126 
 
There were limitations to this study; the control group was not aged-matched and thus the 
changes in NK cell distribution could be potentially attributable to the older age of the 
lipid group patients.  The small number of diabetics included and the incomplete 
collection of data regarding drug history were limitations.  It should be noted also that the 
resuspension medium contained 12.5% foetal bovine serum which is rich in lipoproteins 
and could confound results.  However all assays of NK cell cytotoxicity were carried out 
uniformly. 
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CHAPTER 4 
 
A Study of Natural Killer Cells in Chronic Kidney 
Disease 
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4.1  INTRODUCTION 
 
Chronic renal failure is an immunodeficient state involving defects in both cellular and 
humoral immunity [288].  These patients are at higher risk of infectious complications, 
and among dialysis patients particularly, this leads to a high morbidity and mortality, 
second only to cardiovascular disease as a cause of death [289].  Paradoxically however, 
this often coexists with signs of activation of the immune system.  Infectious 
complications and cardiovascular disease are closely linked to immune function, with 
immune suppression resulting in the increased incidence of infections, and immune 
activation leading to inflammation that may contribute to CVD.   
 
The innate immune system provides a first line of defence against infection, in addition to 
playing a role in the initiation and subsequent direction of adaptive immune responses, 
and contributing to the removal of pathogens that have been targeted by the adaptive 
immune response.  The high frequency of bacterial infections in dialysis patients suggests 
that polymorphonuclear leukocyte dysfunction may be involved in the immune 
deficiency in this population.  It has been shown that higher levels of circulating pro-
inflammatory cytokines are associated with mortality, while immune parameters 
reflecting improved T-cell function are associated with survival in ESRD patients on 
haemodialysis, independent of other medical risk factors [199, 213].  It has also been 
previously shown that haemodialysis induces a decrease in the absolute numbers of 
peripheral blood lymphocytes, with higher numbers of NK- and NKT cells [212], and a 
decrease in the cytotoxic activity of the NK cells compared with controls [290].  A   129 
similar relationship has been shown in patients with cardiovascular disease where 
reduced lymphocyte counts have been identified as predictors of mortality [291, 292].  
Whilst the association between inflammation and cardiovascular disease is well 
documented [293, 294], the immune dysfunction in renal failure is not completely 
understood and has been attributed to uraemic toxins, malnutrition, oxidative stress, 
altered renal metabolism of immunologically active proteins, for example pro-
inflammatory cytokines, and dialysis therapy [209].  Previous studies have focused 
mainly on T- and B-cells.  The role of NK cells in chronic renal failure is less well 
studied, with conflicting results.  Both reduced NK cells numbers and activity [216, 290, 
295, 296], and also enhancement [212, 217] have been reported, focusing mainly on 
dialysis patients.  Our interest in this study was related to the emerging role of NK cells 
in atherosclerosis, and the high incidence of cardiovascular disease in CKD.  The aim of 
this study was to examine the function and phenotype of NK cells in patients with a range 
of chronic renal failure, including dialysis patients, and to correlate this with clinical and 
laboratory parameters. 
 
4.2  METHODS 
 
4.2.1  Patients 
Blood samples were taken from 143 patients across the range of renal function.  Fifty 
millilitres of blood was taken into BD vacutainer collection tubes.  There were 36 healthy 
volunteers, 14 patients with CKD stages 1 and 2, 34 patients with CKD stages 3 and 4, 48 
patients with CKD stage 5, and 11 patients on haemodialysis (HD).  Patients were   130 
divided into 3 groups – controls, CKD 1-4, and CKD 5 which included the dialysis 
patients.  In the patients on HD, blood samples were taken within 15 minutes of the start 
of the dialysis session in all the patients on dialysis.  Biochemical, haematological, and 
clinical parameters including age, gender, BMI, and renal diagnosis were recorded.  None 
of the patients had infection or malignancy, and none were immunosuppressed.  In all 
143 patients, NK cells were isolated and NK cell phenotype and distribution of NKT- and 
T-cells was determined.  Routine biochemical parameters including urea and electrolytes, 
albumin, phosphate, calcium, glucose, lipid profile, and creatinine were obtained from 
biochemistry laboratory reports, and full blood counts were obtained from haematology 
laboratory reports.  LDL-C was not available for all patients as some blood samples were 
obtained from afternoon clinics and afternoon or evening dialysis shifts, and therefore 
patients could not be asked to fast.  LDL-C was calculated (cLDL-C) using the Freidwald 
formula [297]. 
 
4.2.2  Human peripheral blood mononuclear cell isolation 
Peripheral blood mononuclear cells were isolated from peripheral venous blood as 
described in section 2.4.1.3 using Ficoll-Hypaque centrifugation (Histopaque-1077; 
Sigma, Poole, UK). 
 
4.2.3  NK cell isolation 
Natural killer cells were isolated using the MACS NK cell human isolation kit (Miltenyi 
Biotec) as described in section 2.4.2. 
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4.2.4  51-Chromium Release Assay 
Natural killer cell cytotoxicity was measured using a standard 51-Chromium Release 
Assay, using the human chronic myelogenous leukaemia cell line – K562 as target cells, 
as described in section 2.4.3. 
 
4.2.5   Flow Cytometry 
Three colour flow cytometry of PBMCs was carried out (BD Biosciences FASCalibur) 
before isolation of NK cells to determine NK cell phenotype and distribution of NKT- 
and T-cells as described in section 2.4.4.  The NK-, NKT-, and T-cells were expressed as 
a percentage of total lymphocyte count, and the CD56
bright and CD56
dim subsets were 
expressed as a percentage of NK cells. 
 
4.2.6   Statistical Analysis 
Statistical analysis was carried out using SPSS statistical package (version 15.0).  The 
association between continuous variables was analysed using Pearson correlation test.  
Non parametric data were logarithmic transformed and Pearson correlation was used.  
Analysis of variance (ANOVA) was used to test differences between groups with post 
hoc Scheffe‟s test.  Multiple linear regression analysis was used to assess the contribution 
of different factors to changes in lymphocyte subsets and NK cell cytotoxicity.  
Significant was taken to mean p<0.05. 
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4.3  RESULTS 
 
4.3.1  Patient Characteristics and Laboratory Data 
The clinical and laboratory data are shown in Table 4.1 and the primary causes of renal 
disease are shown in Table 4.2.  The renal diagnosis was unavailable for 22 patients.  
There was a statistically significant difference in age between the controls and the CKD1-
4 and CKD5 groups.  There was also a statistically significant difference between 
creatinine and eGFR between all groups as would be expected.  Haemoglobin was lower 
in the CKD5 group.  There was no difference in total white cell count between groups, 
but there was a statistically significant difference in platelet count between all 3 groups, 
being lowest in the CKD5 group.  There was a significant difference in serum phosphate 
between the CKD5 group and all other groups (p<0.001), shown in Figure 4.1, even 
when the HD patients were excluded from analysis.  There was no difference between 
adjusted calcium between groups.  Serum albumin was significantly lower in the CKD1-4 
and CKD5 groups (Figure 4.2), and serum glucose was significantly lower in the CKD1-
4 group.   
 
There was no significant difference in total cholesterol between groups, but HDL-C was 
significantly lower in the CKD1-4 (p<0.05) and CKD5 (p<0.001) groups compared with 
controls.  Triglycerides were significantly higher in the CKD1-4 groups compared with 
controls (p<0.05), but there was no difference in cLDL-C between groups, or in non-
HDL-C. 
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Creatinine correlated significantly with haemoglobin (r = -0.367, p<0.01), platelet count 
(r = -0.355, p<0.01), albumin (r = -0.196, p<0.05), and phosphate (r = 0.513, p<0.01) 
(Figure 4.3).  Haemoglobin had a significant negative correlation with phosphate (r = -
0.438, p<0.01) and positive correlation with albumin (r = 0.470, p<0.01).  Phosphate and 
albumin inversely correlated (r = -0.275, p<0.01).  There was a negative correlation 
between total cholesterol and creatinine (r = -0.260, p<0.01) (see Figure 4.4), and HDL-C 
and creatinine (r = -0.371, p<0.01).  Phosphate had a significant correlation with 
triglycerides (r = -0.234, p<0.01), but not other lipid fractions.  Calculated LDL-C 
correlated weakly but significantly with adjusted calcium (r = 0.186, p<0.05), and with 
platelet count (r = 0.199, p<0.05).  There was also a significant correlation between 
creatinine and age (r = -0.21, p<0.05), and creatinine and SBP (r = 0.27, p<0.05) and 
DBP (r = 0.322, p<0.001) (BP was not available for control patients). 
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1.5 ± 0.5 1.1 ± 0.2 1.1 ± 0.1 Phosphate (mmol/L)
2.4 ± 0.2 2.4 ± 0.1 2.4 ± 0.1 Adjusted calcium (mmol/L)
37.1 ± 4.8 38.4 ± 4.1 41.7 ± 2.5 Serum albumin (g/L)
5.3 ± 1.7 7.3 ± 4.7 5.0 ± 0.9 Serum glucose (mmol/L)
6.9 ± 1.7 7.6 ± 2.2 7.1 ± 2.4 WBC count (x 109/L)
218.0 ± 71.4 249.8 ± 65.8 290.4 ± 50.2 Platelets (x 109/L)
11.8 ± 1.3 12.8 ± 1.7 13.4 ± 1.3 Haemoglobin (g/dL)
4.5 ± 1.2 4.8 ± 1.2 4.9 ± 1.1 Cholesterol (mmol/L)
10.0 ± 3.6 45.9 ± 23.4 79.5 ± 12.2 eGFR (ml/min)
528.6 ± 178.2 148.7 ± 55.1 82.0 ± 10.9 Creatinine (μmol/L)
27.2 ± 8.9 28.2 ± 8.2 24.8 ± 5.0 BMI (kg/m2)
40/19 21/27 10/26 Gender (M/F)
61.9 ± 14.5 60.2 ± 16.3 41.6 ± 12.8 Age (years)
59 48 36 Patient number
CKD5&HD CKD1-4 Controls Clinical Parameters
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Table 4.1.  Clinical characteristics of patients.  Values are expressed as mean ± SD. 
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9.1 Other
7.7 Polycystic 
4.2 Diabetes
9.1 Chronic pyelonephritis/interstitial 
nephritis
12.6 Glomerulonephritis
12.6 Renovascular
14.0 Unknown aetiology
Frequency (%) Renal Diagnosis
9.1 Other
7.7 Polycystic 
4.2 Diabetes
9.1 Chronic pyelonephritis/interstitial 
nephritis
12.6 Glomerulonephritis
12.6 Renovascular
14.0 Unknown aetiology
Frequency (%) Renal Diagnosis
 
Table 4.2.   Renal diagnosis 
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*
*
 
Figure 4.1.  A boxplot showing mean phosphate level. (* p<0.001). 
 
 
 
**
*
 
Figure 4.2.  Mean serum albumin level.  (* p<0.05, ** p<0.001). 
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Figure 4.3.  A scatterplot showing the relationship between creatinine (logarithmic 
transformed) and phosphate. 
 
 
r = -0.26
 
Figure 4.4.  A scatterplot showing the relationship between total cholesterol and 
creatinine.   138 
4.3.2  Distribution of Peripheral Blood Lymphocytes 
The distribution of peripheral blood lymphocyte subsets is shown in Table 4.3.  White 
blood cell counts were similar in all groups but there was a significant reduction in the 
total lymphocyte count in the CKD5 groups compared with controls and the CKD1-4 
group (p<0.05) as shown in Figure 4.5.  There was no significant difference in NK-, 
NKT- or T-cell numbers between groups, although when patients were re-analysed 
according to CKD stage (controls, CKD1&2, CKD3&4, CKD5, and HD patients), there 
was a significant reduction in T cells in the haemodialysis group (p<0.05) compared with 
all other groups except the CKD3&4 group (Figure 4.6).  There were no differences in 
CD56
bright or CD56
dim cells between groups, although on analysing according to CKD 
stage there was a significant reduction in CD56
dim NK cells in the HD groups vs the 
CKD1&2 groups (p<0.05). 
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* P < 0.05  v all groups 
†P < 0.05  v controls, CKD1&2, and CKD5 
‡P < 0.05 v CKD1&2 
**P < 0.05 v controls and CKD1-4 
 
 
Table 4.3.  WCC, lymphocyte and lymphocyte subset counts (expressed as a percentage 
of total lymphocytes). (a) shows patients divided into groups according to CKD stage (b) 
shows patients divided into 3 groups.  (CD56+CD16+CD3- represents NK cells, 
CD56+CD16+CD3+ represents NKT cells, CD56-CD16-CD3+ represents T cells). 
aPercentage of lymphocytes; 
bpercentage of NK cells.   140 
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Figure 4.5.  Distribution of peripheral blood lymphocytes between groups.  (a) shows the 
3 groups described in section 4.2.1.  (b) shows the patients divided according to CKD 
stage, including HD patients to show the significant difference in lymphocytes in the HD 
group. (*p<0.05). 
(b) 
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Figure 4.6.  (a) Distribution of T cells between groups (expressed as a % of lymphocytes) 
(b) Distribution of NK dim cells (expressed as a % of NK cells) between groups 
(*p<0.05). 
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There were no significant correlations between lipid fractions and NK or NKT cell 
number or NK cell phenotype.  There was a weak but significant correlation between T-
cells and total cholesterol (r = 0.185, p < 0.05) and HDL-C (r = 0.176, p < 0.05) (Figure 
4.7), and also between T-cells and cLDL-C (r = 0.195, p < 0.05).  There was a significant 
negative correlation between creatinine and T-cells (r = -0.222, p < 0.001), and a positive 
correlation between albumin and T-cells (r = 0.178, p < 0.05).  There was a weak 
negative correlation between glucose and CD56
bright NK cells (r = -0.191, p < 0.05).  As 
has been shown in previous studies, there was an inverse relationship between age and T 
cells (r = -0.410, p < 0.001) which remained statistically significant adjusting for sex, 
creatinine, eGFR, haemoglobin, white cell count, platelet count, statin treatment, total 
cholesterol, HDL-C, triglycerides, BMI, phosphate, albumin, adjusted calcium, and 
glucose (β coefficient -0.515, SD 0.132, p<0.001).  There were also significant 
correlations between age and NK cells (r = 0.20, p<0.05), NKT cells (r = 0.25, p < 0.01), 
CD56
bright (r = -0.26, p<0.01) and CD56
dim cells (r=0.26, p<0.01).  The relationship 
between age and NK cells, and age and CD56
dim cells also remained significant when 
adjusted for the above variables (β coefficient 0.178, SD 0.79, p<0.05; β coefficient -
0.21, SD 0.9, p<0.05 respectively).  Albumin correlated positively with T cells (r = 0.18, 
p<0.05) but this did not retain significance in multiple regression analysis.  There was no 
significant correlation with NK cell phenotype and creatinine.  There were no 
correlations between T cells, NK and NKT cells, or NK cell phenotypes and BMI or 
blood pressure.  There was a very strong negative correlation between NK bright and NK 
dim cells (r = -0.94, p < 0.001) as would be expected.   143 
 
Figure 4.7.  Scatterplot showing the relationship between T cells and total cholesterol (in 
blue) and HDL-C (in green).  T-cells are expressed as a percentage of lymphocytes. 
 
 
4.3.3  Natural Killer Cell Cytotoxicity 
There was no difference in NK cell cytotoxicity between groups, even when the HD 
patients were excluded from the CKD5 group.  There was a significant correlation 
between NK cell cytotoxicity and creatinine (r = 0.208, p<0.05) [Figure 4.8(a)], which 
remained when the HD patients were excluded from analysis (r = 0.203, p<0.05).  There 
was also a significant correlation between NK cell cytotoxicity and serum phosphate 
when analysed with the HD patients (r = 0.301, p<0.01) and without (r = 0.201, p<0.05) 
[Figure 4.8(b)].  The correlation between phosphate and NK cytotoxicity including the   144 
haemodialysis group remained significant after multivariate analysis (β coefficient 14.6, p 
= 0.006), adjusting for age, total cholesterol, cLDL-C, HDL-C, triglycerides,  log 
creatinine, haemoglobin, white cell count, platelet count, adjusted calcium, albumin, 
glucose, weight, and BMI (Table 4.4).  There was no significant correlation between NK 
cell cytotoxicity and albumin despite the relationship between albumin, creatinine and 
phosphate. 
 
There was no relationship between NK cytotoxicity and any of the lipid fractions.  
Despite the strong negative correlation between NK bright and NK dim cells, and 
significant correlations between total NK cells and NK bright (r = -0.39, p < 0.001) and 
NK dim (r = 0.352, p < 0.001) cell phenotypes, there was no significant correlation 
between NK cell phenotype and NK cell cytotoxicity.  Additionally, there was no 
correlation with age or blood pressure. 
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r = 0.208, p<0.05
(a)
 
(b)
r = 0.301, p<0.01
 
Figure 4.8.  Scatterplots showing the relationship between NK cell cytotoxicity and (a) 
serum creatinine, (b) serum phosphate.  NK cell cytotoxicity is expressed as percentage 
of 
51Cr released. 
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0.087 -0.211 BMI (kg/m2)
0.194 -0.158 Weight (kg)
0.259 -0.141 Glucose (mmol/L)
0.883 0.018 Albumin (g/L)
0.246 -0.144 Adjusted calcium (mmol/L)
0.441 0.100 Platelets (x 109/L)
0.505 -0.083 WCC (x 109/L)
0.410 0.114 Haemoglobin (g/dL)
0.733
0.973
0.388
0.297
0.415
0.636
0.006
P
0.106 cLDL-C (mmol/L)
-0.101 Age (years)
-0.087 Log creatinine (μmol/L)
0.043 Triglycerides (mmol/L)
-0.004 HDL-C (mmol/L)
0.130 Total cholesterol (mmol/L)
14.627 Phosphate (mmol/L)
Multivariable beta 
coefficient
Variable
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Table 4.4  Multivariate predictors of NK cell cytotoxicity 
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4.4  DISCUSSION 
It has recently been recognised that atherosclerosis is a multi-factorial, highly complex 
disease that is now widely accepted as an inflammatory disease, and the participation of 
NK and NKT cells have been demonstrated [69, 87, 89, 298].  In addition, NK cells have 
been identified in atherosclerotic lesions [89], and atherogenic diet fed ldl-r-/- mice 
deficient in functional NK cells had a statistically significant reduction in atherosclerotic 
lesions [87].  There have been few comparable studies in human atherosclerotic disease.  
Human NK cells comprise 15% of all lymphocytes, and are defined phenotypically by 
their expression of CD56 and lack of expression of CD3.  Additionally, NK cells are not 
a homogeneous population.  As mentioned previously it has been recognized that two 
distinct populations of human NK cells can be identified, based upon their cell surface 
density of CD56 [79].  Resting CD56
dim cells are the more cytotoxic subset, whereas the 
CD56
bright NK-cell subset mediates low or no cytotoxicity but has the capacity to produce 
large amounts of various immunoregulating cytokines such as IFN-γ in response to 
interleukin (IL)-12 and IL-18.  All three of these cytokines have been shown to have 
proatherogenic effects [299].   
 
Natural killer cell function in dialysis patients has been analysed previously [212, 216, 
217, 290, 295, 296], but these studies have compared dialysis patients with healthy 
controls, or included patients with CKD but in much smaller numbers, with conflicting 
results.  Our study aimed to assess NK cell function in patients throughout the range of 
renal failure, to look for alterations in NK cell phenotype related to renal function, and to 
correlate this with clinical and laboratory parameters.  Conflicting results from previous   148 
studies looking at NK cells in renal failure and dialysis patients may be explained by 
small patient numbers, and changes in practice in terms of use of statins, phosphate 
binders, and dialysis membranes.   
 
In the present study, we have confirmed the expected correlations between albumin, 
haemoglobin, phosphate, and creatinine in this group of patients.  We found a significant 
reduction in T cells in the RRT group that has been well described [300] and an inverse 
relationship between T cells and age, and although we did not find any alterations in NK 
cell counts with increasing renal failure, we did find a correlation between age and total 
NK cell numbers and CD56
dim NK cells as has been previously described [301], and 
interestingly an inverse relationship between age and CD56
bright NK cells.  The most 
interesting finding was the correlation between NK cell cytotoxicity and phosphate, and 
although there was a correlation between NK cytotoxicity and creatinine, this correlation 
did not retain significance after multivariate linear regression analysis.  However, by the 
strong association creatinine has with phosphate it is intriguing to speculate on an 
association.  Clearly the relationship between increasing creatinine and rising 
cardiovascular risk is indisputable.  There is an abundance of emerging evidence of the 
contribution that phosphate has in cardiovascular disease [223], particularly in the 
dialysis population in the context of cardiovascular calcification [302], and an association 
between phosphate and increased mortality has been described [223].  Phosphate has also 
been found to have a role in proliferation of vascular smooth muscle cells – a contributor 
to the development of atherosclerotic lesions – in vitro [228], and phosphate binders have 
been shown to have anti-inflammatory effects, and favourable effects on lipid profiles   149 
[303].  The phosphate binder sevelamer has also been shown to prevent uraemia-
enhanced atherosclerosis progression in apoE-/- mice [304].  Our findings lend support to 
the role of phosphate and NK cells in cardiovascular disease, particularly in patients with 
CKD. 
   
In patients with chronic heart failure however, NK cells have been shown to be present in 
lower circulating numbers, and to exhibit impaired cytolytic function [86].  Reductions in 
NK cell number with a loss of NK cell function thought to be a quantitative rather than 
qualitative defect has also been described in patients with coronary artery disease [95] 
who were found to have evidence of an enhanced inflammatory response by higher levels 
of C-reactive protein and IL-6, although the authors were unable to exclude statin 
treatment as a cause for the reduced NK cell activity.  An interesting speculation by the 
authors was that a loss of NK cell activity might increase susceptibility to atherosclerosis-
related pathogens.  They went on to find increased numbers of apoptotic NK cells in 
peripheral blood of coronary artery disease patients compared with healthy controls, and 
that the NK cells were more sensitive to spontaneous apoptosis ex vivo [97].  A recent 
study in patients with renal failure found that although NK cell numbers were lower in 
haemodialysis patients compared to healthy controls and undialysed patients with CKD, 
NK cytotoxicity was positively correlated to dialysis duration [295],  a finding that is in 
keeping with the inflammatory state of renal failure and dialysis. 
 
The role of NK cell subsets in vivo is not entirely clear.  For example, normal ratios of 
NK cell subsets have been found to be altered during ageing – numbers of CD56
dim NK   150 
cells are expanded in elderly populations, with no significant change in the numbers of 
CD56
bright NK cells [301].  Functionally, NK cells in the elderly are less responsive to IL-
2-induced proliferation, perhaps as a consequence of an increased percentage of CD56
dim 
NK cells and reduced CD56
bright NK cells.  Our findings are in keeping with this although 
we found a reduction in the CD56
bright subset.   
 
In summary, our results suggest a link between NK cell activity and renal function, and in 
particular serum phosphate, which has been shown to have a role in cardiovascular 
disease.  The finding of increased NK cell numbers and increases in the CD56
dim subset 
with age may have importance given our ageing population and increasing numbers of 
older patients being accepted for RRT.  The state of chronic inflammation, altered 
mineral metabolism, uraemic toxins, dialysis, and other factors such as cytomegalovirus 
(CMV) infection, shown to be significantly associated with atherosclerotic disease in 
patients with end stage renal failure [305], that are specific to renal failure make 
understanding of the immune dysfunction in this group of patients important.  The high 
incidence of cardiovascular disease in this patient population with more evidence of the 
contributing role of the immune system, and in particular NK cells, to atherosclerosis 
stresses the need for further studies to evaluate the role they have to play in CKD patients 
and their link with vascular calcification. 
 
There were limitations to this study; again, the control group was not aged-matched and 
thus any changes in NK cell distribution or indeed cytotoxicity could be potentially 
attributable to the older age of the CKD patients.  The small number of diabetics included   151 
and the small number of HD patients could potentially affect results, although no major 
differences were found when data were analysed excluding the HD patients.  The blood 
samples being taken at the beginning of the dialysis session (within the first 15 minutes) 
in the HD patients may not give a true reflection of lymphocyte numbers and function as 
there is evidence that certainly T-cell function can change acutely during HD [306].  It 
would have been preferable to take samples immediately prior to connection to the 
dialysis machine.  The fact that the samples were non-fasting, hence a laboratory LDL-C 
value was not available was a major limitation, however due to the organisation of the 
renal clinics and dialysis shifts, with the majority of the patients being seen in afternoon 
clinics, it was not felt possible to ask patients to fast for such a prolonged period.  Once 
again, it should be noted also that the resuspension medium contained 12.5% foetal 
bovine serum which is rich in lipoproteins and could confound results.  However all 
assays of NK cell cytotoxicity were carried out uniformly. 
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CHAPTER 5 
 
An in vitro study of membrane cholesterol in natural 
killer cells 
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5.1  INTRODUCTION 
 
Conventional pharmacology is focused on membrane receptor and sub-cellular secondary 
messenger proteins.  However, the cell membrane that supports these proteins and their 
interactions is neither inert nor homogeneous.  Within the plasma membrane, functional 
cholesterol-rich membrane microdomains – lipid rafts – have high concentrations of 
receptors and signal transduction molecules [100, 105].  This arrangement facilitates high 
efficiency signal transduction. 
 
Drugs that inhibit cellular cholesterol synthesis by HMG-CoA reductase – statins – have 
proven benefits in the prevention of cardiovascular events in patients with dyslipidaemia 
and increased cardiovascular risk.  Numerous reports however, suggest that statins have 
effects that extend beyond the lowering of lipid levels, the so-called pleiotropic effects 
[154, 268] that include inhibition of cell proliferation and in particular, 
immunosuppressive [126, 127] actions.  Amongst these pleiotropic effects, statins have 
been demonstrated to impair NK cell cytotoxicity in vivo [307] and in vitro [150].  Two 
mechanisms have been proposed to explain this observation:  reduced production of 
isoprenoid intermediates in the cholesterol biosynthetic pathway which participate in cell 
signalling, and alternatively by depletion of cell membrane lipid rafts.  Natural killer cells 
appear particularly sensitive to the effects of statins, an observation that may reflect the 
critical dependence of NK cell activation and cytotoxicity on membrane rafts.   154 
The aim of this study was to investigate the effects of membrane cholesterol on NK cell 
function and specifically, whether the actions of statins on NK cells are due to depletion 
of membrane cholesterol or inhibition of isoprenylation. 
 
5.2  METHODS 
 
These were in vitro experiments and the NK92MI cell line was used. 
 
5.2.1  Cell Culture 
NK92MI cells were maintained at 37
oC, with 5% CO2 in a water saturated atmosphere in 
alpha minimum essential medium without ribonucleosides and deoxyribonucleosides and 
supplemented with 2mM L-glutamine, 10 U/ml penicillin, 10 μg/ml streptomycin, 0.2nM 
inositol, 0.1mM 2-mercaptoethanol, 0.02mM folic acid, 12.5% horse serum and 12.5% 
fetal bovine serum (all from Gibco, Paisley, UK).  K562 cells were maintained in RPMI 
supplemented with 2mM L-glutamine, 10 U/ml penicillin and 10g/ml streptomycin. 
 
5.2.2  Stock Solutions of cholesterol and statin 
Soluble cholesterol (Sigma, Poole, UK) was dissolved in NK92MI media to a stock 
concentration of 1mg/ml and added to cells at the concentrations indicated.  Simvastatin 
was dissolved in 50μl DMSO, then diluted to a stock concentration of 200ug/ml in 
NK92MI media and added to cells at the concentrations indicated. 
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5.2.3  Cholesterol Loading 
NK92MI cells were treated with increasing concentrations of cholesterol (as a 
cholesterol-methyl-beta-cyclodextran complex [MBCD]) as described in section 2.4.5.  
To load cells, varying concentrations ranging from 5 - 100μg/ml of the cholesterol-
MBCD complex was added to 1 x 10
6 cells/ml to a volume of 2 ml RPMI media.  Cells 
were then incubated at 37
oC for increasing lengths of time; from 30 minutes to overnight 
incubation.  They were then washed with PBS.   
 
To cause raft disruption, NK92MI cells were spun down, resuspended in 1ml of media 
and seeded at a density of 1 x 10
6 cells/ml in 6-well plates, in 2 ml of media in 
combination with either 1mM methyl-beta-cyclodextran or 2μmol of simvastatin. 
 
5.2.4  51-Chromium release assay 
NK92MI cells were seeded at a density of 1 x 10
6 cells/ml in 2.0 ml of media and treated 
with various concentrations of soluble cholesterol (Sigma, Poole, UK).  K562 cells were 
used as target cells for NK cells, and a 51-Chromium release assay was carried out to 
assess NK cell function, as described in section 2.4.3. 
 
5.2.5  Cell Membrane Preparations 
Cell membranes were prepared as described in section 2.5.1.  Membrane pellets were 
resuspended in cold membrane preparation buffer for analysis by SDS-PAGE and 
Western blot.   
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5.2.6  Cholesterol measurement 
Cholesterol quantification was performed with the Amplex Red Cholesterol Assay Kit 
(Molecular Probes, Invitrogen, Paisley, UK) as described in the manufacturer‟s protocol, 
and in section 2.6.1. 
 
5.2.7  Isolation of Lipid Rafts 
The treated NK92MI cells were lysed with MNE and subjected to sucrose gradient 
centrifugation and sucrose layering as described in section 2.5.3.  Volumes were adjusted 
to contain equal protein levels (as determined by Bradford‟s assay).  A fraction of the 
sample was retained to compare expression in whole cell lysates and the rest subjected to 
sucrose gradient centrifugation at 45,000 rpm (287.500 x g) for 18 hours in a SW60-ti 
rotor (Beckman Instruments).  The samples for centrifugation were mixed (1 in 2) with 
80% sucrose MNE, with 30% then 5% sucrose MNE layered on top.  Rafts were 
collected from the 5% and 30% sucrose interface as described in section 2.5.3.1.   
 
5.2.8  Western Blotting 
Cell lysates were resolved by SDS-PAGE and transferred to nitrocellulose membranes 
(NuPage pre-cast gel SDS-PAGEsystem, Invitrogen, Paisley, UK).  Nitrocellulose 
membranes were incubated in blocking buffer (tris-buffered saline containing 0.1% 
Tween 20 and 4% non-fat milk) and incubated overnight at 4
oC with the specified 
primary antibody diluted 1:1000 [Anti-LAT and anti-HMG-CoA Reductase (Upstate, 
Lake Placid, USA); Lyn (Santa Cruz, USA); ERK (New England Biolabs, Ipswich, UK)].  
Membranes were incubated with appropriate horse-radish peroxidase conjugated   157 
secondary antibodies for 1 hour, and developed using the enhanced chemiluminescence 
detection system (Amersham, Buckinghamshire, UK).   
 
5.2.9  Ras activation 
Ras activity was measured using a Ras Activation Assay Kit which is western blot based, 
as described in section 2.6.2.  Ras activation assays were carried out by Dr Dianne 
Hillyard (Renal Research Group, BHF Glasgow Cardiovascular Research Centre). 
 
5.2.10  HMG-CoA Reductase 
We measured gene expression for HMG-CoA reductase in NK92MI cells that had been 
treated with either soluble cholesterol or 5μmol simvastatin, by real time PCR and 
quantified enzyme protein by Western blotting as described in section 2.7.  Real time 
PCR was carried out by Dr Dianne Hillyard (Renal Research Group, BHF Glasgow 
Cardiovascular Research Centre). 
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5.3   RESULTS 
 
5.3.1  Membrane and raft cholesterol measurements 
NK92MI cells were treated with increasing concentrations of cholesterol (as cholesterol-
MBCD complex), and incubated at 37
oC for 1 hour.  Complete membranes were then 
isolated from the NK92MI cells.  The hour long incubation resulted in increasing levels 
of membrane cholesterol with increasing concentrations of cholesterol.  There was no 
significant change in cytosolic cholesterol (Figure 5.1).   
 
Next, NK92MI cells were treated uniformly with 50μg/ml of cholesterol, for increasing 
lengths of time.  MBCD (not complexed to cholesterol) was used as a control to cause 
membrane cholesterol depletion.  Complete membranes were then isolated to measure 
membrane and then raft cholesterol.  Short incubations with MBCD-cholesterol doubled 
the incorporation of cholesterol into NK cell membranes.  Longer periods of exposure 
returned membrane cholesterol towards baseline levels (Figure 5.2). 
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Figure 5.1 (a) A bar chart showing membrane cholesterol content increases with 
increasing concentrations of cholesterol added.  (Representative of 2 experiments, 
expressed as the mean ± SD) (b) Membrane cholesterol increases with increasing 
concentrations of added cholesterol but cytosol cholesterol remains unaltered. 
(a) 
(b)   160 
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Figure 5.2  Increasing duration of incubation time with cholesterol-MBCD results in 
increasing levels of membrane cholesterol incorporation in both the whole cell membrane 
and raft fraction.  However, prolonged (overnight) incubation resulted in levels returning 
to baseline.  MBCD was used as a control to cause membrane cholesterol depletion.  
(Data are expressed as the mean ± SD, and are representative of 2 experiments). 
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Cholesterol-rich membrane microdomains were then investigated.  Rafts were isolated 
from NK92MI cells which were loaded with cholesterol-MBCD as described above, by 
sucrose density centrifugation.  The cholesterol content of the raft fraction increased with 
prolonged exposure to exogenous cholesterol, and then tended to fall, approaching 
baseline levels after overnight exposure (Figure 5.2). 
 
It has been hypothesised that statins disrupt signalling pathways by inhibiting prenylation 
of small G protein signalling molecules [308].  Following statin treatment, mevalonate 
has been shown to restore both isoprenoid and cholesterol synthesis, in contrast to the 
restoration of membrane cholesterol alone by soluble cholesterol.  Thus, we investigated 
the effect of excess cholesterol on simvastatin treated cells.  NK92MI cells were treated 
with 5μmol of simvastatin for 48 hours.  This has previously been shown to be the length 
of time required for simvastatin to alter cell function [150] without causing significant 
statin-induced apoptosis.  This concentration of simvastatin has also been shown to be 
clinically relevant.  Following the incubation with simvastatin, cells were then incubated 
with soluble cholesterol-MBCD, to restore membrane raft cholesterol.  Mevalonate 
rescue was also studied.  Cell membranes and rafts were then isolated.  Simvastatin 
reduced cholesterol content in membranes, however no change in raft-cholesterol could 
be detected using this assay.  This is likely to be a reflection of the sensitivity of the assay 
in view of previous observations [153].  Addition of soluble cholesterol reversed the 
effects of simvastatin on membrane cholesterol content as, although to a lesser extent, did 
mevalonate.  Raft cholesterol content was similarly increased by short-term, and also to a 
lesser extent by longer-term, exposure to soluble cholesterol-MBCD (Figure 5.3).   162 
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Figure 5.3  Cholesterol and mevalonate rescue statin inhibition of membrane and raft 
cholesterol.  NK92MI cells were treated with 5μM of simvastatin for 48 hours and the 
resulting cholesterol inhibition was rescued by incubation with cholesterol for either 3 
hours or overnight, or with 1mM mevalonate incubation overnight.  (a)  3 hour 
cholesterol and overnight cholesterol successfully rescued the inhibition of membrane 
cholesterol by simvastatin.  Mevalonate also rescued the inhibition but to a lesser extent.  
(b)  3 hour cholesterol and overnight cholesterol also successfully rescued the inhibition 
of raft cholesterol content by simvastatin.  (This was the average of 5 experiments.  The 
data are expressed as mean±SD.  Students t-test was used to compare with control.  
*p<0.05, **p<0.005, ***p<0.0005).  
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In order to measure raft-associated signal proteins, specifically LAT and Lyn, isolated 
raft fractions were also subjected to SDS PAGE and Western Blotting (Figure 5.4).  LAT 
is palmitoylated and Lyn is merystolated, and are therefore unlikely to be affected by 
reduced levels of isoprenoids [309].  LAT and Lyn levels were both shown to be reduced 
by simvastatin treatment.  Short term exposure to soluble cholesterol increased both LAT 
and Lyn levels in the raft fractions whereas longer exposure reduced levels towards 
baseline, corresponding with changes in membrane cholesterol levels seen in Figure 5.1.  
Short term soluble cholesterol also rescued statin inhibition, with longer term exposure 
only rescuing LAT (but not Lyn), again corresponding to cholesterol levels in Figure 5.2.   
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Figure 5.4.  Simvastatin reduces raft markers (and therefore rafts).  Rafts were isolated 
from NK92MI cells treated with simvastatin and cholesterol and western blot was carried 
out for the raft markers LAT and Lyn.  Simvastatin reduced both LAT and Lyn, and 
therefore rafts.  Short term incubation (3 hours) increased LAT and Lyn (and rafts), 
whereas longer term incubation with cholesterol (overnight) reduced levels to baseline.  
Cholesterol loading for 3 hours rescued statin inhibition, whereas overnight cholesterol 
only rescued LAT (and not Lyn). 
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5.3.2  Natural killer cell cytotoxicity 
The functional effect of raft disruption on NK cells was investigated by cytotoxicity 
assay.  The NK92MI cells were incubated with 100μg/ml of soluble cholesterol for 
increasing duration, and then incubated with Chromium-51 laden target K562 cells in a 
Chromium release cytotoxicity assay.  NK cell cytotoxicity decreased with time exposed 
to soluble cholesterol (Figure 5.5), in contrast with the increased raft levels in Figures 5.3 
and 5.4.  Additionally, as would be expected NK cell cytotoxicity decreased with 
simvastatin and MBCD treatment, corresponding with decreased raft levels in Figure 5.3. 
 
-100
-75
-50
-25
0
C
o
n
t
r
o
l
S
i
m
v
 
(
5
µ
M
)
3
h
r
 
c
h
o
l
(
1
0
0
µ
g
/
m
l
)
O
/
N
 
c
h
o
l
(
1
0
0
µ
g
/
m
l
)
3
h
r
c
h
o
l
+
s
i
m
v
O
/
N
c
h
o
l
+
s
i
m
v
M
B
C
D
c
y
t
o
t
o
x
i
c
i
t
y
 
a
s
 
%
 
o
f
 
c
o
n
t
r
o
l
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
 
 
Figure 5.5.  Shows that NK cytotoxicity decreases with time incubated with cholesterol.  
Data are expressed as a percent change from time 0.  The data are expressed as the mean 
± SD.  Student‟s t-test was used to compare with controls.  **p<0.005, ***p<0.0005.  
(This was the average of 6 experiments).   167 
5.3.3  Isoprenylated Proteins 
The discrepancy found between changes in membrane cholesterol, raft associated 
proteins and cytotoxicity described above, did not fit with the original hypothesis that 
changes in membrane cholesterol (membrane rafts) was the predominant mechanism 
through which statins exert their effect on NK cells (outlined in the introduction chapter).  
We therefore measured active Ras by Western Blotting in the cell membranes.  Ras is a 
small G-protein that is localised in membrane rafts when activated and, unlike LAT or 
Lyn, the localisation is dependant on isoprenylation [12, 310].  Treatment of NK cells 
with simvastatin reduces Ras isoprenylation within the raft fraction of the cell membrane, 
and this reduction is not rescued by the addition of soluble cholesterol (Figure 5.6).  
Surprisingly, soluble cholesterol alone also reduced active Ras concentration.   
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Figure 5.6  Soluble cholesterol dose not affect prenylation of Ras and does not rescue 
inhibition of isoprenylation by simvastatin.  Fixed target K562 cells were used to activate 
Ras in NK92MI cells.  Active Ras was measured by a Ras activity kit and intensity of 
bands measured by densitometry.  The lower band represents isoprenylated Ras.  
Simvastatin inhibits isoprenylation of Ras and therefore its activity.  Soluble cholesterol 
had no effect on prenylation of Ras but did reduce Ras activity and did not rescue the 
inhibition of isoprenylation caused by simvastatin.  Fixed K562 cells did not contribute 
any Ras activity.  The data are expressed as the mean ± SEM. 
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These findings suggest that statins deplete membrane cholesterol and raft associated 
proteins in addition to inhibiting isoprenylation.  Replenishment of membrane cholesterol 
restores non-isoprenylated, raft-associated proteins such as LAT and lyn, but does not 
correct the functional effects of statins on NK cells.  One unexpected observation was the 
contrasting effects of long versus short exposure to soluble cholesterol.  One hypothesis 
is that this may be a consequence of negative feedback of supplemented exogenous 
cholesterol on HMG-CoA reductase, resulting in a similar effect to the addition of statins.  
To investigate this, NK92MI cells were treated with 100μg/ml soluble cholesterol, and/or 
5 μmol of simvastatin for 3 hours or overnight, and then HMG-CoA reductase gene 
expression was quantified using real time PCR.  Results are shown in Figure 5.7.  
Simvastatin alone increased HMG-CoA reductase greater than 2-fold, whereas soluble 
cholesterol reduced its expression.  The addition of soluble cholesterol to simvastatin 
treated cells reduced the expression, perhaps due to negative feedback of the exogenous 
cholesterol on the HMG-CoA reductase.  This was also confirmed by protein expression, 
shown by Western blot.  ERK was used as a protein loading control as it has been 
previously shown to be unaffected by statins [161].   170 
 
Figure 5.7.  Real time PCR of HMG-CoA reductase; shows that prolonged exposure to 
soluble cholesterol does down regulate HMG-CoA reductase gene.  This was also 
confirmed by protein expression, shown by western blot.  ERK was used as a protein 
loading control (as it is unaffected by statin treatment).  (Average of 6 experiments). 
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5.4  DISCUSSION   
 
Cholesterol is a major and essential component of the plasma membrane as well as of 
lipid rafts, contributing to the normal functioning of the cells.  It is now established that 
atherosclerosis is an inflammatory disorder with cholesterol acting as the major 
precipitating factor for the inflammatory process, however the mechanism linking the 
progression of cholesterol-related disease and inflammation remains unclear. 
 
It has previously been shown that statin therapy inhibits lymphocyte function [150] and 
NK cell cytotoxicity.  These actions are part of the spectrum of pleiotropic effects of 
statins that are thought to be independent of circulating cholesterol and are widely 
believed to be mediated by a reduction in intracellular isoprenoids [311].  However, more 
recent studies have suggested that statins in fact cause depletion of membrane cholesterol 
and raft-associated proteins that are not isoprenylated, and that inhibition of membrane 
cholesterol synthesis, and specifically disruption of membrane lipid rafts, is responsible 
for the pleiotropic effects [153].  What may actually be more physiologically relevant is 
the effect of increasing membrane cholesterol levels.  In these studies I have explored this 
hypothesis by modification of membrane cholesterol to see whether cholesterol 
enrichment of rafts might alter functionally important raft structural properties.  The 
results suggest that the pleiotropic effects of statins on NK cell function probably involve 
both inhibition of isoprenylation and cholesterol depletion, and that isoprenylated 
proteins including Ras play a central role in NK cell mediated cytotoxicity.  
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With previous work from this group showing that the depletion of cell membrane lipid 
rafts using MBCD reduced raft associated proteins and accordingly NK cell cytotoxicity 
[153], I attempted to augment membrane rafts by the use of a cholesterol-MBCD 
complex to cholesterol load the cells.  The MBCD acts as a vector through which 
cholesterol is incorporated directly into the cell membrane.  Consistent with this 
mechanism of action, the amount of cholesterol within the membrane and the raft 
fractions was able to be increased, using short term incubations.  This did not however 
result in an increase in NK cell cytotoxicity as originally hypothesised.  Following 
depletion of membrane rafts and raft-associated proteins with simvastatin, membrane 
cholesterol was restored with the use of cholesterol-MBCD.  This reversed the effects of 
statins on membrane cholesterol, and also on some raft associated proteins, specifically 
Lyn and LAT.  These proteins are myristoylated and palmitoylated respectively.  Despite 
the apparent restoration of rafts and raft-associated proteins however, NK cell 
cytotoxicity remained impaired, suggesting that raft function had not returned to normal 
as lipid rafts have been shown to be required for NK cell activation [312].  Further 
investigation determined the absence of active Ras – an isoprenylated protein – within 
these reconstituted rafts.  The findings of these studies thus suggests that both 
isoprenylation and intact membrane lipid rafts are essential for NK cell cytotoxicity at 
least in vitro.  It is therefore possible to impair NK cytotoxicity through depletion of rafts, 
for example with MBCD or statins, or effective isoprenylation inhibitors.  The variable 
pleiotropic effects of statins on different cell types is likely to reflect the relative 
dependence of cell functions on isoprenylation or rafts.  Where both are essential – as in 
NK cell cytotoxicity – then statins are likely to be particularly effective.  Although Ras is   173 
an example of an isoprenylated protein, other specific isoprenylated proteins required for 
NK cell cytotoxicity are unclear. 
   
The finding of altered cell function in the face of increased membrane cholesterol is 
interesting given the current understanding of the inflammatory nature of atherosclerosis 
which occurs in the context of hyperlipidaemia.  In line with this, increases in T cell 
membrane cholesterol associated with aging have been shown to inhibit T cell signalling 
through lipid rafts by impairing the recruitment of signalling proteins [313].  Elevated 
membrane cholesterol has also been found to alter macrophage signalling and function 
[314], more specifically, cholesterol loading inactivates RhoA in macrophages, inhibiting 
cell migration [315] – the Rho family of small GTPases are involved in migration 
through regulation of F-actin organization and actin-myosin contraction [316].  This has 
been offered as an explanation as to why macrophages are retained and accumulate 
within atherosclerotic lesions that are rich in lipids.  Variation in the cholesterol content 
of cells is likely to be a physiological regulator of membrane receptor function that 
affects all cells, indeed we have shown here that NK cell function is also related to 
circulating cholesterol levels at least in vitro.  In vivo, cells are continuously exposed to 
cholesterol in an equilibrium where cholesterol desorbs from albumin to cell membranes.  
The effects of diet, specifically malnutrition states, and also catabolic disease states can 
lead to marked variations in serum albumin concentrations which may be reflected in the 
cholesterol membrane content of cells.  Similarly, high serum or tissue-free cholesterol 
availability may lead to increases in the cholesterol content of cell membranes which   174 
could translate to alterations in the activation of immune cells, which in the case of high 
cholesterol levels could contribute to the progression of atherosclerotic lesions. 
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CHAPTER 6 
 
A study of biomarkers in patients at high risk of 
cardiovascular disease 
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6.1  INTRODUCTION 
 
Inflammation is now widely regarded as a contributor to morbidity in cardiovascular 
disease, and inflammatory markers are a subject of much interest, as potential non-
traditional cardiovascular risk factors.  Inflammatory proteins such as CRP have been 
shown to predict and correlate independently with, major cardiovascular end-points such 
as myocardial infarction and death [39, 40, 317].  The traditional risk factors for 
cardiovascular disease, such as family history, hypertension, smoking and dyslipidaemia, 
explain the majority of morbidity and mortality, however, these traditional risk factors do 
not fully account for the cardiovascular burden in certain populations, such as diabetics, 
and in particular, those with CKD.  Attention has therefore been recently focusing on 
whether the non-traditional risk factors are in fact independently associated with 
cardiovascular risk. 
 
C-reactive protein, the archetypal biomarker has been independently demonstrated to 
have associations with cardiovascular events and mortality among apparently healthy 
men and women [30, 33] as mentioned above.  It has also been shown to be associated 
with comorbidity and clinical events in haemodialysis patients [318] and also patients 
with CKD stages 3 to 5, along with other markers of inflammation such as 
hypoalbuminaemia [319].  An elevated serum hsCRP level has been shown to be a 
stronger predictor of incident cardiovascular events in healthy men than LDL-C and to be 
additive to the Framingham risk score [39].  Evidence supporting a role for CRP in 
atherogenesis is mounting.  It has been demonstrated in atherosclerotic plaques [44] and   177 
causes adverse changes to cultured endothelial cells [27].  It has been shown to be 
chemoattractant for monocytes [44], to directly affect endothelial function by altering NO 
bioavailability [27], and to up regulate Lectin-like oxidized LDL receptor-1 (LOX-1), 
which in turn promotes endothelial dysfunction [49].  Additionally, local administration 
of CRP in a rat balloon injury model increased neointimal formation [48]. 
 
Interleukin-6 plays a pivotal role in inflammation as it is an inducer of the hepatic acute 
phase response, with CRP the prototype of this response.  It is therefore unsurprisingly 
up-regulated in renal failure leading to elevated levels of IL-6 in ESRD patients [199].  
Along with CRP, IL-6 has been shown to be a strong predictor of mortality in both  
haemodialysis [173, 198]  and peritoneal dialysis [320] patients, and in patients with 
normal renal function [232].  More specifically, IL-6 has been shown to mediate 
malnutrition in dialysis patients, itself a strong predictor of outcome [321] and stimulates 
breakdown of muscle proteins [322].  Like CRP, evidence is emerging of a direct role of 
IL-6 in atherogenesis, for example, it has been demonstrated that injection of 
recombinant IL-6 exacerbates early atherosclerosis in apoE-deficient mice [323].  A 
clinical study showed that elevated circulating IL-6 levels were independently associated 
with progressive carotid atherosclerosis during the first 12 months of dialysis treatment 
[324]. 
 
Adiponectin is produced by adipocytes and found in the circulation.  It appears to play a 
protective role in experimental models of vascular injury and has unusual properties that 
inhibit inflammation and enhance insulin sensitivity, glucose transport, and fatty acid   178 
oxidation.  It has also been shown to suppress the attachment of monocytes to endothelial 
cells [252]. Low circulating adiponectin is generally found in populations at enhanced 
risk of cardiovascular disease [325], and low adiponectin levels have been shown to 
predispose healthy individuals to the later development of insulin resistance [326].   
Adiponectin is also known to be inversely related to BMI.  An inverse relationship 
between adiponectin and CRP has been shown which has prompted the suggestion that 
hypoadiponectinaemia can result in a low-grade systemic chronic inflammatory state 
[258].  Plasma adiponectin levels are generally elevated in patients with CKD [251], with 
previous studies showing conflicting results with elevated levels associated both with a 
positive and an inverse relationship with mortality [251, 327, 328].   
 
The long pentraxin 3 (PTX-3) is a member of the pentraxin family of acute-phase 
proteins, and is involved in innate immunity.  The physiological function of PTX-3 is 
similar to CRP but unlike CRP it is produced by many different cell types, including 
endothelial cells, smooth muscle cells, fibroblasts and monocytes [329].  Levels are 
known to be associated with CVD and levels are known to be higher in renal failure.  It 
has been only recently studied in the setting of CKD, and of much interest is the 
hypothesis that PTX-3 levels may represent a more accurate picture of local inflammation 
as it is produced at sites of disease activity.  The relationship between PTX-3 and NK cell 
function has not been previously examined. 
 
Serum soluble ST2 receptor (sST2) is an IL-1 receptor that has recently been described as 
a biomarker of biomechanical stress of the myocardium that has been shown to be   179 
physiologically linked to cardiac hypertrophy, fibrosis, and ventricular dysfunction.  It is 
associated with increased mortality following MI and in also in both acute and chronic 
cardiac failure, and higher levels have been found in various autoimmune diseases and 
also in severe sepsis [330].  The role of sST2 in has not been studied in CKD patients. 
 
Patients with dyslipidaemia and patients with CKD are amongst the highest risk of CVD, 
most likely attributable to the increased risk of inflammation.  Inflammation is strongly 
associated with adverse outcomes such as loss of physical function, dyslipidaemia, and 
anaemia.  It is also associated with CV events, increased hospitalisation, and death.  The 
causes of inflammation are multifactorial, but some sources are recognisable and 
treatable, and therefore recognition is important.  Additionally, it is known that 
proinflammatory cytokines play a significant role in the pathogenesis of atherosclerosis.  
As such there is much interest in the role of biomarkers and in particular in the prognostic 
information on outcomes.  The aim of this study was to evaluate the relationship between 
NK cells and potential CV risk biomarkers in a population at high risk of CVD, 
specifically in patients with CKD, and additionally, to investigate the association of 
biomarker levels with renal function and other routine laboratory parameters.  If there 
was a relationship with these CV risk markers, it would lend further support to the role 
that NK cells have to play in atherosclerosis. 
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6.2  METHODS 
 
6.2.1  Patients 
Blood samples were taken from 207 patients from six groups of patients.  There were 36 
healthy volunteers who acted as the normal controls, 63 patients with treated 
dyslipidaemia recruited from the lipid clinic on a variety of lipid lowering therapies as 
described in chapter 3, 14 patients with CKD stages 1 and 2, 34 patients with CKD stages 
3 and 4, 49 patients with CKD stage 5, and 11 haemodialysis patients.  Patients were 
recruited from the lipid clinic, nephrology clinics and the regular dialysis unit, following 
consent. 
 
6.2.2  Blood Sampling 
Fifty millilitres of blood was taken into BD vacutainer tubes, as described in section 2.2.  
In the patients on haemodialysis, blood samples were taken within 15 minutes of the start 
of the dialysis session.  Biochemical, haematological, and clinical parameters including 
age, gender, BMI and renal diagnoses (in the CKD patients) were recorded.  None of the 
patients were known to have active infection, none had malignancy, and none were 
immunosuppressed.  Routine biochemical parameters including urea and electrolytes, 
albumin, phosphate, calcium, glucose, lipid profile, and creatinine were obtained from 
biochemistry laboratory reports, and full blood counts were obtained from haematology 
laboratory reports.  In all patients, NK cells were isolated and NK cell phenotype and 
distribution of NKT- and T-cells was determined. 
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6.2.3  Human peripheral blood mononuclear cell isolation 
Peripheral blood mononuclear cells were isolated from peripheral venous blood as 
described in section 2.4.1.3 using Ficoll-Hypaque centrifugation (Histopaque-1077; 
Sigma, Poole, UK). 
 
6.2.4  NK cell isolation 
Natural killer cells were isolated using the MACS NK cell human isolation kit (Miltenyi 
Biotec) as described in section 2.4.2. 
 
6.2.5  51-Chromium Release Assay 
Natural killer cell cytotoxicity was measured using a standard 51-Chromium Release 
Assay, using the human chronic myelogenous leukaemia cell line – K562 as target cells, 
as described in section 2.4.3. 
 
6.2.6  Flow Cytometry 
Three colour flow cytometry of PBMCs was carried out (BD Biosciences FASCalibur) 
before isolation of NK cells to determine NK cell phenotype and distribution of NKT- 
and T-cells as described in section 2.4.4.  The NK-, NKT-, and T-cells were expressed as 
a percentage of total lymphocyte count, and the CD56
bright and CD56
dim subsets were 
expressed as a percentage of NK cells. 
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6.2.7  Measurement of biomarkers 
Blood for measurement of biomarkers was collected in plain tubes and allowed to clot at 
room temperature.  Samples were then centrifuged at 3000rpm for 15 minutes at ambient 
temperature, the supernatant serum was then collected and immediately frozen and stored 
at -70
oC until later analysis. 
 
High sensitivity CRP, IL-6, pentraxin-3, adiponectin and serum soluble ST2 
measurements were performed as described in section 2.6.  
 
6.2.8  Statistical Analysis 
Statistical analysis was carried out using SPSS statistical package (version 15.0).  Non 
parametric data were expressed as medians.  The Wilcoxon rank sum test was used to 
compare groups, and the Kruskal-Wallis test was used to compare more than 2 groups.  
The association between continuous variable was analysed using the Pearson correlation 
test.  The data that were non-parametric were logarithmic transformed and the Pearson 
correlation test was used to examine the association between variables, or alternatively 
non-parametric correlations were carried out with the Spearman rank correlation.  
Analysis of variance (ANOVA) was used to test differences between groups with post 
hoc Scheffe‟s test.  Multiple linear regression analysis was used to assess the contribution 
of different factors to changes in lymphocyte subsets and NK cell cytotoxicity. 
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6.3  RESULTS 
 
6.3.1  Patient characteristics and laboratory data 
Three patients were excluded from analysis due to abnormally high biomarker results, 
suggestive of an occult infection.  One was from the lipid group, one from the CKD 3&4 
group, and one from the CKD 5 group, leaving a total of 204 patients.  The baseline 
characteristics and biochemical and haematological parameters have already been 
described in Chapters 3 and 4, and are summarised in Table 6.1.  The creatinine and 
eGFR results in the HD patient group are included for data but I acknowledge that eGFR 
in particular cannot be used in a comparable way with the other groups.     184 
  Controls (n=36)  Lipid (n=62)  CKD1&2 (n=14)  CKD3&4 (n=33)  CKD5 (n=48)  HD (n=11) 
Sex (m/f)  10/26  45/17  7/7  13/20  32/16  8/3 
Age (years)
a  41.7*  58.0  47.4  65.2  62.6  59.0 
BMI (kg/m
2)
 a  24.8 5.02  30.4±5.94  26.8±5.01  29.4±9.11  27.8±9.49  24.3±4.37 
Creatinine (μmol/l)
 a  82.1±10.8  98.3±25.5  85.9±14.3  172.1±41.4**  495.7±146.9**  604.0±296.6** 
eGFR (ml/min/1.73m
2)
 a  79.5±12.2  71.5±17.7  78.1±12.2  33.0±10.1**  10.2±2.9**  16.1±12.8** 
Albumin (g/l)
 a  41.8±2.7  40.7±3.5  39.1±4.1  38.2ﾱ4.2†  36.2ﾱ3.9†  41.2±6.1 
Total cholesterol
 a  4.9±1.1  5.3±1.2  5.2±1.3  4.7±1.2  4.7±1.2  3.8ﾱ1.0†† 
hsCRP (mg/l)
b  1.84 (0.59-2.63)  2.02 (0.82-6.32)  2.52 (1.21-5.03)  2.09 (1.12-6.22)  5.97 (2.35-
13.12)‡ 
4.14 (2.99-6.14) 
Interleukin-6 (pg/ml)
 a  13.7 ± 27.3  14.5 ± 33.7  40.6 ± 79.0  5.8 ± 21.1  30.1 ± 61.0  28.6 ± 69.6 
Pentraxin-3 (pg/ml)
 b  1063.0 (506.0-
1407.0) 
909.0 (515.0-
1293.5) 
636.5 (350.0-
1197.3) 
608.0(327.5-
832.0) 
1746.0 (1125.0-
2616.0)
# 
1901.0 (1542.0-
2061.0)
# 
Adiponectin (ug/ml)
 b  3.8 (2.7-5.4)  2.6 (1.6-3.8)
##  6.6 (5.6-7.6)  5.8 (4.0-7.6)  5.3 (4.2-5.8)  45.8 (32.7-55.2)§ 
Soluble ST-2 (pg/ml)
 b  20.9 (0.4-79.4)  37.4 (1.4-106.2)  72.6 (7.2-237.6)  27.4 (0.4-76.3)  42.3 (6.4-149.0)  43.7  (0.4-76.8) 
 
aMean ± SD, 
bMedian (IQR) 
 
* p<0.05 v lipid, CKD3&4, CKD5 and HD groups 
** p<0.05 v control, lipid and CKD1&2 groups 
† p<0.05 v control, lipid, CKD1&2 and HD groups 
†† p<0.05 v lipid group 
‡ p<0.05 v control and lipid groups 
# p<0.05 v control, lipid, CKD1&2 and CKD3&4 groups 
## p<0.05v control, CKD1&2, CKD3&4 and CKD5groups 
§ p<0.01 v control, lipid, CKD1&2, CKD3&4 and CKD5 groups 
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6.3.2  High Sensitivity CRP 
There were significant differences in hsCRP between the CKD5 group and the control 
and lipid groups (p<0.05).  Median values of hsCRP for each group and interquartile 
range are detailed in Table 6.1.  High sensitivity CRP correlated significantly with 
creatinine (r = 0.362, p<0.01) [Figure 6.1(a)] which remained significant when the HD 
patients were excluded from analysis (r = 0.363, p<0.01).  This correlation also remained 
significant this time excluding both the HD patients, and also the CKD5 patients, as this 
group had significantly higher levels of hsCRP (r = 0.206, p<0.05).  In keeping with the 
correlation with creatinine, there was a correlation between hsCRP and phosphate (r = 
0.255, p<0.01), which again remained significant when the HD patients were excluded (r 
= 0.265, p<0.01), but not when the CKD5 patients were excluded also.  It should be noted 
that unsurprisingly, serum phosphate was significantly higher in the CKD5 group 
compared with all others (p<0.05).  There were also correlations between hsCRP with 
age (r = 0.196, p<0.01), inversely with HDL-C (r = -0.211, p<0.01), haemoglobin (r = -
0.249, p<0.01), white cell count (r = 0.276, p<0.01), and strongly with albumin (r = -
0.436, p<0.01) [Figure 6.1(b)].  There were no correlations with BMI or weight. 
 
There was no association between hsCRP and NK cell cytotoxicity, NK- and NKT-cell 
number.  There was also no correlation between hsCRP and NK cell phenotype.  There 
was however a significant correlation between hsCRP and T cells (r = -0.177, p<0.05). 
 
Including all patient groups, but selecting only those with a hsCRP of less than 2 mg/dL 
(Figure 6.2), using the cut-off used in the JUPITER trial [263], thereby excluding   186 
“inflamed” patients, the correlation between hsCRP and creatinine remained significant (r 
= 0.268, p<0.05), as did the correlation between hsCRP and phosphate (r = 0.217, 
p<0.05).  The correlations with age, HDL, haemoglobin were lost, but correlations 
between albumin (r = -0.281, p<0.01) and white cell count (r = 0.296, p<0.01) remained.  
There were no correlations with any of the lipid fractions.  No correlations were 
unmasked between hsCRP and NK cell cytotoxicity, number, or phenotype in those “non-
inflamed patients”, but HDL-C did now correlate with CD56
bright cells (r = 0.380, p<0.01) 
and CD56
dim cells (r = -0.371, p<0.01).  Interestingly, in patients with hsCRP < 2mg/dL, 
the correlation between NK cell cytotoxicity and creatinine and phosphate described in 
chapter 4 is lost.  However, when “inflamed” patients with hsCRP > 2 are analysed, there 
is a significant correlation between NK cell cytotoxicity and creatinine (r = 0.212, 
p<0.01) and phosphate (r = 0.338, p<0.01).  In keeping with this, the correlations 
between hsCRP and creatinine and phosphate remain significant (r = 0.229, p<0.05; r = 
0.202, p<0.05).  There was no significant difference in creatinine within groups when 
comparing those with hsCRP > or < 2 to account for this.   To compare creatinines within 
groups, once patients had been coded into those with hsCRP > or < 2mg/dL, data were 
split and organised according to group code, a Mann-Whitney U test was then carried out 
using a grouping variable of hsCRP cut off of > or < 2mg/dL. 
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r = 0.363
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r = -0.436
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Figure 6.1.  Scatterplots showing the relationship between (a) hsCRP and creatinine and 
(b) hsCRP and albumin. 
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Figure 6.2.  Bar chart showing the number of patient with hsCRP > or < 2mg/dl in the 
different groups 
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6.3.3  Interleukin-6 
Unfortunately, the ELISA kit used was not sensitive enough to detect very low levels, 
and the lower limit of detection of IL-6 was 1.0 pg/ml.  There were no significant 
differences in IL-6 levels between groups.  Mean values are summarised in Table 6.1.  
There was no correlation with age or sex.  There were no significant correlations with 
creatinine, phosphate, adjusted calcium, albumin, glucose, haemoglobin and white cell 
count.  There was a correlation between IL-6 and platelets (r = -0.295, p<0.01).  There 
were also significant correlations between IL-6 and cLDL-C (r = 0.237, p<0.05), but not 
with other lipid fractions.  This correlation remained when only those with a hsCRP < 
2mg/L were analysed (r = 0.388, p<0.05) but lost when hsCRP > 2mg/dL.  
 
Interleukin-6 did not correlate with NK cell cytotoxicity, NK-, NKT-, or T-cells.  No 
correlations were unmasked by separating analysis into “inflamed” or “not-inflamed” 
patients, by using a cut-off level of hsCRP greater than or less than 2mg/dL. 
 
6.3.4  Pentraxin-3 
There were significant differences in PTX-3 between groups as shown in Figure 6.3 and 
Table 6.1.  Pentraxin-3 correlated significantly with creatinine (r = 0.327, p<0.01) (Figure 
6.4).  There were also significant correlations between PTX-3 and phosphate (r = 0.158, 
p<0.05), glucose (r = -0.203, p<0.01), and platelets (r = -0.229, p<0.01).  The correlation 
between PTX-3 and creatinine is lost when analysis includes only those patients with 
hsCRP < 2mg/dL, however this relationship is strengthened when only those with hsCRP 
> 2mg/dL are included (r = 0.429, p<0.01).  When all patients were included in analysis,   189 
there were no correlations between PTX-3 and any lipid fractions.  When those patients 
with hsCRP < 2mg/dL were analysed, PTX-3 correlated with total cholesterol (r = 0.367, 
p<0.05).  Looking at those inflamed patients with hsCRP > 2mg/dL, PTX-3 correlated 
inversely with total cholesterol (r = -0.216, p<0.05), triglycerides (r = -0.208, p<0.05), 
and non-HDL-C (r = -0.215, p<0.05). 
 
Overall, there were no correlations between PTX-3 and NK cytotoxicity, NK-, NKT-, or 
T-cells.  However there was a correlation with NK cell phenotype; PTX-3 correlated with 
CD56
bright cells (r = 0.173, p<0.05), and inversely with CD56
dim cells (r = -0.206, 
p<0.01).  Excluding patients with hsCRP > 2mg/dL, PTX-3 correlates with NK 
cytotoxicity (r = -0.234, p<0.05), and also with NK cell phenotype, with CD56
bright cells 
(r = 0.242, p<0.05) and CD56
dim cells (r = -0.271, p<0.05).  There were no significant 
correlations with age, sex, BMI, or blood pressure.  In only those patients with a hsCRP > 
2mg/dl, there was a significant correlation between PTX-3 and BMI (r = -0.233, p<0.05).  
There was no correlation between PTX-3 and presence of known IHD. 
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Figure 6.3.  A boxplot diagram showing the differences in PTX-3 between groups and 
median values shown by the black line.  Pentraxin-3 values have been logarithm 
transformed.  
* p < 0.01, 
** p < 0.05
 
 
r = 0.327
p<0.01
 
Figure 6.4.  A scatterplot showing the relationship between creatinine and pentraxin-3.  
Both have been logarithmic transformed. 
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6.3.5  Adiponectin 
There were significant differences between groups as shown in Figure 6.5.  Median 
values and interquartile range for each group are detailed in Table 6.1.  Adiponectin was 
significantly higher in the HD group and lower in the lipid patient group.  There was no 
correlation between adiponectin and age.  Adiponectin levels were higher in women, with 
a mean of 8.01±12.03ug/ml, and 6.55±10.94ug/ml for men (Figure 6.6).  There were no 
correlations with lipid fractions.  There was a significant correlation with creatinine (r = 
0.317, p<0.01) and eGFR (r = -0.366, p<0.01), but not with phosphate, adjusted calcium, 
serum albumin or glucose.  The correlation with creatinine remained significant when the 
haemodialysis patients were removed from analysis (r = 0.262, p<0.01).  This correlation 
remained significant after adjusting for age, sex, BMI, total cholesterol, LDL-C, 
phosphate, albumin, glucose, and BP.   
 
Adiponectin correlated with haemoglobin (r = -0.315, p<0.01), platelets (r = -0.190, 
p<0.01), and total lymphocytes (r = -0.281, p<0.01).  There was also an inverse 
correlation with T-cells (r = -0.398, p<0.01) (Figure 6.7), and also with CD56
bright cells (r 
= 0.218, p<0.01) and CD56
dim cells (r = -0.240, p<0.01).  However, there were no 
correlations with NK-, or NKT-cells, or with NK cell cytotoxicity.  Adiponectin 
correlated negatively with BMI (r = -0.211, p<0.05) but did not correlate with blood 
pressure. 
 
Analysing the patients with a hsCRP < 2mg/dl, the correlation between adiponectin and 
creatinine is lost, but there is a correlation between adiponectin and non-HDL-C (r = -  192 
0.232, p<0.05).   The correlation between adiponectin and BMI is strengthened (r = -
0.459, p<0.01).  In those patients with a hsCRP > 2mg/dl, adiponectin now correlates 
with total cholesterol (r = -0.277, p<0.01), triglycerides (r = -0.277, p<0.01), and non-
HDL-C (r = -0.310, p<0.01).  The correlation with creatinine is still significant (r = 0.342, 
p<0.01), as is the correlation between haemoglobin (r = -0.221, p<0.05), and platelets (r = 
-0.210, p<0.05).  In these presumably “inflamed” patients, adiponectin now correlated 
more strongly with T-cells (r = -0.490, p<0.01), and the correlation with CD56
bright cells 
and CD56
dim cells still exists (r = 0.275, p<0.01; r = -0.290, p<0.01).  Interestingly, the 
relationship with BMI is lost. 
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Figure 6.5.  A boxplot diagram showing the differences in adiponectin levels between 
groups.  The black line represents the median.  Adiponectin values have been logarithmic 
transformed.  
* p < 0.01, 
** p < 0.05 
*
 
Figure 6.6.  A boxplot diagram showing the difference in adiponectin levels between 
males and females.  
*p < 0.05   194 
(%)
r = -0.368
P<0.01
 
Figure 6.7.  A scatterplot showing the relationship between adiponectin and T-cells.  
Adiponectin was logarithm transformed.  T-cells are expressed as a percentage of total 
lymphocytes. 
 
 
6.3.6  Serum soluble ST2 
There were no significant differences between serum sST2 levels between groups, and 
the median and interquartile range of each group is shown in Table 6.1.  There were no 
correlations between sST2 and age, sex, BMI, or BP.  There were no correlations 
between creatinine, phosphate, albumin, glucose, or any lipid fractions.  There were no 
correlations between routine haematological parameters.  There were also no correlations 
between NK cytotoxicity, NK-, NKT-, or T-cells, or NK cell phenotype.  No correlations 
were unmasked by analysing only those patients with a hsCRP > 2mg/dl.  In those 
patients with hsCRP < 2mg/dl, sST2 correlated negatively with phosphate (r = -0.338, 
p<0.01).     195 
 
6.3.7   Correlations between biomarkers 
High sensitivity CRP correlated with PTX-3 (r = 0.171, p<0.05), but not with any of the 
other biomarkers studied.  Interleukin-6 correlated with PTX-3 (r = 0.426, p<0.01).  
Pentraxin-3 also correlated with adiponectin (r = 0.239, p<0.01).  Serum sST2 correlated 
with IL-6 (r = 0.508, p<0.01), and PTX-3 (r = 0.311, p<0.01) (Figure 6.8).  It is worth 
remembering that hsCRP correlates with creatinine (r = 0.362, p<0.01).  Although a 
correlation between creatinine and cytotoxicity was found in patient with CKD (Chapter 
4), when all patients in this study were analysed there was no correlation between 
creatinine and NK cell cytotoxicity, and there is no correlation between any of the 
biomarkers studied and NK cytotoxicity. 
 
 
All patients (r)
- -0.019 0.311** 0.508** 0.038 sST2
-0.019 - 0.239** 0.214** 0.082 Adiponectin
0.311** 0.239** - 0.426** 0.171* PTX-3
0.508** 0.214** 0.426** - 0.070 IL-6
0.038 0.082 0.171* 0.070 - hsCRP
sST2 Adiponectin PTX-3 IL-6 hsCRP
All patients (r)
- -0.019 0.311** 0.508** 0.038 sST2
-0.019 - 0.239** 0.214** 0.082 Adiponectin
0.311** 0.239** - 0.426** 0.171* PTX-3
0.508** 0.214** 0.426** - 0.070 IL-6
0.038 0.082 0.171* 0.070 - hsCRP
sST2 Adiponectin PTX-3 IL-6 hsCRP
 
Table 6.2  Correlations among inflammation markers in all patients (r, Spearman rank 
correlation). *p<0.05, **p<0.001. 
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p<0.01
(a) (b)  
Figure 6.8.  Scatterplots showing the relationship between (a) sST2 and IL-6, and (b) 
sST2 and PTX-3. 
 
 
If the patients are again separated by hsCRP > or < 2mg/dl, in the patients who have 
hsCRP > 2mg/dl, creatinine now correlates with NK cytotoxicity (r = 0.194, p<0.05), 
however there is still no correlation between NK cytotoxicity and any of the biomarkers 
studied.  The correlations described in the first part of this section remain.  In those 
patients with hsCRP < 2mg/dl, creatinine still correlates with hsCRP, but now does not 
correlate with NK cytotoxicity, however NK cytotoxicity now correlates with PTX-3 (r = 
-0.234, p<0.05) (Figure 6.9).  Additionally, hsCRP now correlates with sST2 (r = -0.252, 
p<0.05).  Pentraxin-3 no longer correlates with hsCPR, IL-6, or adiponectin.  Serum 
sST2 still correlates with IL-6 and PTX-3, but now also with hsCRP (r = -0.252, p<0.05).   197 
r=-0.234
p<0.05
 
 
Figure 6.9  A scatterplot showing the relationship between PTX-3 and NK cell 
cytotoxicity in patients with hsCRP < 2mg/dl 
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6.4  DISCUSSION 
Inflammatory and immunopathological processes play a crucial role in the pathogenesis 
of atherosclerosis.  Moreover, patients with CKD have inflammatory and immunological 
alterations that differ from the non-CKD population, which are not completely 
understood, but are almost certainly responsible for the increase in mortality seen in these 
patients, in particular in ESRD patients, from both CV (not explained by traditional CV 
risk factors) and infective causes.  The role of NK cells in both atherosclerosis and their 
contribution in ESRD has not been widely studied, but there is mounting evidence of 
their involvement.  The aim of this study was to evaluate the relationship between NK 
cells and potential CV risk biomarkers in a population at high risk of CVD, specifically in 
patients with CKD and dyslipidaemia, and examine the relationships with biochemical 
and haematological parameters.   
 
To date, CRP is the most common biomarker to assess the inflammatory status, although 
it remains unclear whether CRP is a marker or a mediator of inflammation and vascular 
disease.  This study demonstrates expected correlations between hsCRP and creatinine 
and phosphate.  It has shown a relationship between PTX-3 and creatinine and phosphate, 
and also total cholesterol in non-inflamed patients, with an inverse relationship with total 
cholesterol and BMI in inflamed patients.  PTX-3 correlated positively with CD56
bright 
cells and inversely with CD56
dim cells, and in inflamed patients there was a relationship 
between PTX-3 and NK cytotoxicity.  Adiponectin has also been shown to correlate with 
creatinine and was significantly higher in HD patients.  It correlated positively with 
CD56
bright and negatively with CD56
dim cells, and inversely with T-cells.  The well   199 
described inverse correlation between adiponectin and BMI was confirmed.  Splitting 
analysis into inflamed and non-inflamed patients, additional correlations become 
apparent.  There were no significant correlations between serum sST2 and routine 
biochemical parameters or NK cells.  PTX-3 correlated with hsCRP, IL-6 and 
adiponectin, and sST2.  Serum sST2 also correlated with IL-6. 
 
This study has confirmed the well recognised process of an inflammatory state in CKD 
with correlations between hsCRP and creatinine.  It is known that a relationship exists 
between CRP and CV events in healthy men and women, and patients with CKD and 
ESRD [318, 319].  The relationship between hsCRP and phosphate is interesting.  
Numerous studies have shown that both the inflammatory state of CKD and abnormal 
mineral metabolism results in increased cardiovascular mortality, however the 
relationship between these two factors has not been examined in great depth.  Two 
studies have shown an association with a high calcium x phosphorus product and a high 
CRP [331, 332], and in a more recent study in patients with CKD stages 3 to 4, serum 
phosphate was significantly associated with CRP and IL-6, and was an independent risk 
factor for the presence of an inflammatory state [333], suggesting that 
hyperphosphataemia itself may promote the development of inflammation in these 
patients.  The anti-inflammatory effect of phosphate binders also supports this [334].  The 
relationship found between phosphate and PTX-3 in this study is interesting, and gives 
more weight to the correlation between phosphate and NK cell cytotoxicity described in 
Chapter 4.  The relationships may of course simply be a function of renal function, but 
evidence is increasing to support hyperphosphataemia as an independent risk factor for   200 
inflammation and CVD.  There were no actual correlations between hsCRP and NK cell 
cytotoxicity, however, in inflamed patients a correlation developed between NK cell 
cytotoxicity and creatinine.  This association would appear to fit with the general 
inflammatory state of patients with advancing renal failure, where NK cells are more 
active and may contribute to the increasing rate of CV disease.  The inverse correlation of 
hsCRP with albumin is consistent with inflammation. 
 
IL-6 did correlate with cLDL-C, but this relationship was lost in inflamed patients.  One 
hypothesis would be that the normal relationships between CV risk and lipids are lost in 
inflamed patients, and this may be a function of more advanced renal dysfunction, where 
there is known to be a “J-shaped” relationship between lipid levels and all cause 
mortality.  IL-6 did not however correlate with hsCRP, and had no relationship with NK 
cells.  It must be acknowledged that the ELISA kit used had a lower limit of detection of 
1.0pg/ml and therefore may simply have been too insensitive to detect any meaningful 
relationships. 
 
Whereas CRP is produced primarily in the liver, PTX-3 is an acute phase protein 
produced by many cell types, including dendritic cells, endothelial cells, VSMCs, 
fibroblasts and monocytes.  Because of this, it has been postulated that PTX-3 levels are a 
more accurate indicator of disease activity produced at actual sites of inflammation.  Its 
production is induced by inflammatory mediators such as lipopolysaccharide, IL-1β and 
TNF-ʱ, but not IL-6.  It has a similar physiological function to CRP and is involved in 
innate immunity [238] with associations with CAD and PVD [335, 336].   It is also   201 
known to increase following MI, and to be a predictor of outcome [337].  Levels of PTX-
3 are known to be significantly increased in HD patients [335] and also in patients with 
CKD, correlating negatively with GFR, with higher levels when inflammation, PEW and 
CVD exist together, where it has been found to be associated with all-cause mortality in 
incident dialysis patients [336].  One study looking at PTX-3 levels in both HD and CKD 
patients (mean creatinine clearance 56.54ml/min) divided patients into those with high 
(>2ng/ml) and low (<2ng/ml) PTX-3 levels, and found significant differences in HDL-C 
and BMI, and a negative correlation between PTX-3 and HDL-C and BMI in those 
patients with high levels of PTX-3, supporting the idea of malnutrition and inflammation 
[338].  Reassuringly, the levels of PTX-3 for controls in this study are comparable to 
previous studies [245, 335].  The relationship between PTX-3 and TC in non-inflamed 
patients fits with an association between PTX-3 and CAD and PVD.  The inverse 
relationships with TC and BMI in inflamed patients support the idea of PEM, 
inflammation and the concept of “reverse epidemiology” know to occur in inflamed 
patients, such as those with ESRD.  In concordance with the development of an 
association between NK cell cytotoxicity and creatinine in inflamed patients, the 
relationship between PTX-3 and NK cytotoxicity in inflamed patients follows, supporting 
the notion that in inflamed patients, NK cells may become more active, and possibly 
therefore contribute to increasing the incidence of CVD seen in inflamed patients. 
 
Adiponectin is an adipocytokine produced by adipose tissue and is considered to be anti-
inflammatory and anti-atherogenic, and therefore protective against CVD [339].  
Circulating levels of adiponectin are known to be paradoxically lower in the obese, and   202 
also in type 2 diabetics, to be higher in women than men, and adiponectin is know to 
correlate negatively with plasma glucose, insulin, triglycerides and insulin-resistance 
[340].  In other words, hypoadiponectinaemia is found in populations at enhanced risk of 
CVD.  In patients with CKD and ESRD however, levels are markedly increased despite 
the high CV risk known to exist.  Whether the increased levels can be completely 
explained by elimination of adiponectin by the kidneys has not yet been completely 
elucidated, although levels are known to fall after successful renal transplantation, and 
interestingly, the reverse epidemiology relationships that exist in ESRD become 
normalised following renal transplantation.  It also remains unclear as to whether the 
relationships with CV risk in the general population also apply, as adiponectin has been 
found to be both an independent inverse predictor of CV outcomes in CKD populations 
[251, 327] even when adjusted for stage of CKD [325], and also to be an independent 
predictor of total mortality in both CKD [328] and HD patients [327].  The levels of 
adiponectin found in this study are comparable to previous studies [325].  A correlation 
with creatinine was confirmed, as well as the markedly increased levels in HD patients.  
The positive correlation with CD56
bright and negative correlation with CD56
dim cells is 
interesting, suggesting that there might be a decrease in NK cell cytotoxicity.  It has been 
postulated that the high levels of adiponectin in CKD patients are a compensatory 
response to inflammation and the malnutrition that occurs.  Indeed in one study which 
found adiponectin to be associated with increased mortality, when malnourished patients 
(those with an albumin ≤ 3.5g/dL) were excluded, adiponectin levels were not a 
significant predictor of mortality [327].  Additionally, adiponectin has been demonstrated 
to be a negative regulator of IL-2-induced NK cell activation [341], providing further   203 
evidence that it may act as an in vivo regulator of anti-inflammatory functions.  The 
inverse correlations found with TC, triglycerides and non-HDL-C in inflamed patients 
would seem consistent with this theory that adiponectin secretion is increased to try to 
counteract the inflammation in CKD as cholesterol levels are known to fall in 
malnourished and inflamed patients, another example of reverse epidemiology.  The 
correlation found between adiponectin and IL-6 supports this.  The relationship between 
adiponectin and BMI is difficult to interpret in patients with CKD and in particular 
ESRD, where paradoxically a higher BMI confers a survival advantage, although lower 
adiponectin levels are seen with higher BMIs.  The inflammation/PEM seen in these 
patients will confound the effects of adiponectin on clinical variables. 
 
Serum soluble ST2 is a member of the IL-1 receptor family and is a biomarker of 
mechanical stress which is up regulated in isolated cardiomyocytes exposed to 
mechanical strain.  ST2 is expressed in a transmembrane form (ST2 ligand [ST2L]) and a 
soluble circulating form (sST2).  IL-33 has recently been identified as the ligand for 
ST2L.  ST2L serves a negative regulatory function for toll-like receptor (TLR) signalling 
which when uncontrolled can result in excessive inflammation.  It has been suggested 
that sST2 acts as a decoy receptor by binding IL-33, thereby inhibiting signalling by 
ST2L [342].  Too much sST2 in the context of potential stretch-induced injury to the 
heart may therefore result in inadequate cardioprotection from IL-33, with an increased 
risk for cardiac remodelling, ventricular dysfunction, or death.  Both forms are induced in 
cardiomyocytes and fibroblasts exposed to biomechanical stress.  After pressure overload 
by transverse aortic constriction, ST2
-/- mice had more left ventricular hypertrophy,   204 
myocardial fibrosis, and chamber dilation, and decreased fractional shortening and 
survival compared with wild-type littermates [342].  Recombinant IL-33 treatment was 
found to reduce hypertrophy and fibrosis leading to improved survival after transverse 
aortic constriction in wild-type mice but not ST2
-/- littermates.  In patients with acute MI, 
elevated sST2 levels are associated with an increased risk of mortality or heart failure 
[343].    Increased levels have also been found in patients with acute dyspnoea, whether 
or not this is due to decompensated cardiac failure, with baseline values predictive of 1 
year mortality [344].  High levels of ST2 have also been found in patients with severe 
chronic heart failure [345], in various immune disorders such as asthma, pulmonary 
fibrosis and various autoimmune diseases, and more recently in patients with severe 
sepsis, irrespective of the source of sepsis, which correlated with disease severity and 
mortality [330].   
 
In this study, no significant correlations between sST2 levels and renal function were 
found.  There were no correlations with any biochemical parameters, and there were no 
correlations with any lipid fractions.  No correlations were found with either NK cell 
function or phenotype.  In the non-inflamed patients, there was a correlation with 
phosphate however this correlation is difficult to explain in the non-inflamed patients.  
Interestingly, sST2 did correlate with IL-6 and PTX-3 in all patients, in keeping with 
previous findings of higher levels in inflammatory states such as severe chronic heart 
failure and sepsis.  A correlation exists between hsCRP and sST2 in non-inflamed 
patients, suggesting that perhaps PTX-3 is a better inflammatory biomarker in this group 
of patients than CRP.  It is perhaps not surprising that no correlations were found given   205 
that any patients with infection or a known inflammatory process were excluded.  This 
was a group of stable out-patients, therefore none were in overt heart failure.  The 
inflammation that exists in CKD is due to the uraemic milieu and likely to represent a 
different inflammatory process than that occurring in sepsis, autoimmune disease and 
cardiac failure.  Although many similarities exist with chronic heart failure patients, for 
example PEW and malnutrition, this is probably more relevant to patients with ESRD on 
RRT, of which there were only 11 in this study.  Patients with ESRD are continuously 
subjected to cardiac stressors, in particular chronic volume overload which results in left 
ventricular hypertrophy, and undoubtedly biomechanical strain on cardiac myocytes.  
This is a patient group that should be investigated in more detail, as to date there are no 
studies looking at ST2 levels in patients with ESRD.  If a biomarker existed that could 
indicate whether there was significant subclinical “cardiac stress” which was predictive 
of outcome, strategies to improve volume status more rigidly, for example nocturnal or 
daily dialysis could be considered. 
 
There were several limitations to this study.  Firstly, the small number of diabetic patients 
and the small number of HD patients recruited may be too small to provide statistically 
significant information.  The fact that samples from some of the CKD and all of the HD 
patients were non-fasting may affect the accuracy of the lipid profile.  As pointed out 
already, the IL-6 assay was unfortunately not sensitive enough to detect very low levels, 
and therefore results may be skewed as the lower limit of detection was 1.0pg/ml and 
may not have been sensitive enough to detect any meaningful relationships.  
Additionally, a single plasma sample at a certain time point may fail to reflect the natural   206 
course of the process studied, or provide as accurate a measurement as an average.  The 
presence of a range of comorbid conditions in a population on multiple drugs represents 
an additional limitation on the interpretation of the data. 
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CHAPTER 7 
 
General discussion and conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
   208 
7.0  GENERAL DISCUSSION 
 
7.1  Natural killer cells and dyslipidaemia 
The aim of this thesis was to assess the role of NK cells in CVD, and to address the 
hypothesis that changes in NK cell function may result in their participation in the 
development of atherosclerosis, particularly in high risk patient groups.  The groups of 
patients studied were those with dyslipidaemia attending a lipid out-patient clinic, and 
patients with CKD, who will be discussed in the next section.  The limitations of the 
studies have been discussed at the end of each chapter.  
 
The role of plasma lipoproteins in atherogenesis is well recognised, but the physiological 
relevance of their immunoregulatory properties is not fully established.  Previous work 
by this research group assessed T-cell proliferation and NK cell cytotoxicity in a group of 
thirteen healthy volunteers before and after treatment with 40mg simvastatin for four 
weeks [150].  This study showed that simvastatin treatment reduced NK cytotoxicity ex 
vivo by 30±34%, with levels returning to normal following cessation of therapy.  Overall, 
there was a close relationship between the reduction in LDL-C and inhibition of NK cell 
killing.  A further study assessed NK cytotoxicity in a wide ranging and varied patient 
population including immunosuppressed renal transplant recipients, patients with CKD 
and ESRD on HD, and patients with CAD, and found a trend towards higher levels of 
cytotoxicity at higher cholesterol levels [153], identifying total cholesterol and weight as 
the main factors associated with cytotoxicity.   
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In the study detailed in Chapter 3, we specifically sampled patients attending a lipid 
clinic to ensure that they had dyslipidaemia, and were therefore at higher risk of CVD.  
These patients were on a variety of lipid lowering treatments and it was notable that TC 
and LDL-C were higher in those patients not on statin treatment.  We did not find any 
correlations between lipid levels and NK cell numbers, phenotype, or cytotoxicity, 
although triglycerides did correlate with T cell numbers.  The presence of statin therapy 
did not affect NK-, NKT-, or T-cell numbers.  We did not confirm a reduction in NK 
cytotoxicity in patients on statin treatment or indeed on any other lipid lowering 
treatment, and unexpectedly, there seemed to be an inverse correlation between NK 
cytotoxicity and LDL-C which did not appear to be a lipid lowering treatment effect as 
this relationship existed in the control group also.  We did confirm a positive correlation 
between CD56
dim cells and age.  The differences in the findings of this study compared to 
the two previous studies described above may be partially explained by the fact that the 
cytotoxicity assays in this study used isolated NK cells, whereas previously a crude 
lymphocyte preparation was used.  Another possibility could be a recent finding that 
lipophilic, but not hydrophilic statins inhibit NK cytotoxicity [346].  A significant 
proportion of the patients sampled were on rosuvastatin, a hydrophilic statin, the previous 
studies used the lipophilic statins simvastatin and fluvastatin.   
 
The original hypothesis that membrane and plasma cholesterol change in parallel, and 
that changes in immune cell function may occur as a consequence of changes in 
circulating cholesterol levels (and thus changes in cell membrane cholesterol) has not 
been answered in this study.  The idea that treatments that lower circulating cholesterol   210 
are therefore likely to reduce membrane cholesterol, resulting in impaired or altered cell 
functions that are dependent on membrane cholesterol has also not been confirmed.  Our 
findings are consistent with other previous studies as detailed in Chapter 3 however there 
are numerous conflicting studies.  There is an abundance of experimental, clinical and 
epidemiologic data which has established hypercholesterolaemia as a major causative 
factor in atherogenesis.  Additionally, numerous prospective epidemiologic studies have 
indicated that low serum cholesterol is associated with increased age-adjusted mortality 
from non-atherosclerotic diseases, not just in ESRD populations [281], and the link 
would appear to be between serum lipids and immune function.  Lymphocytes receive 
cholesterol, essential for maintaining cell membrane structure, from circulating 
lipoproteins as well as synthesising cholesterol de novo.  A concept that has emerged is 
that atherosclerosis to some extent can be viewed as an autoimmune disease in which the 
adaptive immune system is targeted against vascular self-antigens modified by 
hypercholesterolaemia [347].  Hypocholesterolaemic healthy volunteers have been shown 
to have lower numbers of circulating lymphocytes and T-cells, but no changes were noted 
in NK cell numbers between hypo- and hypercholesterolaemic subjects [283].  One group 
studied distribution of NK cell subsets and NK cytotoxic activity in patients with stable 
CAD and acute coronary syndrome (ACS) [95].  They found significantly lower numbers 
of NK cells and CD56
dim cells in the ACS and stable CAD groups compared with 
controls, and additionally lower NK cell cytotoxicity in the ACS and CAD groups. There 
was however no difference in the calculated cytolytic activity per NK cell between 
groups, so they have described the impaired NK cell function in the CAD patients as a 
mainly quantitative defect.  They also found no correlations between NK cell parameters   211 
and lipid levels.  Another group also looked at lymphocyte subtypes in patients with 
stable CAD and ACS.  Conversely, they found that the relative number of NK cells was 
significantly raised in patients with ACS in comparison to controls, and in fact followed 
the pattern of ACS > stable CAD > controls [348].  The elevation of NK cell ratio was 
accompanied by a decrease in the total T-cell count in both the ACS and stable CAD 
groups, which was hypothesised to be due to migration of T-cells from the peripheral 
circulation to the site of atherosclerotic lesions.  The possibility remains that the higher 
numbers of CD56
dim cells seen in the lipid patient group in the present study may be a 
characteristic of the disease itself, although this was not possible to determine given the 
varied drug treatment.  For example, increased NK cell apoptosis has been found in CAD 
patients compared with controls [97], and furthermore the NK cells were more 
susceptible to oxidized lipids ex vivo.  Increased spontaneous apoptosis of CD56
dim cells 
has also been demonstrated in patients with malignancy [349].  Statins are known to 
protect against oxidative stress, and statin treatment may explain why higher numbers of 
CD56
dim cells were seen in the lipid patient group. 
 
7.2  Natural killer cells and chronic kidney disease 
In Chapter 4, we investigated whether any changes in the distribution of NK cell subsets 
or NK cell-mediated cytotoxicity could be observed in patients with CKD, the aim of the 
study being to provide a quantitative, functional and phenotypic multivariate analysis of 
NK parameters in relation to clinical and laboratory parameters of patients with CKD.  
Chronic renal failure is an immunodeficient state which is not completely understood, 
and results in a high morbidity and mortality from cardiovascular disease and infectious   212 
complications.  It is also associated with a 30% increase in malignant tumours [350], 
diminished serological responses to vaccination, and reduced fertility.  It is known that 
patients with  CKD and those with ESRD undergoing HD have decreased lymphocyte 
counts [212, 213] with altered function, but there is comparatively little information 
regarding the role of NK cells in CKD, and the studies in the current literature report 
conflicting results.  Of the previous studies examining NK cell function and renal failure, 
some report increases in NK cell numbers [212, 217, 351] or decreases in numbers and 
activity [216, 217, 352] or no change [353].  All of these studies were small and involved 
only patients on RRT.  None were carried out on undialysed patients with CKD in 
relation to renal function and these studies did not examine NK cell subsets.  One more 
recent study [295] did involve both patients on HD and “uraemic undialysed” patients, 
although it is unclear what the degree of renal dysfunction was in these undialysed 
patients. They found that NK cell counts were lower in HD patients compared with 
controls, and although not statistically significant NK cell counts in the undialysed 
patients were lower and at an intermediate level between the HD patients and controls.  
Multivariate analysis of the undialysed group showed that creatinine clearance (Cockcroft 
and Gault) was positively correlated to NK cell counts.  They found no alterations in NK 
cytotoxicity in HD patients compared to controls, but did find that cytotoxicity was 
positively correlated with time on dialysis, with patients on HD for over 5 years 
exhibiting higher cytotoxic potential.  They did not however examine NK cell 
cytotoxicity in the undialysed CKD group in whom they had noted a positive relationship 
between NK cell counts and creatinine clearance.   
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To the best of my knowledge, we are the first to have examined NK cell numbers, 
subtypes, and function in a group of patients across the range of CKD.  We did find a 
correlation between NK cell cytoxicity and creatinine, although this did not retain 
significance after multivariate analysis.  There was also a correlation between NK 
cytotoxicity and phosphate which remained significant after stepwise multivariate 
regression.  We are the first to report a relationship between phosphate and NK 
cytotoxicity.  This is an interesting finding in light of the increasing evidence supporting 
a role for phosphate in cardiovascular disease and increased mortality, not only in the 
ESRD population [223] but also in populations without CKD [219], and the emerging 
evidence for the role of NK cells in atherosclerosis.  In cross-sectional studies, each 1-
mg/dl rise in serum phosphorous was associated with a 23% increased risk of death 
[220].  Hyperphosphatemia is also correlated with an increased risk of soft tissue and 
vascular calcification, which may provide the link between CKD and CVD.  There has 
been much interest recently in the use of calcium containing versus non-calcium 
containing phosphate binders, as there is evidence that use of the non-calcium containing 
phosphate binder sevelamer leads to better survival [354].  In the future, in treatment of 
hyperphosphatemia in CKD patients, vascular risk reduction and mortality need to be 
considered in addition to effects of mineral homeostasis and reduction of serum 
phosphate level. 
 
7.3  Membrane cholesterol and natural killer cells 
It has long been accepted that hypercholesterolaemia correlates with the development of 
atherosclerosis, and more recently that progression of cholesterol-related disease requires   214 
inflammation, but the mechanisms linking those events are as yet unknown.  Reductions 
in membrane cholesterol have been shown to affect cell function, presumably by altering 
membrane lipid organisation.  High serum cholesterol availability therefore might also 
activate immune cells that contribute to the progression of atherosclerosis.  Activation of 
immune cells by cholesterol may explain the association that has been found between 
atherosclerosis and CRP [33].    We have postulated that some of the reported pleiotropic 
effects of statins on cell signalling and immunity may reflect altered cell membrane, and 
in particular lipid raft structure and function due to reduced cholesterol availability.  As a 
consequence, hypocholesterolaemia as is seen in malnourished, acutely or chronically 
unwell patients such as those with malignancy, cardiac failure or ESRD, could lead to 
reduced inflammatory responses, which may contribute to the increased susceptibility 
these patients have to infections.  One study found that cholesterol loading macrophages 
with MBCD affected F-actin organisation, increased membrane pinocytic activity, and 
decreased cell migration [314], changes that were similar to those observed when 
macrophages were treated with modified lipoproteins, suggesting that the changes 
induced by modified lipoproteins are partly attributable to changes in cellular cholesterol 
levels.  These findings may explain how macrophages within atherosclerotic lesions 
continue to take up retained lipoproteins, becoming foam cells that are then unable to 
migrate from the atherosclerotic lesions.  Another study investigated the effects of 
cholesterol depletion (using MBCD) on polymorphonuclear neutrophil rafts, to assess the 
effects of raft disruption on G protein-coupled Ca
2+ mobilisation [355].  Regulated Ca
2+ 
entry is a primary mechanism of immune cell activation and therefore inflammation, and 
receptors that activate phospholipases can initiate Ca
2+ entry through transient receptor   215 
potential calcium (TRPC) channels.  They found that cholesterol bioavailability regulated 
membrane raft composition and the TRPC1 redistributed to raft fractions in response to 
cholesterol.  If Ca
2+ entry can be regulated in this way by cholesterol availability, this 
may provide the link to the regulation of immune cell activity.  The association between 
hypercholesterolaemia and inflammation may therefore in part reflect cholesterol-
dependent changes in lipid raft structure that regulate immune cell calcium entry [355]. 
 
Although we have concentrated on the actions of statins in this study, variation in the 
cholesterol content of cells is likely to be a physiological regulator of membrane receptor 
function that affects all cells.  The cholesterol within the cell membrane comes from 
recycled circulating lipids and that produced by HMG-CoA reductase within individual 
cells.  HMG-CoA reductase is regulated by exogenous lipid, as we have shown here, and 
NK cell function is also related to circulating cholesterol levels.  The effect of diet, 
specifically starvation, on NK cell function is well known and may contribute to 
susceptibility to infection in malnourished individuals.  Cholesterol excess or deficiency 
may alter cell signalling in ways that are therefore modifiable by dietary or 
pharmacologic cholesterol control.  However, the relationship between circulating and 
membrane cholesterol, and cell function, and the concept of statins as membrane 
modifying agents merits further study. 
 
7.4  Biomarkers in chronic kidney disease 
Cardiovascular disease is the leading cause of morbidity and mortality in patients with 
ESRD, and even the presence of mild CKD has been shown to be associated with a   216 
higher prevalence of CVD [2] therefore early identification of patients who are at 
heightened CV risk may facilitate more aggressive and focused treatment.  To do this, 
there is an increasing need to identify an ideal biomarker that will be able to facilitate the 
clinical diagnosis of CVD.  In fact CKD itself may be considered a biomarker of CVD.  
The CV risk is increased very early on in the evolution of CKD, at a GFR of about 
75ml/min, and increases continuously with decreasing renal function [356].  In this group 
of patients in particular, prediction models using traditional risk factors underestimate 
CVD risk.  Additionally, the pattern of CVD in ESRD differs from the general population 
and although there is an increase in atheromatous CAD and its sequelae, there is a 
broader range of CVD with CV calcification, LVH, and sudden cardiac death, possibly 
related to “uraemic cardiomyopathy” and associated heart failure or arrhythmia, which 
may not be as dependent on cholesterol levels.  To further complicate matters, the 
conventional relationships between existing biomarkers and CV risk may be reversed in 
the ESRD population, with many confounders, particularly inflammation, making 
interpretation more complex.  Decreased renal clearance of inflammatory markers and the 
high incidence of co-morbid conditions may also contribute to a confusing picture. 
 
In Chapter 6, we have not been able to determine any definite relationships between the 
biomarkers studied and NK cell function.  There was an association between PTX-3 and 
NK cytotoxicity that was found only in inflamed (hsCRP>2mg/L) patients.  There was 
also a positive correlation between adiponectin and CD56
bright cells which are the 
cytokine producing NK cell.  This would be consistent with the idea of increased 
adiponectin (and perhaps other cytokine) production in increasingly inflamed patients to   217 
try to counteract the inflammation that occurs in CKD.  In mice, atherosclerotic lesions 
are generally driven by the increased expression of proinflammatory cytokines, produced 
by NK cells.  The activation of NK cells eventually leads to enhanced stimulation of 
macrophages, B and T cells which further perpetuates this process [69].  We were able to 
confirm established relationships between hsCRP, PTX-3, adiponectin and renal function, 
as well as lesser know relationships – hsCRP and phosphate, and PTX-3 and phosphate.  
Taken together with the significant correlation between phosphate and NK cytoxicity 
found in Chapter 4, this provides more support for serum phosphate itself being 
associated with inflammation, and as a result perhaps leading to formation of 
atherosclerotic lesions.  
 
7.5    Clinical implications and further work 
There are a number of clinical implications from the findings and observations in this 
thesis.  The relationships between NK cell cytotoxicity and creatinine, and NK cell 
cytotoxicity and phosphate are important given the increasing evidence implicating 
hyperphosphataemia in increased CV risk in both the general population [219] and in the 
CKD population [223].  In considering treatment of hyperphosphataemia in patients with 
CKD; at present, the current KDIGO guidelines for chronic kidney disease-mineral bone 
disorder (CKD-MBD) [357] suggest that in CKD stages 3-5 serum phosphorous is 
maintained in the normal range, and in CKD stage 5D, elevated phosphorous levels 
should be lowered towards the normal range, using phosphate-binding agents.  A 
recommendation is made to restrict the dose of calcium-based phosphate binder (and 
vitamin D supplements) in the presence of persistent hypercalcaemia and arterial 
calcification.  Whilst hypercalcaemia can be easily monitored, the presence of arterial   218 
calcification may be asymptomatic.  The presence of vascular calcification is associated 
with all-cause and CV mortality in ESRD [358], and few studies have addressed 
interventions to decrease vascular calcification.  It would therefore seem sensible to adopt 
an approach of prevention, therefore in considering treatment, not only the reduction of 
phosphate, but an assessment of vascular risk reduction and mortality need to be 
considered.  No prospective studies have been carried out to examine the benefits of 
targeting different phosphate levels to determine the effect on patient-level end points.  
Further studies need to be carried out to determine whether we should be lowering 
phosphate more aggressively and in a more targeted fashion as part of specific CV risk 
reduction.  Further studies could be carried out in a larger patient population with CKD, 
examining NK cell function in those treated with calcium and non-calcium based 
phosphate binders.  In vitro studies examining the effect on NK cell function of uraemic 
serum from hyperphosphataemic patients and patients with well controlled phosphate 
levels and Ca x P product would be an interesting next step.  Additionally, studies to 
determine whether other immune abnormalities occur in the context of 
hyperphosphataemia would be of interest. 
 
Whilst in our patient cohort we did not confirm the previously observed relationships 
between NK cell function and lipid levels in vivo, we have shown that NK cell function is 
related to circulating cholesterol levels at least in vitro.  Variation in the cholesterol 
content of cells is likely to be a physiological regulator of membrane receptor function 
that affects all cells. These findings suggest that cholesterol excess or deficiency may 
alter cell signalling in ways that are modifiable by dietary or pharmacologic cholesterol   219 
control.  In other words, immune functions are affected by nutritional status which is 
particularly important in CKD/ESRD patients.  Further work needs to be done to tease 
out the reverse relationships that exist in this population, when inflammation has been 
excluded.  The evidence for lipid lowering in ESRD remains unclear, with the 4D study 
[259] showing no benefit in treating diabetic dialysis patients with atorvastatin vs 
placebo, and the AURORA study [260] showing no benefit in treating a more wide-
ranging population of dialysis patients with rosuvastatin vs placebo.  The SHARP study 
(Study of Heart and Renal Protection) [359] to assess the effects of cholesterol lowering 
with a combination of simvastatin and ezetimibe, aiming to recruit around 9000 patients 
with CKD is ongoing, and may shed more light on this important area. 
 
The relationship between CD56
dim cells and ageing that is already established and 
confirmed in this thesis may have significance in the future in view of our ageing general, 
and therefore CKD population who will accrue increasing CV risk.  Establishing the role 
that NK cells play in atherosclerosis is therefore important.  Whether increasing NK 
cytotoxicity results in an increased inflammatory response (as indicated by the 
relationships with the biomarkers in Chapter 6), or whether conversely given their 
capacity to control infections, a loss of NK cell activity might lead to increased 
susceptibility to atherosclerosis-related pathogens (with consequences, such as increased 
plaque burden and enhanced formation of vulnerable plaques) remains unclear.  The 
pleiotropic effects of statins on NK cell function probably involve both inhibition of 
isoprenylation and cholesterol depletion.  It may be that in the future, the clinical use of   220 
statins will not only be simply for cholesterol reduction, but for immunomodulation in 
patients at high risk of CVD, for example as part of treatment of hyperphosphataemia. 
 
There is little doubt now that immune cells and inflammatory mediators which are 
present either in the circulation or at the site of inflammation can result in atherosclerotic 
lesions.  It may be that in the future, along with conventional CV risk reduction therapies 
such as anti-platelet and lipid lowering agents, immune-based therapies for prevention 
and treatment of CV disease may become a reality. 
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